Patterns of Lung Cancer Care and Associated Health Outcomes Among Elderly Medicare Fee For Service Beneficiaries in West Virginia and in the United States by Nadpara, Pramit Amrutlal
Graduate Theses, Dissertations, and Problem Reports 
2013 
Patterns of Lung Cancer Care and Associated Health Outcomes 
Among Elderly Medicare Fee For Service Beneficiaries in West 
Virginia and in the United States 
Pramit Amrutlal Nadpara 
West Virginia University 
Follow this and additional works at: https://researchrepository.wvu.edu/etd 
Recommended Citation 
Nadpara, Pramit Amrutlal, "Patterns of Lung Cancer Care and Associated Health Outcomes Among Elderly 
Medicare Fee For Service Beneficiaries in West Virginia and in the United States" (2013). Graduate 
Theses, Dissertations, and Problem Reports. 4984. 
https://researchrepository.wvu.edu/etd/4984 
This Dissertation is protected by copyright and/or related rights. It has been brought to you by the The Research 
Repository @ WVU with permission from the rights-holder(s). You are free to use this Dissertation in any way that is 
permitted by the copyright and related rights legislation that applies to your use. For other uses you must obtain 
permission from the rights-holder(s) directly, unless additional rights are indicated by a Creative Commons license 
in the record and/ or on the work itself. This Dissertation has been accepted for inclusion in WVU Graduate Theses, 
Dissertations, and Problem Reports collection by an authorized administrator of The Research Repository @ WVU. 
For more information, please contact researchrepository@mail.wvu.edu. 
 
Patterns of Lung Cancer Care and Associated Health Outcomes Among Elderly 
Medicare Fee For Service Beneficiaries in West Virginia and in the United States 
 
 
Pramit Amrutlal Nadpara 
 
Dissertation Submitted to the 
School of Pharmacy 
at West Virginia University 
in partial fulfillment of the requirements 
for the degree of 
 
 
Doctor of Philosophy 
in 
Pharmaceutical and Pharmacological Sciences 
 
 
S. Suresh Madhavan, MBA, Ph.D., Chair 
Cindy Tworek, Ph.D., M.P.H. 
Usha Sambamoorthi, Ph.D. 
Michael Hendryx, Ph.D. 
Mohammed Almubarak, MD 
 
 
 
Department of Pharmaceutical Systems and Policy 
 
 
Morgantown, West Virginia 
2013 
 
 
Keywords: Lung cancer, Elderly, Neoplasm, Medicare, and Disparities 
 
Copyright 2013 Pramit Amrutlal Nadpara 
Abstract 
 
Patterns of Lung Cancer Care and Associated Health Outcomes Among Elderly 
Medicare Fee For Service Beneficiaries in West Virginia and in the United States 
 
Pramit Amrutlal Nadpara 
 
The elderly carry a disproportionate burden of lung cancer in the US. Although 
significant improvements have been made during the past decade in cancer treatment, 
substantial disparities still exist in guideline-based lung cancer care and outcomes. 
Such variation in lung cancer care is a cause for major concern in rural areas like West 
Virginia (WV). The purpose of this study was to do a comprehensive evaluation of 
variations in lung cancer care and associated health outcomes in the elderly. This 
retrospective study was conducted using SEER-Medicare and WVCR–Medicare linked 
data files for the years 2002-2007. As part of the project, three studies were conducted.  
In the first study, we compared geographic variations in clinical guideline-based lung 
cancer care and associated health outcomes among elderly Medicare Fee-for-service 
(FFS) beneficiaries. The study found disparities in receipt of minimally appropriate care 
in both the WV and US populations. Receipt of minimally appropriate care was found to 
be associated with longer survival times.  In the second study, we compared geographic 
variations in timeliness of lung cancer care and found significant variation in delays in 
diagnosis and treatment in both the WV and US populations. However, non-timely care 
was not associated with poorer prognosis. The third study determined the patterns of 
receipt of tobacco-use cessation counseling services and found such services to be 
received by more than half of all beneficiaries. Overall, the findings highlight the critical 
need to address disparities in receipt of guideline-based appropriate and timely lung 
cancer care among Medicare FFS beneficiaries. The findings also reveals the urgent 
need for future cancer prevention efforts directed towards promoting smoking cessation 
in the rural WV population. In the long run, such cancer prevention efforts can help to 
reduce lung cancer incidence, which in turn can help to reduce the geographic 
disparities in lung cancer mortality. 
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 1
CHAPTER 1: 
INTRODUCTION 
 
Overview of Lung Cancer 
Lung cancer is the cancer that starts in the lungs.  In the United States (US), lung 
cancer is the second most diagnosed cancer in both men and women.  During 2012, an 
estimated 226,160 new cases of lung cancer were expected to be diagnosed, 
representing about 14% of all cancer diagnoses.1  The elderly carry a disproportionate 
burden of lung cancer, as approximately 81% of those living with lung cancer are 60 
years of age or older.2  This pattern is expected to persist as the estimated number of 
elderly in the US doubles to nearly 70 million by 2030.  Based on cell histology, there 
are two main types of lung cancer: (1) Non-small cell lung cancer, and (2) Small cell 
lung cancer.  Non-small cell lung cancer (NSCLC) is the most common type of lung 
cancer, and it makes up about 80% of all lung cancer cases.3  It usually grows and 
spreads more slowly than Small cell lung cancer (SCLC). 
In the US, lung cancer is also the leading cause of cancer deaths in both men 
and women.1;2  It causes more deaths than the next three most common cancers 
combined (colon, breast, and prostate).1;2;4  In women, the deaths from lung cancer 
surpassed those due to breast cancer in 1987.2  In men, approximately 31% of cancer 
deaths are attributable to lung cancer.  The number of deaths due to lung cancer has 
increased approximately 4.3% between 1999 and 2008, from 152,156 to 158,656.5  
While the number of deaths among men has reached a plateau, the number is still rising 
among women.5  The age-adjusted death rate for lung cancer is higher for men (63.6 
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per 100,000) than for women (39.0 per 100,000).  It is also higher for Blacks (53.4 per 
100,000) as compared to Whites (50.2 per 100,000).  While Black men have a far 
higher age-adjusted lung cancer death rate than White men, Black and White women 
have similar rates.1;2   
Substantial geographic variation in lung cancer incidence and mortality rates has 
also been observed in the US.  In 2009, Kentucky (KY) followed by West Virginia (WV) 
had the highest age-adjusted lung cancer incidence rate (KY: 96.9 per 100,000, WV: 
82.7 per 100,000), and mortality rate (KY: 69.0 per 100,000, WV: 67.0 per 100,000).6  
These state-specific rates were parallel to smoking prevalence rates, and are much 
higher than the average US lung cancer incidence and mortality rates (64.3 per 100,000 
and 48.5 per 100,000, respectively).6  Utah had the lowest age-adjusted lung cancer 
incidence and mortality rates (28.1 per 100,000 and 20.4 per 100,000, respectively).6  
  
Etiology of lung cancer 
A single etiologic agent, cigarette smoking, is by far the leading cause of lung cancer, 
and it accounts for approximately 90% of lung cancer cases in the US.7  The causal 
association of cigarette smoking with lung cancer is one of the most thoroughly 
documented causal relationships in biomedical literature.8;9  Compared to never 
smokers, smokers have an approximately 20 times increased lung cancer risk.  The risk 
of lung cancer among cigarette smokers increases with the duration of smoking and the 
number of cigarettes smoked per day.10  While trends in lung cancer occurrence closely 
reflect patterns of smoking, the rates of occurrence lag smoking rates by about 20 
years. 
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 While the predominant cause of lung cancer is now well-known, there are other 
causes as well.  They include exposure to radon, arsenic, asbestos, chromates, 
chloromethyl ethers, nickel, polycyclic aromatic hydrocarbons, and other carcinogenic 
agents.3  Outdoor air pollution, which includes combustion generated carcinogens, is 
also considered to contribute to lung cancer risk in an urban population.3  Some of 
these risk factors can also act in concert with smoking to synergistically increase risk of 
lung cancer. 
 
Prevention of lung cancer 
There are many interventions that might be considered as strategies for reducing lung-
specific cancer risks including smoking prevention and cessation, lifestyle as well as 
dietary or nutritional changes, and effective screening of identified high-risk individuals 
among others.  Of these strategies, only smoking prevention and cessation has been 
shown to reduce lung cancer risk.11  Research has shown a close association between 
national mortality rates and smoking.12  Prevention approaches that delay the age of 
onset of smoking in a population could have a substantial impact on the incidence of 
lung cancer by shortening the duration of smoking.  Furthermore, smoking cessation 
has shown to reduce the risk of lung cancer, regardless of sex, and type of tobacco 
smoked.13
 
Screening for lung cancer 
Similar to any other cancer, if lung cancer is diagnosed at an early stage, the treatment 
options and survival benefits are better compared to that of late stage cancer.  
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Therefore, it makes sense to have screening tests that can increase the rate of 
detection at an early stage.  Chest X-rays (CXR), sputum cytology and Low-Dose 
computed tomography (LDCT) are the commonly used non-invasive diagnostic tests for 
lung cancer screening.  Prior studies assessing the utility of these non-invasive tests for 
lung cancer screening purposes in asymptomatic individuals have shown mixed 
results.14;15
While, conventional CXR detect tumors about 1 to 2 cm (0.4 to 0.8 inches) in 
size, computed tomography (CT) is very sensitive, and is capable of routinely detecting 
nodules as small as 2 to 3 mm in size.  Previous screening studies have shown that, 
screening increases the rate of detection of early-stage lung cancer, but it fails to 
reduce the number of late-stage lung cancers or the risk for dying from lung cancer.16-18  
This is because screening detects a large number of small, slowly growing, less 
aggressive lung cancers that are unlikely to progress to a point that they cause clinical 
disease while missing cancers that advance rapidly and cause the majority of deaths 
from lung cancer.  Currently, no clinical evidence-based guidelines support the use of 
any test for screening purposes in the general population.  However, the evidence is 
changing, especially with results from the National Lung Screening Trial,14 and as new 
data become available, the guidelines may be updated.  The National Lung Screening 
Trial was a randomized national trial involving more than 53,000 current and former 
heavy smokers ages 55 to 74, which compared the effects of two screening procedures 
for lung cancer: low-dose helical CT; and CXR, on lung cancer mortality.  This study 
was designed to have a 90% power to detect a mortality reduction of 20% by 2009.  The 
initial results show 20 percent fewer lung cancer deaths among trial participants 
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screened with low-dose helical CT compared to those screened with CXR.  In addition, 
deaths from all-causes (including lung cancer) were 7% lower among those who 
received the low-dose helical CT scans.  In light of these findings, screening with low-
dose spiral CT scans has been recommended for individuals at an increased risk of 
lung cancer by the American College of Chest Physicians (ACCP) and the American 
Society of Clinical Oncology (ASCO).19
 
Diagnosis and staging of lung cancer 
A majority (90%) of patients with lung cancer are symptomatic at presentation.  The 
symptoms may be due to: (1) Primary tumor, example: cough, dyspnea, chest pain, and 
hemoptysis; (2) Intrathoracic spread of lung cancer, example: recurrent laryngeal nerve 
palsy, phenic nerve paralysis, and Horner syndrome; (3) Extrathoracic metastases, 
example: bone pain, and weight loss; and/or (4) Paraneoplastic syndromes related to 
malignant disease, example: hypercalcemia, and Cushing syndrome.  The diagnosis is 
usually suspected following an abnormality on the chest radiograph.  All patients 
suspected of lung cancer undergo a thorough medical history, physical examination, 
and standard laboratory tests, as a screen for metastatic disease.   
The basis for staging lung cancer is the American Joint Committee on Cancer 
(AJCC), TNM (Tumor, Node, and Metastasis) system.20;21  Correctly staging lung cancer 
is extremely important because the prognoses differ significantly by stage.  Several 
noninvasive imaging studies are available to aid in identifying the disease, both within 
and outside of the chest.  They include chest CT scanning, and whole-body positron 
emission tomography (PET) scanning.22  In cases where noninvasive radiographic 
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staging is not reliable, invasive staging procedures are sometimes used to confirm the 
stage and diagnosis.  These invasive staging tests include mediastinoscopy, 
thoracoscopy (video-assisted thoracoscopic surgery), transbronchial needle aspiration 
(TBNA), transthoracic needle aspiration (TTNA), and endoscopic ultrasound with fine 
needle aspiration (EUS-NA).23
 
Treatment of lung cancer 
Lung cancer treatment options primarily depend on the type of cancer and the stage at 
diagnosis.  The treatment options for early stage NSCLC (Stage I-III), include surgery, 
chemotherapy, radiation, or its combination.24  Surgical treatment options include 
lobectomy (removal of a lobe of the lung), segmentectomy (removal of an anatomic 
division of a particular lobe of the lung), pnemonectomy (removal of an entire lung), and 
wedge resection.  Five year survival rates of approximately 40% are anticipated with 
standard surgical resection.25  Unfortunately, only a few NSCLC patients are diagnosed 
at an early stage, and approximately 70% of all NSCLS patients present with advanced 
stage III and IV disease.25  Treatment options for advanced stage NSCLC patients 
(Stage IV) are limited and include chemotherapy, radiation therapy or its combination for 
palliation of symptoms.24  The median survival times are typically 6 to 10 months and 
most patients die within 1 to 2 years of diagnosis.25
Small cell lung cancer without treatment has the most aggressive clinical course 
with median survival from diagnosis of only 2 to 4 months.26;27  Approximately 30% of 
patients with SCLC present with limited-stage disease (Stage I-III) and their treatment 
options include chemotherapy and radiation therapy.26  Median survival of 16 to 24 
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months and 5-year survivals of 14% with current forms of treatment have been reported 
in this group.26  However, in SCLC patients with extensive-stage disease (Stage IV), 
median survival of only 6 to 12 months has been reported.26  
 
Healthcare utilization and costs associated with lung cancer 
The economic burden of lung cancer in the US is significant.  The National Institutes of 
Health estimates that approximately $10.3 billion per year is spent in the US on lung 
cancer treatment alone.28  Compared to patients without cancer, patients with lung 
cancer have greater health care service utilization and costs for hospitalization, 
emergency room visits, outpatient office visits, radiology procedures, laboratory 
procedures and pharmacy-dispensed drugs.  The main cost drivers found in one study 
were hospitalization (49.0% of costs) and outpatient office visits (35.2% of costs).29  In 
the same study, monthly initial treatment phase costs ($11,496 per patient) were higher 
than costs during the secondary treatment phase ($3,733) or terminal care phase 
($9,399).29  Over the course of the 2-year study period, patients had total costs of 
$120,650, compared with $45,953 for those receiving initial treatment only.29  Strategies 
for increased prevention, reduced hospitalizations, and reduced treatment failure are 
much needed, which may help reduce both resource use and healthcare costs. 
 
Evidence Based Lung Cancer Care 
Significant improvements have been made during the past decade in treatment and 
survival after the diagnosis of cancer.30  Substantial disparities still exist in both cancer 
outcomes and the receipt of guideline-based cancer-related health care.31  Lack of 
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timely and high quality cancer care is still a concern,32;33 reflecting the extensively 
documented similar concern about the quality of US health care in general.34;35  In 1999, 
the National Cancer Policy Board of the Institute of Medicine (IOM) released a report 
entitled, “Ensuring Quality Cancer Care”, stating that many cancer patients might not be 
receiving the most effective care for their conditions.32  This might be attributable to 
variations in the use of appropriate standards of care and the resulting treatment 
variations.32
 
Appropriateness of care 
To ensure uniformity of care, clinical guidelines, or statements of evidence for the 
management and treatment of lung cancer, have been issued by the American College 
of Chest Physicians (ACCP), the American Society for Clinical Oncology (ASCO), the 
National Cancer Institute (NCI), and others.36-40  Clinical practice guidelines are defined 
as “systematically developed statements to assist practitioner and patient decisions 
about appropriate health care for specific clinical circumstances.”41  They are thought to 
be capable of improving quality, appropriateness, and cost-effectiveness of care.41
   
Timeliness of care 
Timeliness of care is another important dimension of cancer care quality. As, lung 
cancer care requires complex coordination of services by different health care 
professionals, the traditional approach of referring patients for consultation with multiple 
specialists in a sequential fashion often results in care that is perceived as slow and 
poorly coordinated.  More diagnostic and treatment options are now available in the 
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outpatient settings resulting in fewer inpatient hospital stays.42 Clinical opinion-based 
guidelines have been published by the British Thoracic Society (BTS), the RAND 
Corporation, and the ACCP to establish standards for timely care for lung cancer 
patients.43-45
 
Preventive care 
Clinical practice guidelines for preventive care in lung cancer have been published by 
ASCO, authors Biesalski et al, Cancer Guidance Group (CGG), College des Medecins 
du Quebec, National Cancer Institute (NCI), US Department of Health and Human 
Services (DHHS), and US Preventive Services Task Force.46-51  Smoking cessation is 
strongly encouraged among lung cancer patients in these guidelines, as it may reduce 
the rate of development of metachronous tumors.  Continued smoking is also known to 
interfere with cancer treatment. 
 
Disparities in Lung Cancer Care and Health Outcomes 
Despite the availability of clinical practice guidelines, numerous studies of clinical 
practice patterns in US have documented variations in the management of lung cancer 
patients according to age, race or ethnicity, education, comorbidity, insurance and 
hospital type.52-58  Most of these studies include the elderly population aged 65 years 
and older.52-54;56;58  In their analysis of Surveillance, Epidemiology, and End Results 
(SEER)-Medicare linked dataset, Bach and colleagues (1999)56 reported that lower 
survival rates among black patients with early-stage NSCLC, as compared to white 
patients is largely explained by lower rates of surgical treatment among blacks.  
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Similarly, likelihood of undergoing surgical resection was also found lower among dually 
(Medicare-Medicaid) eligible patients with NSCLC compared to Medicare eligible 
patients.52  Wide variation in the utilization of palliative chemotherapy also exists among 
SEER-Medicare patients diagnosed with stage IV NSCLC.55  While overall use of 
recommended therapies for NSCLC is low in the elderly, large variations exist in the use 
of therapies according to age, race and ethnicity, and marital status.53
Extensive studies in European Union member countries have found delays in 
diagnosis and treatment of lung cancer than recommended in clinical opinion based 
guidelines.59-73  Five studies performed in the US have show mixed results.74-78  This 
included one large study from Hawaii,76 one small study from Massachusetts78 and 
three small studies conducted in Veterans Affairs (VA) facilities.74;75;77  In one of these 
studies, Dransfield and colleagues (2006)75 found median time to resection among 
NSCLC patients (104 days) exceed the 56-day maximum recommended by BTS.  In 
contrast, Riedel and colleagues (2006)74  found less than expected median time to 
treatment initiation (22 days), while evaluating the benefits of multidisciplinary thoracic 
oncology clinics in a VA setting.  In the study from Massachusetts, no differences in 
time to treatment were observed between Asian immigrants compared to non-Asians.78  
Multidisciplinary clinics have been recommended in the literature to improve timeliness 
of care.45  However in the US, patient care coordination through a dedicated lung mass 
clinic or a multidisciplinary clinic has not shown any reduction in delays with either 
approach.74;75  Even with timely care, Quarterman and colleagues (2003)77 found no 
benefits in survival, making it unclear whether more timely care improves health 
outcomes.  Delay in treatment also did not explain the observed higher mortality risk 
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from NSCLC in the only large population based study from Hawaii.76  While no US study 
has identified the predictors of timely care, studies in other countries have found 
atypical symptoms, comorbid conditions, teaching hospital setting, receipt of curative 
(versus palliative) radiotherapy, initial referral to a non-respiratory physician, 
requirement for multiple diagnostic tests, and care received at more than one health 
care facility, to be associated with less timely care.63;66;79-82  Household income,66;80 
gender,80 hospital volume,80 rural residence80 and distance travelled to obtain care66 
were not associated with timeliness in these studies.  Mixed results were observed in 
studies that examined effect of age on timeliness of care.63;79-81
Given the fact that smoking is common in patients with lung cancer, there is a 
profound impact of preventive care services such as smoking cessation counseling.  
Gritz and colleagues studied smoking behavior in 840 adults with stage I NSCLC who 
had participated in clinical trials.83  They found that at the time of diagnosis, of the 60% 
of the patients who were smokers only 40% had quit smoking after 2 years.83  
Richardson et al found that the relative risk of developing a second lung cancer 
following curative-intent therapy for SCLC was lower for those who had stopped 
smoking.84  Tucker and colleagues found that continuing to smoke increased the risk of 
metachronous lung cancers in SCLC survivors.85
 
Geographic Variation 
A significant reduction in lung cancer mortality can be achieved if patients receive timely 
and medically effective therapies.  Unfortunately, many rural areas of the US are 
economically underdeveloped and medically underserved.86;87  The patients in these 
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regions carry a higher burden of lung cancer compared to their urban counterparts.88  
These rural areas are also known to report a higher prevalence of lung cancer and a 
higher crude all-cause mortality rate.89  One such area is the Appalachian region, a 
population representing 8.1% of the total US population.90;91  Forty-two percent of the 
Appalachian population live in rural areas, compared to 20% of the national 
population.91  The lung cancer death rate in rural Appalachia is higher than all of 
Appalachia, and it is significantly higher than the national lung cancer death rate.90  The 
observed lung cancer disparities in this rural population can be attributed to limited 
access to quality medical care facilities, less access to or utilization of early cancer 
detection programs, increased prevalence of behavioral risk factors like tobacco use 
and sedentary life style, obesity, radon exposure, and socioeconomic factors, such as 
low income and education.92-98 In addition to being medically underserved, this rural 
population also experiences variations in the quality, availability, and accessibility of 
services when compared to their urban counterparts.99
West Virginia is the only state situated entirely within the Appalachian region and 
is the third most rural state in the nation.  Fifty of the 55 counties in the state are 
designated as medically underserved areas, and all or part of 40 counties in the state 
are classified as health professional shortage areas.100  During 2002-2006, the age-
adjusted lung cancer incidence rate (WV: 481.5 per 100,000, US: 378.5 per 100,000), 
and mortality rate (WV: 390.6 per 100,000, US: 310.8 per 100,000) among the elderly 
were higher in the state in comparison to the rest of the country.101;102
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Study Need 
I.  Need to compare the appropriateness of lung cancer care and associated health 
outcomes among elderly in West Virginia and in the United States  
While numerous studies have examined lung cancer treatment variations in the US, 
comprehensive evaluation of variations in clinical guideline based lung cancer care and 
its impact on health outcomes in the elderly, remains unknown.  Furthermore, a majority 
of studies completed to-date have been conducted using the SEER-Medicare data, a 
dataset that represents only 17 cancer registries and states/regions, and which reflects 
a population that is more likely to reside in urban settings.103  Limited information is 
currently available with respect to the variation in cancer care among elderly diagnosed 
with lung cancer from rural settings and from non-SEER states.  Population-based 
cancer research aimed at identifying such variation in cancer care and improving cancer 
outcomes in the rural and medically underserved elderly population is much needed.  
Such studies would also help to explain the observed geographic disparities in lung 
cancer mortality among elderly.   
Chapter 2 in this study assesses the appropriateness of lung cancer care and 
associated health outcomes among elderly Medicare Fee-for-service (FFS) 
beneficiaries in WV, and in a representative US population.  Appropriateness of care 
was determined using the comprehensive ACCP clinical practice guidelines for lung 
cancer care.37  West Virginia is representative of Appalachia and is similar to many 
other rural and medically underserved states.  It therefore serves as an excellent 
laboratory for studying and addressing lung cancer disparities in a rural and medically 
underserved elderly population.  As lung cancer is most common in the elderly, 
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Medicare administrative claims data were used to determine health service utilization.  
Medicare is the federally funded program that provides health insurance for more than 
47 million people, including nearly all persons age 65 years and older.  Cancer registry 
data were also used to identify disease characteristics of lung cancer patients.  This 
chapter provides a thorough evaluation of appropriateness of lung cancer care and its 
impact on health outcomes among the elderly in the WV and US populations.  
Specifically the objectives of this study include: (1) to compare treatment patterns 
among elderly with lung cancer in the WV-US populations; (2) to compare the 
proportion of elderly receiving minimally appropriate clinical guideline based lung cancer 
care in the WV-US populations; (3) to compare the factors associated with receipt of 
minimally appropriate clinical guideline based lung cancer care in the WV-US elderly 
populations; (4) to compare the survival benefits associated with receipt of minimally 
appropriate clinical guideline based lung cancer care in the WV-US elderly populations; 
and (5) to compare lung cancer mortality risk associated with non-receipt of minimally 
appropriate clinical guideline based lung cancer care, in the WV-US elderly populations. 
  
II.  Need to compare the timeliness of lung cancer care and associated health 
outcomes among elderly in West Virginia and in the United States 
Improving timeliness of lung cancer care is important, regardless of its effect on heath 
outcomes.  Although prior studies have provided useful information concerning the 
timeliness of care in lung cancer patients, a majority of them have been conduced on 
European Union member countries.  This limits the conclusion that one can make about 
lung cancer care in non-European Union healthcare settings.  Studies performed in the 
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US are also limited by small sample sizes, with the exception of the study from Hawaii 
that included more that 1000 patients.  As lung cancer is most often diagnosed among 
the elderly, studies that describe timeliness of care in the US elderly population are 
required.  Furthermore, given that many rural areas of the US are economically 
underdeveloped and medically underserved, studies that compare the timeliness of lung 
cancer care in such states within the US are required.  Such studies would also help to 
explain the observed geographic disparities in lung cancer mortality among elderly. 
Chapter 3 assesses the timeliness of lung cancer care and associated health 
outcomes among elderly Medicare FFS beneficiaries in WV, and in a representative US 
population.  Timeliness of care was determined using the BTS, and the RAND 
Corporation clinical opinion-based guidelines for lung cancer care.44;45  West Virginia 
was again chosen as a representative of other rural and medically underserved states.  
Medicare administrative claims data and cancer registry data were used to identify 
timeliness of lung cancer care in elderly patients.  This chapter provides a thorough 
evaluation of timeliness of lung cancer care and its impact on health outcomes among 
elderly in the WV and US populations.  Specifically, the objectives of this study include: 
(1) to compare delays in diagnosis and treatment among elderly with lung cancer in the 
WV-US populations; (2) to compare the proportion of elderly receiving timely lung 
cancer care based on clinical opinion-based guidelines in the WV-US populations; (3) to 
compare the factors associated with receipt of timely lung cancer care based on clinical 
opinion-based guidelines in the WV-US elderly populations; (4) to compare survival 
outcomes by receipt of timely lung cancer care based on clinical opinion-based 
guidelines in the WV-US elderly populations; and (5) to compare lung cancer mortality 
 16
risk associated with non-receipt of timely lung cancer care based on clinical opinion-
based guidelines in the WV-US elderly populations. 
 
III.  Need to assess patterns of receipt of tobacco-use cessation counseling services 
and the impact on health outcomes among elderly lung cancer patients with a 
history of tobacco use in West Virginia 
Continued smoking following lung cancer diagnosis can interfere with cancer therapies, 
such as radiation therapy and chemotherapy; increase risk of infection due to surgery 
and decrease post-operative wound healing; and, increase the rate of development of 
metachronous tumors.  Promoting smoking cessation following lung cancer diagnosis is 
much needed.  Many insurance programs including Medicare, cover tobacco-use 
cessation counseling services to promote smoking cessation.  Still a majority of patients 
continue to use tobacco following lung cancer diagnosis.  Studies that identify patterns 
of receipt of tobacco-use cessation counseling service and the impact on health 
outcomes among elderly lung cancer patients are needed. 
Chapter 4 in this study determines the patterns of receipt of tobacco-use 
cessation counseling services and the impact on health outcomes among elderly 
Medicare FFS beneficiaries with lung cancer and a history of tobacco use in WV.  West 
Virginia was again chosen for this study, as it has the highest smoking prevalence rate 
(26.8%) in the nation.104  Lung cancer incidence and mortality rates in WV are also 
higher than the US, and these rates are parallel to smoking prevalence rates within the 
state.101;102  Therefore, West Virginia serves as an excellent laboratory for studying the 
patterns of receipt of tobacco-use cessation counseling services and the impact on 
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health outcomes among elderly lung cancer patients with a history of tobacco use.  
Medicare administrative claims data and cancer registry data were used to identify 
receipt of tobacco-use cessation counseling services.  Specifically, the objectives of this 
study include: (1) to determine the proportion of elderly lung cancer patients receiving 
tobacco-use cessation counseling services; (2) to determine the factors associated with 
receipt of tobacco-use cessation counseling services among elderly lung cancer 
patients; (3) to determine survival benefits associated with receipt of tobacco-use 
cessation counseling services among elderly lung cancer patients; and (4) to determine 
lung cancer mortality risk associated with non-receipt of tobacco-use cessation 
counseling services among elderly lung cancer patients. 
 
Significance of the study 
This study aims to provide in-depth information concerning patterns of lung cancer care 
and associated health outcomes among elderly Medicare FFS beneficiaries in the WV 
and US populations.  First, appropriateness of lung cancer care is determined among 
elderly in the WV and US populations using ACCP evidence-based guidelines for 
diagnosis and management of lung cancer.  These data enable us to understand the 
variation in receipt of minimal appropriate lung cancer care among the elderly.  It also 
helps us understand the impact of receipt of minimal appropriate care on health 
outcomes.  Second, the study identifies the delays in lung cancer care and the 
proportion of elderly that do receive timely lung cancer care based on BTS and RAND 
Corporation clinical opinion-based guidelines.  It also helps us to understand the impact 
of delayed care on health outcomes.  Finally, the study determines the patterns of 
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receipt of tobacco-use cessation counseling service among elderly lung cancer patients 
with a history of tobacco use in WV.  Overall, this study will help to fill critical gaps in 
clinical guidelines based lung cancer care and outcomes literature.  Furthermore, the 
results from this study will help to explain the observed geographic disparities in lung 
cancer mortality among elderly in the WV and US populations. 
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CHAPTER 2: 
APPROPRIATENESS OF LUNG CANCER CARE AND ASSOCIATED HEALTH 
OUTCOMES AMONG ELDERLY MEDICARE FEE-FOR-SERVICE BENEFICIARIES IN 
WEST VIRGINIA AND IN THE UNITED STATES 
 
Introduction 
In the United States (US), lung cancer is the leading cause of cancer deaths in both 
men and women.1;2  It causes more deaths than the next three most common cancers 
combined (colon, breast, and prostate).1-3  The elderly carry a disproportionate burden 
of lung cancer, since approximately 81% of those living with lung cancer are 60 years of 
age or older.2  This pattern is expected to persist as the estimated number of elderly in 
the U.S. doubles to nearly 70 million by 2030. 
Although lung cancer in the elderly is associated with a poor prognosis, several 
treatment strategies can cure, or at least prolong survival.  These treatment options 
primarily depend on the type of lung cancer and the stage at diagnosis.  Non-small cell 
lung cancer (NSCLC) is the most common type of lung cancer, and it makes up about 
80% of all lung cancer cases.4  The treatment options for early stage NSCLC (Stages I-
III), include surgery, chemotherapy, radiation, or its combination.5  Five year survival 
rates of approximately 40% are anticipated with standard surgical resection.6  
Treatment options for individuals with advanced stage NSCLC (Stage IV) are limited 
and include chemotherapy, radiation therapy, or its combination for palliation of 
symptoms.5  The median survival times are typically 6 to 10 months and most 
individuals die within 1 to 2 years of diagnosis.6  Compared to NSCLC, small cell lung 
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cancer (SCLC) grows and spreads more quickly, and without treatment has the most 
aggressive clinical course with median survival time from diagnosis of only 2 to 4 
months.7;8  Approximately 30% of individuals with SCLC present with limited-stage 
disease (Stages I-III) and their treatment options include chemotherapy and radiation 
therapy.8  Median survival time of 16 to 24 months and 5-year survivals of 14% with 
current forms of treatment have been reported in this group.8  However, in individuals 
with extensive-stage SCLC (Stage IV), median survival time of only 6 to 12 months has 
been reported.8
A significant reduction in lung cancer mortality can be achieved if the elderly 
receive timely and medically effective therapies.  To that end, specific strategies for the 
management and treatment of lung cancer have been recommended in clinical 
guidelines by the American College of Chest Physicians (ACCP), the American Society 
for Clinical Oncology (ASCO), the National Cancer Institute (NCI), and others.9-13  
These clinical guidelines ensure uniformity of care, and are thought to be capable of 
improving quality, appropriateness, and cost-effectiveness of care.14  However, 
numerous studies of clinical practice patterns in the US have documented variations in 
the management of individuals with lung cancer according to age, race or ethnicity, 
education, comorbidity, insurance and hospital type.15-21  In one study, lower rates of 
surgical treatment among elderly black individuals with early-stage NSCLC, as 
compared to white individuals, largely explained the survival difference by race.19  In 
another study, the likelihood of undergoing surgical resection among elderly with 
NSCLC was found to be lower among dually (Medicare-Medicaid) eligible individuals 
compared to Medicare eligible individuals.15  Besides treatment with curative intent, 
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wide variation in the utilization of palliative chemotherapy also exists among individuals 
diagnosed with stage IV NSCLC.18  Lack of high quality cancer care remains a concern, 
and it is attributable to variations in the use of appropriate standards of care.22-24
While variations in lung cancer management and outcomes exist across the 
nation, it is a cause for major concern in the rural areas.  Many rural areas of the US are 
economically underdeveloped and medically underserved.25;26  The elderly in these 
regions carry a higher burden of lung cancer compared to their urban counterparts.27  
These rural areas are also known to report a higher prevalence of lung cancer and a 
higher crude all-cause mortality rate among the elderly.28;29  One such area is the 
Appalachian region, a population representing 8.1% of the total US population.29  West 
Virginia (WV) is the only state situated entirely within the Appalachian region and is the 
third most rural state in the nation.29  Fifty of the 55 counties in the state are designated 
as medically underserved areas, and all or part of 40 counties in the state are classified 
as health professional shortage areas.30  During 2002-2006, the age-adjusted lung 
cancer incidence rate (WV: 481.5 per 100,000, US: 378.5 per 100,000), and mortality 
rate (WV: 390.6 per 100,000, US: 310.8 per 100,000) among the elderly were higher in 
the state in comparison to rest of the country.31;32  Interestingly, the proportional 
difference in age-adjusted lung cancer mortality rates among the elderly from WV and 
the US was lower than the difference in age-adjusted lung cancer incidence rates.  This 
might suggest better survival outcomes among elderly lung cancer patients in WV as 
compared to the US; however, such a hypothesis remains unexplored.  The observed 
lung cancer disparities in the rural population can be attributed to limited access to 
quality medical care facilities; less access to, or utilization, of early cancer detection 
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programs; increased prevalence of behavioral risk factors, such as tobacco use and 
sedentary life style, and socioeconomic factors, such as low income and education.33-39  
In addition to being medically underserved, the rural population may also experience 
variations in the quality, availability, and accessibility of services when compared to 
urban counterparts.40   
While numerous studies have examined lung cancer treatment variations in the 
US, comprehensive evaluation of variations in clinical guideline based lung cancer care, 
and its impact on health outcomes in the elderly remains unknown.  Furthermore, 
comparison of geographical variations in clinical guideline based lung cancer care and 
associated health outcomes among the elderly from a diverse region like WV with those 
in the US is much needed.  Such studies would help to explain the observed regional 
disparities in lung cancer mortality among the elderly.  To this end, the main focus of 
this study is to investigate and compare the appropriateness of lung cancer care based 
on clinical guidelines among the elderly in WV, and in a representative US population.  
Specifically the objectives of this study include: (1) to compare treatment patterns 
among elderly with lung cancer in the WV-US populations; (2) to compare the 
proportion of elderly receiving minimally appropriate clinical guideline based lung cancer 
care in the WV-US populations; (3) to compare the factors associated with receipt of 
minimally appropriate clinical guideline based lung cancer care in the WV-US elderly 
populations; (4) to compare the survival benefits associated with receipt of minimally 
appropriate clinical guideline based lung cancer care in the WV-US elderly populations; 
and (5) to compare lung cancer mortality risk associated with non-receipt of minimally 
appropriate clinical guideline based lung cancer care, in the WV-US elderly populations. 
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Methods 
 
Data sources 
This retrospective study was conducted using cancer registry linked Medicare data files 
for the years 2002 through 2007.  Cancer registry data files provided clinical, 
demographic, cause of death, and initial treatment information for elderly individuals 
with lung cancer in selected geographic regions.  The Medicare administrative data files 
provided the health service claims information for care provided by physicians, inpatient 
hospital stays, hospital outpatient clinics, home health care agencies, skilled nursing 
facilities, and hospice programs.   
Specifically, the Surveillance, Epidemiology, and End Results (SEER) - Medicare 
linked data files were purchased from the National Cancer Institute, and were used to 
estimate the appropriateness of lung cancer care based on clinical guidelines in the 
elderly US population.  Data from the SEER program are representative of US cancer 
incidence and mortality, as they contain information from 20 population-based cancer 
registries covering approximately 28 percent of the US population.41
To estimate the appropriateness of lung cancer care based on clinical guidelines 
in the elderly WV population, we used West Virginia Cancer Registry (WVCR) - 
Medicare linked data files.  The WVCR-Medicare linked data files are similar in structure 
to the SEER-Medicare linked data files, and represent data from the West Virginia 
Cancer Registry, which does not participate in the SEER program.  Details on the 
creation of WVCR-Medicare linked data files can be found elsewhere.42
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Study populations 
We initially identified all Medicare Fee-for-service (FFS) beneficiaries aged 66 years 
and older, with incident lung cancer (Stages I-IV) diagnosis, between July 1, 2003 and 
December 31, 2006, from the SEER-Medicare linked data files (hereafter referred to as 
‘US population’), and the WVCR-Medicare linked data files (hereafter referred to as ‘WV 
population’), separately.  Lung cancer diagnosis was identified among individuals in the 
cancer registry files using the International Classification of Diseases for Oncology 
(ICD-O) codes (C34.0, C34.1, C34.2, C34.3, C34.8, C34.9, and C33.9).  Lung cancer 
stage was identified using American Joint Committee on Cancer (AJCC), Tumor Node 
Metastasis (TNM), 3rd edition stage (for 2003 diagnosis) and 6th edition stage (for 2004-
2006 diagnosis).43;44  While Medicare eligibility starts at age 65, we only included 
beneficiaries aged 66 years and older at the time of diagnosis, so that we would have a 
full year of Medicare claims before lung cancer diagnosis for assessing comorbidity.  
We then excluded individuals with multiple primary cancer diagnosis or whose diagnosis 
was made only at the time of death (death certificate review/autopsy diagnosis).  We 
also excluded beneficiaries who were enrolled in a Medicare managed care plan or who 
had non-continuous Medicare Part A and Part B enrollment, in the year prior to 
diagnosis, and during the year following diagnosis.  This is because their Medicare files 
would not have complete treatment information.  The remaining cohorts of continuously 
enrolled elderly Medicare FFS beneficiaries in WV and the US population (study 
cohorts) were then used to compare treatment patterns, to compare the proportion of 
beneficiaries receiving minimally appropriate clinical guideline based lung cancer care, 
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and to compare the factors associated with receipt of minimally appropriate clinical 
guideline based lung cancer care. 
Given the limited years of data available for follow up in our data sources, we 
further subset the above study cohorts for survival analysis.  Specifically, from the study 
cohorts we selected beneficiaries with lung cancer diagnosis between July 1, 2003 and 
December 31, 2004, and then followed them for three years following the incident lung 
cancer diagnosis to determine lung cancer specific mortality.  These subsets of study 
cohorts in WV and the US population were then used to compare survival benefits 
associated with receipt of minimally appropriate clinical guideline based lung cancer 
care, and to compare lung cancer mortality risk associated with non-receipt of minimally 
appropriate clinical guideline based lung cancer care. 
 
Assessing receipt of clinical guideline based lung cancer care 
Continuously enrolled elderly Medicare FFS beneficiaries in WV and in the US 
population were followed for one year after an incident lung cancer diagnosis to 
determine receipt of minimally appropriate clinical guideline based lung cancer care 
(hereafter referred to as ‘minimally appropriate care’).  Minimally appropriate care was 
defined using the ACCP evidence-based guidelines for diagnosis and management of 
lung cancer, published in January, 2003.10  We choose ACCP evidence-based 
guidelines, as they are the most comprehensive of all published clinical guidelines.9-13  
Figure 2.1 shows the algorithm adapted from the ACCP guidelines, and used to 
determine receipt of minimally appropriate care.  Lung cancer specific treatments and 
procedures were identified from the Medicare claim data files using appropriate 
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International Classification of Diseases (ICD-9) diagnosis and procedure codes, 
Healthcare Common Procedure Coding System (HCPCS) codes, Current Procedural 
Terminology (CPT) codes and revenue center codes (Appendix 1).  Considering the 
poor quality of life following curative treatment among some individuals with stage IV 
lung cancer, clinical guidelines recommend ‘no curative treatment’ for such individuals, 
except for palliation of symptoms.  We therefore excluded beneficiaries with stage IV 
lung cancer from our analysis, except for separately reporting the proportion of 
beneficiaries receiving minimally appropriate care with curative intent. 
 
Dependent variables 
The primary outcome of interest was receipt of minimally appropriate clinical guideline 
based lung cancer care, which was categorized as (a) minimally appropriate care or (b) 
inappropriate care.  Treatment patterns were categorized as ‘surgery only’, ‘radiation 
only’, ‘chemotherapy only’, ‘combination treatment’, or ‘no treatment’.  Combination 
treatment included any combination of surgery, radiation, and chemotherapy.  Survival 
time in days was calculated for each beneficiary from the time of incident lung cancer 
diagnosis to date of death or the three year follow-up cutoff date, which ever came first.  
To estimate lung cancer specific survival, beneficiaries who were not found to be 
deceased by the cutoff date, or who died due to causes other than lung cancer were 
censored at that time and considered to be alive.  We measured lung cancer specific 
survival instead of overall survival, as we wanted to determine the association between 
minimally appropriate clinical guideline based lung cancer care and survival. 
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While exact date of lung cancer diagnosis was available in the WVCR-Medicare 
linked data files to calculate survival time, the SEER-Medicare linked data files only 
contained the month and year of diagnosis.  Hence to approximate the date of lung 
cancer diagnosis in the US population, we used the earliest Medicare claim date, which 
had a lung cancer diagnosis code, and which was in the month of lung cancer 
diagnosis.  This approximation is appropriate given the high level of agreement (nearly 
90%) within one month of diagnosis between the SEER diagnosis date and the first 
Medicare claim date with a cancer diagnosis.45  In cases where beneficiaries had no 
Medicare claims with a lung cancer diagnosis code, earliest date from any claim in the 
month of cancer diagnosis was used as the date of diagnosis.  Finally, among 
beneficiaries with no Medicare claim in the month of diagnosis, the date of diagnosis 
was approximated as the 15th day of the diagnosis month.  Date of death was identified 
from Medicare enrollment records. 
 
Independent variables 
The main independent variables were lung cancer type and stage, age at diagnosis, 
gender, race, urban-rural residence, Charlson comorbidity index score, and census tract 
level measures of education and income.  These variables were considered in our 
analysis because of their prognostic significance.  Lung cancer type was categorized 
based on cell histology.  Beneficiaries with ICD-O histology codes 8000-8040 or 8046-
9989 were categorized as NSCLC, and those with codes 8041-8045 were categorized 
as SCLC.  Lung cancer stage was categorized based on AJCC TNM staging 
system.43;44  Age at diagnosis was categorized as 66-69 years, 70-74 years, 75-79 
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years, and 80 years and older.  Given that WV population is predominantly White, race 
was classified as White and others.  Based on Rural-Urban Continuum codes 
developed by the US Department of Agriculture (USDA), urban-rural residence was 
categorized as Metro, Urban, or Rural.  Charlson comorbidity index score was 
calculated using diagnosis and procedure codes reported in Medicare inpatient claims 
from the year prior to incident lung cancer diagnosis.46-48  Comorbidities related to 
cancer were excluded from the index score.  The Charlson comorbidity index score was 
used to categorize comorbidity into three groups: 0, 1 and 2 or more, with a higher 
score indicating a greater burden of comorbid illness.   
Given the lack of individual socioeconomic status measures in our data sources, 
we used as proxy, the year 2000 US Census tract level measures of college education 
and income.49  Specifically, we used the percentage of individuals in the census tract 
with some college education as a proxy measure for education, and categorized it 
based on tercile distribution (using WV population) as 0%-0.10%, 0.11%-0.20%, and 
0.21% or greater.  Similarly, we used median household income at the census tract 
level as a proxy measure of income, and categorized it based on tertile distribution 
(using WV population) as $0-25,000, $25,000-50,000, and $50,001 or more.   
 
Data Analysis 
The Pearson chi-square test was used to determine unadjusted associations between 
categorical variables of interest.  Three hierarchical generalized logistic models were 
constructed with PROC GLIMMIX procedure in SAS 9.2 50 to assess the association 
between independent variables and the receipt of minimally appropriate care.  In each 
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model, the estimated probability of a beneficiary receiving minimally appropriate care 
conditioned on a set of predictor variables was modeled.  First and second models 
included beneficiaries from the WV and US populations, respectively.  The third model 
was constructed to determine population variation in likelihood of beneficiaries receiving 
minimally appropriate care, and therefore included beneficiaries from both populations 
combined.  The hierarchical model was chosen, as individual measures of 
socioeconomic status were not available in our data sources, and we relied on census 
tract level measures of education and income.  This was done by treating census tract 
as a random effect to account for potential correlation among beneficiaries within the 
same county.  Odds ratios, 95% confidence intervals, and two-sided p-values were 
calculated for each predictor. 
Non-parametric estimates of the survivor function, by receipt of minimally 
appropriate care, were calculated for each population using the Kaplan-Meier method.  
The log-rank test was used to assess the statistical significance of the differences 
between the survival curves.  Three-year survival estimates were also computed by 
receipt of minimally appropriate care within each population.  Stratified analysis was 
performed by lung cancer type and stage within each population. 
Three multivariate Cox proportional hazards models were constructed to 
estimate lung cancer mortality risk associated with non-receipt of minimally appropriate 
care.  First and second model included beneficiaries from the WV and US populations, 
respectively.  The third model was constructed to determine population variation in lung 
cancer mortality risk, and therefore included beneficiaries from both populations 
combined.  To evaluate the proportional hazards assumption, we plotted smoothed 
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Schoenfeld residuals against time and found no evidence of a systematic deviation from 
proportional hazards in any model.  Variance in all Cox models were adjusted to 
account for patient clustering at the census tract level by use of the robust inference of 
Lin and Wei.51  Adjusted hazard ratios, 95% confidence intervals and their two-sided p-
values were calculated for each predictor. 
All data were analyzed using the SAS Version 9.2 (SAS Institute, Cary, NC) 
statistical software package.50  Results were considered to be statistically significant 
when p ≤ 0.05.  The study was approved by the West Virginia Institutional Review 
Board, and is in full compliance with federal, state, and institutional regulations and 
guidelines. 
 
 
Results 
 
Study population characteristics 
Based on study inclusion and exclusion criteria, we identified 1,689 beneficiaries in WV 
population, and 42,323 beneficiaries in the US population.  Table 2.1 shows the 
distribution of clinical and sociodemographic characteristics of these beneficiaries by 
type of lung cancer.  Compared to beneficiaries with NSCLC in the US population, 
beneficiaries with NSCLC in WV population were younger, male, white, resided in non-
metro areas, had higher comorbidity score, and were diagnosed at earlier stages (p ≤ 
0.05).  Similarly, compared to beneficiaries with SCLC in the US population, 
beneficiaries with SCLC in WV population were of white race, resided in non-metro 
areas, and were diagnosed at earlier stages (p ≤ 0.05).  In both populations, 
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beneficiaries with SCLC were diagnosed at late stages, compared to beneficiaries with 
NSCLC (p ≤ 0.05).  In the US population, compared to beneficiaries with SCLC, 
beneficiaries with NSCLC were older, male, resided in metro areas, and had lower 
comorbidity scores (p ≤ 0.05). 
 
Treatment patterns 
Table 2.2 shows the descriptive characteristics by type of treatment among 
beneficiaries in the WV and US populations.  Overall, proportion of beneficiaries 
receiving no treatment was lower in the WV population, as compared to the US 
population (26.8% vs. 33.4%) (p ≤ 0.05).  Significant population variation in treatment 
patterns were observed by lung cancer type, stage, age, gender, race, urban-rural 
residence, comorbidity score, and by year of diagnosis (p ≤ 0.05).  The proportion of 
beneficiaries receiving treatment as ‘surgery alone’, ‘radiation alone’, or ‘combination 
treatment’ was higher in WV population, compared to the US population (p ≤ 0.05).  
However, proportion of beneficiaries receiving treatment as ‘chemotherapy alone’ was 
lower in the WV population, compared to the US population (p ≤ 0.05).  In both 
populations, the proportion of beneficiaries receiving treatment as ‘surgery alone’ or 
‘radiation alone’ was higher among beneficiaries with NSCLC, compared to 
beneficiaries with SCLC (p ≤ 0.05).  Similarly, the proportion of beneficiaries receiving 
treatment as ‘surgery alone’ was also higher among those with early stage disease, 
compared to those with late stage disease in both populations (p ≤ 0.05).  Within the 
two populations, variations in treatment patterns were also observed by age, gender, 
urban-rural residence, and comorbidity score (p ≤ 0.05).  Significant variation in 
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treatment patterns by race and by year of diagnosis were only observed among 
beneficiaries in the US population (p ≤ 0.05). 
 
Receipt of minimally appropriate care 
Table 2.3 shows the descriptive characteristics of beneficiaries by receipt of minimally 
appropriate care in the WV and US populations.  Overall, the proportion of beneficiaries 
receiving minimally appropriate care was 46.5% in WV population, and 44.7% in the US 
population.  However, this population variation in overall receipt of minimally appropriate 
care was not significant.  Significant population variations in receipt of minimally 
appropriate care were observed only among female beneficiaries.  Specifically, the 
proportion of female beneficiaries receiving minimally appropriate care was higher in 
WV population as compared to the US population (51.2% vs. 44.8%) (p ≤ 0.05).  Within 
the WV population, receipt of minimally appropriate care was also higher among female 
beneficiaries as compared to male beneficiaries (p ≤ 0.05).  In both populations, 
compared to beneficiaries receiving inappropriate care, beneficiaries receiving minimally 
appropriate care were of young age (p ≤ 0.05).  Variations in receipt of minimally 
appropriate care by race, urban-rural residence, comorbidity score, and year of 
diagnosis were only observed among beneficiaries in the US population (p ≤ 0.05).  
Table 2.4 shows the proportion of beneficiaries receiving minimally appropriate 
care by lung cancer type and stage in the WV and US populations.  The proportion of 
beneficiaries with NSCLC receiving minimally appropriate care was slightly higher in 
WV population, than in the US population (47.2% vs. 44.3%).  However, the proportion 
 43
of beneficiaries with SCLC, receiving minimally appropriate care was lower in the WV 
population, than in the US population (40.0% vs. 48.0%).   
Among beneficiaries with stage IV lung cancer, the overall proportion of 
beneficiaries receiving minimally appropriate care with curative intent was 24.2% in the 
WV population, and 21.6% in the US population.  Among beneficiaries with NSCLC 
(Stage IV), this proportion was 17.8% in WV population and 16.3% in the US 
population.  Similarly, among beneficiaries with SCLC (Stage IV) this proportion was 
47.7% in the WV population and 45.7% in the US population. 
 
Factors associated with receipt of minimally appropriate care 
Controlling for all sociodemographic variables, age remained a strong predictor of 
receipt of minimally appropriate care in all models (Table 2.5).  Compared to 
beneficiaries aged 80 years and older, beneficiaries aged 66 to 69 years were more 
than twice likely to receive minimally appropriate care, and these odds gradually 
decreased with increase in age.  Gender was only significant in model 1 (WV 
population), with males 27% less likely to receive minimally appropriate care as 
compared to females.  Race, comorbidity score, and census tract level measure of 
income, were the other significant predictors of receipt of minimally appropriate care in 
model 2 (US population) and model 3 (Combined population).  Specifically, beneficiaries 
of non-white race were 21% less likely to receive minimally appropriate care as 
compared to whites.  The likelihood of receipt of minimally appropriate care was also 
higher among beneficiaries with low comorbidity score as compared to those with high 
comorbidity score.  Finally, the likelihood of receipt of minimally appropriate care 
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decreased with decrease in median household income.  Census tract level measure of 
education and urban-rural residence were not statistically significant in any model.  After 
controlling for all sociodemographic variables, population variation in likelihood of 
beneficiaries receiving minimally appropriate care was not significant. 
 
Survival benefits associated with receipt of minimally appropriate care 
Figure 2.2 compares the three year Kaplan-Meier survival curves by receipt of minimally 
appropriate care in the WV and US populations.  In both populations, the three year 
survival rates and median survival times were significantly greater for beneficiaries 
receiving minimally appropriate care as compared to beneficiaries receiving 
inappropriate care (p ≤ 0.05).  Specifically, with receipt of minimally appropriate care the 
three year median survival time exceeded by 433 days in WV population, and by 487 
days in the US population (p ≤ 0.05).  Compared to the US population, the median 
survival times by receipt of minimally appropriate care were significantly greater among 
beneficiaries in WV population (p ≤ 0.05).  However, the three year survival rates 
among beneficiaries receiving minimally appropriate care were lower in WV population 
as compared to the US population (p ≤ 0.05).   
 Table 2.6 shows the three year survival rates and median survival times among 
beneficiaries receiving minimally appropriate care by lung cancer type and stage, in the 
WV and US populations.  In WV population, survival benefits associated with receipt of 
minimally appropriate care were significant only among beneficiaries with SCLC (Stages 
I-III) (p ≤ 0.05).  However, in the US population, survival benefits associated with receipt 
of minimally appropriate care were significant for all beneficiaries except for 
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beneficiaries with SCLC (stage I or stage II) (p ≤ 0.05).  Significant population variations 
in survival among beneficiaries receiving either minimally appropriate care or 
inappropriate care were also observed by lung cancer type and stage (p ≤ 0.05).  
 
Lung cancer mortality risk associated with non-receipt of minimally appropriate care  
In all Cox proportional hazards models, the adjusted lung cancer mortality risk was 
significantly higher among beneficiaries not receiving minimally appropriate care, 
relative to those who did receive minimally appropriate care (Table 2.7).  Specifically, 
lung cancer mortality risk among beneficiaries not receiving minimally appropriate care 
increased by 60% in WV population, by 91% in the US population, and by 90% in the 
combined population (p ≤ 0.05).  In all models, NSCLC diagnosis and early stage 
disease were the only other factors independently associated with lower lung cancer 
specific mortality (p ≤ 0.05).  In model 1 (WV population), less education was the only 
other factor significantly associated with higher lung cancer specific mortality (p ≤ 0.05).  
Older age, male sex, White race, higher comorbidity score, and lower income were the 
only other factors significantly associated with higher lung cancer specific mortality in 
model 2 (US population) and model 3 (Combined population).  After controlling for all 
clinical and sociodemographic variables and for appropriateness of care, population 
variation in lung cancer mortality risk was not significant. 
 
Discussion 
Compared to other types of cancer, lung cancer diagnosis in the elderly is usually 
associated with poor prognosis.  This burden is especially higher among elderly residing 
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in rural and medically underserved regions of the US.25-27  Appropriate use of treatment 
options, as recommended in evidence-based clinical guidelines, has the potential to 
cure the disease, or prolong survival in this population.  Prior studies have found 
variation in receipt of recommended lung cancer care according to age, race, 
comorbidity, and hospital type.15-21  However, these studies mainly represented NSCLC 
individuals from non-rural populations.  In this study, using cancer registry linked 
Medicare administrative data files, we compare geographic variations in clinical 
guideline based lung cancer care and associated health outcomes among elderly in a 
representative rural and medically underserved state population, with a representative 
US population. 
Overall, treatment patterns varied significantly among beneficiaries with lung 
cancer in the WV and US populations.  Despite availability of various treatment options 
to treat the disease, many beneficiaries did not receive any treatment in either 
population.  Among those beneficiaries who did receive treatment, other than 
chemotherapy alone, the proportions were higher among beneficiaries in the WV 
population, as compared to the US population.  Similar population variation in treatment 
patterns was also seen by lung cancer type and stage.  These observed population 
variations in treatment patterns may be related to differences in disease severity, 
comorbid illness burden, physician judgment, and/or individual preferences.   
Minimally appropriate care was only received by less than half of all beneficiaries 
in each population.  More female beneficiaries in the WV population received minimally 
appropriate care, as compared to that in the US population.  Controlling for other 
factors, increasing age at diagnosis was associated with a decline in receipt of 
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minimally appropriate care in both populations.  This finding is similar to that reported in 
prior studies, and may be due to physician treatment choice, and/or individual treatment 
preferences.16;17;20;21  Compared to younger individuals, some physicians may be 
conservative in their choice of curative treatment for the elderly given its impact on 
patient morbidity and quality of life.  Gender disparities in receipt of minimally 
appropriate care were observed only in WV population, with males less likely to receive 
minimally appropriate care.  Racial differences in receipt of minimally appropriate care 
were observed only in the US population, with non-white beneficiaries having less 
likelihood of receipt of minimally appropriate care than white beneficiaries.  These racial 
differences are similar to that reported in prior studies.16;19  Similar to results found in 
prior studies, comorbidity was inversely associated with receipt of minimally appropriate 
care in the US population.16  This may be due to less aggressive treatment approach by 
physicians in elderly with higher comorbidities, or due to individual preference to avoid 
aggressive treatments in favor of better quality of life.  Increasing poverty was 
associated with decrease in likelihood of receipt of minimally appropriate care only in 
the US population.  Compared to the US population, the WV population is much poorer, 
and that may explain the non-significance of income on receipt of minimally appropriate 
care among beneficiaries in the WV population.  Urban-rural residence and education 
had no impact on receipt of minimally appropriate care in either population.  After 
controlling for all sociodemographic variables, likelihood of receipt of minimally 
appropriate care among beneficiaries in the WV and US populations were not 
significantly different. 
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Receipt of minimally appropriate care by beneficiaries was associated with longer 
survival times in both populations.  Although beneficiaries receiving minimally 
appropriate care in the WV population had greater median survival times, compared to 
the US population, their three year survival rates were significantly lower.  Survival 
benefits associated with receipt of minimally appropriate care also varied by lung cancer 
type and stage among beneficiaries in both the populations.  In both populations, we 
found the adjusted lung cancer mortality risk significantly higher among beneficiaries not 
receiving minimally appropriate care than those who did receive such care.  However, 
the magnitude of risk associated with non-receipt of minimally appropriate care was 
lower in the WV population, than in the US population.  These findings highlight the fact 
that significant survival benefits can be achieved in beneficiaries, if they receive 
minimally appropriate care.  Early stage disease and NSCLC diagnosis were the only 
other factors independently associated with lower lung cancer mortality risk in both 
populations.  This is true given that the treatment management for beneficiaries is 
easier among those with early stage disease compared to late stage disease, and is 
also easier among those with NSCLC diagnosis compared to SCLC diagnoses.  Lung 
cancer mortality risk varied significantly by census tract measure of education, only in 
the WV population, as risk increased with less education.  Variation in lung cancer 
mortality risk by age, sex, race, comorbidity score, and income were only observed in 
the US population.  After controlling for the variability associated with receipt of 
minimally appropriate care and all sociodemographic variables, lung cancer mortality 
risk was no different among beneficiaries in the WV and US populations. 
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Although treatment patterns varied between the two populations, significant 
population variation in receipt of minimally appropriate care and associated lung cancer 
mortality risk were not observed in this study.  These findings are contrary to what 
would be expected given that the WV population is more rural and medically 
underserved, and has higher lung cancer mortality rates as compared to the US 
population.  The finding suggests that observed geographic differences in lung cancer 
mortality may not be associated with variation in receipt of minimally appropriate care 
among elderly beneficiaries with an incident diagnosis of lung cancer.  Furthermore, 
higher lung cancer incidence in the WV population, as compared to the US population, 
may partly explain the disparities seen in lung cancer mortality among these 
populations.  Future cancer prevention efforts directed towards promoting smoking 
cessation are much needed in the rural WV population, where the smoking prevalence 
rates are the highest in the nation.  In the long run, these cancer prevention efforts can 
help to reduce the incidence of lung cancer in this rural population, which in turn can 
help to reduce the geographic disparities in lung cancer mortality. 
The findings from this study are subject to several limitations.  Although we used 
cancer registry linked claims data, an inherent limitation of using administrative claims 
data for epidemiologic studies is the possibility of misclassification as a result of coding 
errors.52;53  However, claims data have been evaluated for their utility as a source of 
epidemiologic or health services information in cancer patients.52-56  Increasing the use 
of these types of data to assess the quality of cancer care has also been identified as a 
priority by the Institute of Medicine.57  Studies using claims data are usually population 
based and have the potential to address a number of priority questions regarding the 
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quality of cancer care and health care disparities.  These population based studies 
provide valuable information for future planning and prioritization of health programs 
that improve cancer outcomes.  Therefore, there is increasing interest in analyzing large 
health claims databases to assess treatment and outcomes for cancer.52;53;57
The results of this study are generalizable only to the elderly Medicare FFS 
population aged 66 years and older, as encounter data for Medicare recipients enrolled 
in the managed care plan were not available for this study.  There was a small increase 
in percentage of Medicare recipients enrolled in managed care during the study years in 
both populations; in 2007 it was ~16% in WV population and ~19% in the US 
population.58  Information on care received by the Medicare recipients outside of the 
Medicare system, or through non-Medicare providers, was also not available in the 
claims data for our study.  However, Medicare is the largest and most comprehensive 
insurance provider for the elderly in the United States.  Racial disparities in cancer 
outcomes could not be ascertained in this study, as the populations were predominantly 
White. 
One of the inclusion criteria for cohort selection in this study was continuous 
enrollment in Medicare Part A and B during the study period.  This resulted in the non-
inclusion of individuals with non-continuous enrollment and the loss of individuals who 
were enrolled intermittently.  We acknowledge that various clinical guidelines have been 
published for lung cancer diagnosis and management, each with recommendations that 
are more or less the same.9-13  For the purpose of this study, we chose ACCP 
guidelines for lung cancer management and outcomes, as it is the most comprehensive 
of all available guidelines.10  The algorithm we adapted from these guidelines to identify 
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minimally appropriate care takes into account the limitations in our data sources.  
Specifically, information on various lung function test results and lung performance 
scores were not available in our data source, and were not considered in our analysis.  
However, these indicators of lung performance are most crucial only in planning for 
chemotherapy in NSCLC stage IV individuals who we excluded from our analysis.  Our 
estimates of proportion of beneficiaries receiving minimally appropriate care may be 
biased slightly upward as we included patients who received minimally appropriate care 
and additional unproven therapies.  We also acknowledge that our definition of receipt 
of minimally appropriate care may be too narrow, and that given the heterogeneity of 
patients seen by physicians, receipt of no therapy may still be considered as 
appropriate care.  None the less, our definition of receipt of minimally appropriate care 
provides a conceptual framework to assess and compare patterns of care that were 
prevalent during the years 2002 through 2007.  Because of limited data availability at 
the time of study, we were unable to conduct a long-term (5-10 year) follow-up to 
assess the health outcomes associated with receipt of minimally appropriate care.  
Individual-level socioeconomic measures of educational attainment, marital status, and 
family income were also unavailable for this study.  However, aggregate measures of 
socioeconomic status at the census tract level from 2000 decennial census data were 
used as a proxy.  Finally, our definition of minimally appropriate versus inappropriate 
care is limited to the data recorded in the claims such as the presence or absence of 
ICD-9 diagnosis and procedure codes, HCPCS procedure codes, CPT procedure codes 
and revenue center codes.  Future studies can overcome the barriers seen in this study 
by collecting data on physician behaviors and patient preferences on treatment choices. 
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This study is the first of its kind to compare geographic variations in clinical 
guideline based lung cancer care and associated health outcomes among elderly 
Medicare FFS beneficiaries.  Although lung cancer diagnostic and management 
services are covered under the Medicare program, underutilization of these services 
among recipients in the Medicare FFS population is a concern.  Results of this study 
also emphasize the need to address disparities in receipt of minimally appropriate care 
among recipients in the Medicare FFS population.  Reducing observed treatment 
variations according to individual characteristics can help to improve the use of clinical 
guideline based treatments in the elderly and that in turn would improve health 
outcomes.  Furthermore, increased lung cancer risk and incidence among the elderly 
from economically underdeveloped and medically underserved regions, such as WV, 
may be the reason behind observed geographical disparities in lung cancer mortality.  
Promoting smoking cessation among individuals residing in such rural areas has the 
potential to reduce observed geographic disparities in lung cancer mortality. 
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Figure 2.1. Algorithm adapted from American College of Chest Physicians (ACCP) 
evidence-based guidelines for diagnosis and management of lung cancer published in 
January, 2003, and used to determine receipt of minimally appropriate clinical guideline 
based lung cancer care. 
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Figure 2.2. Kaplan-Meier survival estimates with 95% confidence limits by receipt of 
minimally appropriate clinical guideline based lung cancer care among continuously 
enrolled Medicare Fee-for-service beneficiaries with incident diagnosis of lung cancer 
(Stages I-III) in West Virginia and in the United States, July 2003 through December 
2004.  Curves (unadjusted) show cause-specific mortality.  
 
WV = West Virginia population, US = United States population represented by the Surveillance, Epidemiology and End Results 
(SEER) population, CI = confidence interval. 
*  Survival times and rates were obtained from Kaplan-Meier survival estimates. 
Minimally appropriate care determined using American College of Chest Physicians (ACCP) evidence-based guidelines for 
diagnosis and management of lung cancer published in January, 2003. 
Log-rank test (p ≤ 0.05) comparing differences in survival by receipt of minimally appropriate care, among beneficiaries within US 
population.  
Log-rank test (p ≤ 0.05) comparing differences in survival by receipt of minimally appropriate care, among beneficiaries within WV 
population.  
Log-rank test (p ≤ 0.05) comparing population differences in survival among beneficiaries receiving minimally appropriate care.  
Log-rank test (p ≤ 0.05) comparing population differences in survival among beneficiaries receiving inappropriate care. 
Source: West Virginia Cancer Registry - Medicare linked data files, 2002-2007, Surveillance, Epidemiology and End Results - 
Medicare linked data files, 2002-2007. 
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Table 2.1. Descriptive characteristics of continuously enrolled Medicare Fee-for-service 
beneficiaries with incident diagnosis of lung cancer in West Virginia and in the United 
States, July 2003 through December 2006. 
  Proportion (%) 
 NSCLC  SCLC Characteristics 
 WV  US  WV   US 
          
Overall, n (%) 
 
1,444    
(85.5)  
36,417  
(86.0)  
245       
(14.5)  
5,906     
(14.0) 
          
AJCC TNM stage * # + ^         
 I  26.9  20.6  6.9  5.1 
 II  9.8  4.7  4.5  2.2 
 III  23.3  28.4  25.3  29.8 
 IV  40.0  46.2  63.3  62.9 
          
Age (years) * ^         
 66-69  23.0  19.2  24.9  24.0 
 70-74  29.4  25.8  30.6  28.8 
 75-79  26.0  25.9  23.7  26.2 
 80 or more  21.5  29.1  20.8  21.0 
          
Gender * ^         
 Male  58.2  51.9  51.8  47.4 
 Female  41.8  48.1  48.2  52.6 
          
Race * # ^         
 Other  2.2  13.3  0.8  9.2 
 White  97.8  86.7  99.2  90.8 
          
Urban-rural residence * # ^         
 Metro  54.8  83.1  60.0  80.2 
 Urban  39.5  14.9  32.2  17.2 
 Rural  5.6  2.0  7.8  2.6 
          
Comorbidity, Charlson score * ^         
 0  26.5  31.7  30.2  29.7 
 1  29.9  28.5  29.4  28.8 
 2 or more  43.6  39.8  40.4  41.5 
          
Year of diagnosis * ^         
 2003 (July-Dec)  11.4  15.3  13.5  15.3 
 2004  28.9  28.3  29.4  30.0 
 2005  29.4  28.4  29.4  28.1 
  2006   30.2  28.0  27.8   26.7 
WV = West Virginia population, US = United States population represented by the Surveillance, Epidemiology and End Results 
(SEER) population, NSCLC = Non-Small Cell Lung Cancer, SCLC = Small Cell Lung Cancer, AJCC = American Joint Committee 
on Cancer, TNM = Tumor Node Metastasis. 
*  Chi-square test (p ≤ 0.05) measuring association between beneficiary characteristics and population type, among beneficiaries 
with non-small cell lung cancer.  
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#  Chi-square test (p ≤ 0.05) measuring association between beneficiary characteristics and population type, among beneficiaries 
with small cell lung cancer.   
+  Chi-square test (p ≤ 0.05) measuring association between beneficiary characteristics and cancer type, among beneficiaries in 
West Virginia population.  
^  Chi-square test (p ≤ 0.05) measuring association between beneficiary characteristics and cancer type, among beneficiaries in 
United States population.  
Source: West Virginia Cancer Registry - Medicare linked data files, 2002-2007, Surveillance, Epidemiology and End Results - 
Medicare linked data files, 2002-2007. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.2. Descriptive characteristics by type of treatment among continuously enrolled Medicare Fee-for-service 
beneficiaries with incident diagnosis of lung cancer in West Virginia and in the United States, July 2003 through 
December 2006.    
  Proportion (%) #
 No Treatment  Surgery Only  Radiation Only  Chemotherapy Only  
Combination 
Treatment Characteristics 
 WV  US  WV  US  WV  US  WV  US  WV  US 
                      
Overall, n (%) *
 
453 
(26.8)  
14,137 
(33.4)  
228 
(13.5)  
4,172 
(9.9)  
321     
(19.0)  
6,730 
(15.9)  
176     
(10.4)  
5,461 
(12.9)  
511     
(30.3)  
11,832 
(27.9) 
                      
Cancer type + ^                     
 NSCLC *  26.7  34.1  15.7  11.4  20.6  17.1  8.4  11.2  28.6  26.2 
 SCLC  27.8  28.9  0.4  0.5  9.4  8.4  22.5  23.6  40.0  38.7 
                      
AJCC TNM stage + ^                    
 I  17.5  23.7  43.2  41.0  11.4  12.7  3.0  3.6  24.9  19.0 
 II  19.6  17.0  22.2  19.7  12.4  10.7  2.6  4.9  43.1  47.8 
 III  25.9  32.5  3.5  3.5  18.3  14.5  11.8  13.1  40.5  36.5 
 IV  34.0  39.1  0.7  0.8  25.0  18.4  15.4  17.1  25.0  24.5 
                      
Age (years) + ^                     
 66-69 *  20.6  23.0  14.0  9.8  13.0  12.9  10.4  13.8  42.0  40.5 
 70-74  21.8  26.1  14.6  10.4  18.4  14.7  11.0  13.7  34.2  35.0 
 75-79  27.9  32.5  14.1  11.3  21.2  15.9  10.4  13.9  26.5  26.5 
 80 or more *  39.2  48.5  10.8  8.1  23.8  19.2  9.7  10.6  16.6  13.7 
                      
Gender + ^                     
 Male *  29.6  33.4  12.4  8.8  18.3  15.9  9.8  13.0  29.9  28.8 
 Female *  23.1  33.4  15.0  11.0  19.9  15.9  11.2  12.8  30.7  27.0 
                      
Race ^                     
 58
 Other  44.1  37.9  11.8  7.0  11.8  17.6  14.7  12.4  17.7  25.1 
 White *  26.5  32.7  13.5  10.3  19.2  15.7  10.3  13.0  30.5  28.3 
                      
Urban-rural 
residence + ^                     
 Metro *  27.6  32.9  13.4  10.1  20.7  16.1  8.4  13.1  29.9  27.8 
 Urban  26.8  36.2  14.2  8.7  17.1  15.1  12.2  11.6  29.8  28.5 
 Rural  20.0  34.2  10.0  8.2  16.0  14.8  18.0  13.6  36.0  29.2 
                      
Comorbidity, 
Charlson score + 
^
 
                   
 0  31.3  33.1  10.3  7.9  17.9  14.9  10.9  13.2  29.5  31.0 
 1 *  21.6  29.4  15.7  11.2  18.8  15.6  10.1  13.2  33.7  30.6 
 2 or more *  27.6  36.6  14.0  10.4  19.8  16.9  10.3  12.5  28.3  23.6 
                      
Year of diagnosis ^                    
 
2003 (July-
Dec)  25.8  33.6  15.7  9.4  19.7  15.2  11.1  13.3  27.8  28.5 
 2004 *  24.9  32.2  14.5  9.5  17.8  14.5  10.0  13.4  32.9  30.5 
 2005 *  27.4  33.2  12.9  9.7  16.9  15.0  11.1  13.5  31.8  28.6 
  2006 *   28.6   34.8  12.3  10.6  22.0  18.7  9.9  11.6  27.2  24.4 
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WV = West Virginia population, US = United States population represented by the Surveillance, Epidemiology and End Results (SEER) population, NSCLC = Non-Small Cell Lung 
Cancer, SCLC = Small Cell Lung Cancer, AJCC = American Joint Committee on Cancer, TNM = Tumor Node Metastasis. 
#  Proportions reported are row percentages of beneficiaries receiving particular treatment within WV or the US population.  
*  Chi-square test (p ≤ 0.05), measuring association between type of treatment and population type, among beneficiaries within each row category.  
+  Chi-square test (p ≤ 0.05) measuring association between beneficiary characteristics and type of treatment, among beneficiaries in West Virginia population. 
^  Chi-square test (p ≤ 0.05) measuring association between beneficiary characteristics and type of treatment, among beneficiaries in United States population.   
Source: West Virginia Cancer Registry - Medicare linked data files, 2002-2007, Surveillance, Epidemiology and End Results - Medicare linked data files, 2002-2007.  
   
 
 
 
 
 
 
 
Table 2.3. Descriptive characteristics by receipt of minimally appropriate clinical 
guideline based lung cancer care among continuously enrolled Medicare Fee-for-
service beneficiaries with incident diagnosis of lung cancer (Stages I-III) in West Virginia 
and in the United States, July 2003 through December 2006.     
  Minimally Appropriate Care ~  Inappropriate Care 
 WV  US  WV  US Characteristics 
 No.  % #  No.  % #  No.  % #  No.  % #
                  
Overall  445  46.5  9,736  44.7  511  53.5  12,048  55.3 
                  
Age (years) + ^                 
 66-69  118  51.8  2,325  55.7  110  48.2  1,849  44.3 
 70-74  159  53.9  2,899  50.4  136  46.1  2,851  49.6 
 75-79  112  45.0  2,576  45.0  137  55.0  3,152  55.0 
 80 or more  56  30.4  1,936  31.6  128  69.6  4,196  68.4 
                  
Gender +                 
 Male  231  42.9  4,930  44.6  307  57.1  6,130  55.4 
 Female *  214  51.2  4,806  44.8  204  48.8  5,918  55.2 
                  
Race ^                 
 Other  7  38.9  1,090  39.7  11  61.1  1,654  60.3 
 White  438  46.7  8,646  45.4  500  53.3  10,394  54.6 
                  
Urban-rural 
residence ^
                
 Metro  254  46.8  8,101  45.3  289  53.2  9,793  54.7 
 Urban  170  47.2  1,446  42.0  190  52.8  1,995  58.0 
 Rural  21  39.6  189  42.1  32  60.4  260  57.9 
                  
Comorbidity, 
Charlson score 
^                 
 0  103  45.0  2,820  46.0  126  55.0  3,314  54.0 
 1  139  49.3  3,040  48.2  143  50.7  3,265  51.8 
 2 or more  203  45.6  3,876  41.5  242  54.4  5,469  58.5 
                  
Year of diagnosis 
^                
 2003 (July-Dec) 43  43.9  1,511  42.5  55  56.1  2,046  57.5 
 2004  135  45.8  2,846  46.5  160  54.2  3,274  53.5 
 2005  136  48.2  2,788  45.5  146  51.8  3,344  54.5 
  2006   131   46.6  2,591  43.4  150  53.4   3,384  56.6 
WV = West Virginia population, US = United States population represented by the Surveillance, Epidemiology and End Results 
(SEER) population.  
~  Minimally appropriate care determined using American College of Chest Physicians (ACCP) evidence-based guidelines for 
diagnosis and management of lung cancer published in January, 2003. 
#  Proportions reported are row percentages of beneficiaries receiving minimally appropriate care, or inappropriate care, within WV 
or the US population.  
*  Chi-square test (p ≤ 0.05), measuring association between receipt of minimally appropriate care and population type, among 
beneficiaries within each row category.  
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+  Chi-square test (p ≤ 0.05) measuring association between beneficiary characteristics and receipt of minimally appropriate care, 
among beneficiaries in West Virginia population. 
^  Chi-square test (p ≤ 0.05) measuring association between beneficiary characteristics and receipt of minimally appropriate care, 
among beneficiaries in United States population.   
Source: West Virginia Cancer Registry - Medicare linked data files, 2002-2007, Surveillance, Epidemiology and End Results - 
Medicare linked data files, 2002-2007. 
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Table 2.4. Minimally appropriate clinical guideline based lung cancer care by cancer 
type and stage, among continuously enrolled Medicare Fee-for-service beneficiaries 
with incident diagnosis of lung cancer (Stages I-III) in West Virginia and in the United 
States, July 2003 through December 2006. 
  Minimally Appropriate Care ~  Inappropriate Care 
 WV  US  WV  US 
Characteristics 
*
 No.  % #  No.  % #  No.  % #  No.  % #
                  
NSCLC                 
 Stage I  209  53.9  4,188  55.7  179  46.1  3,332  44.3 
 Stage II  67  47.2  844  49.1  75  52.8  876  50.9 
 Stage III  133  39.6  3,653  35.3  203  60.4  6,701  64.7 
 Stages I-III  409  47.2  8,685  44.3  457  52.8  10,909  55.7 
                  
SCLC                 
 Stage I  6  35.3  130  43.2  11  64.7  171  56.8 
 Stage II  2  18.2  59  45.7  9  81.8  70  54.3 
 Stage III  28  45.2  862  49.0  34  54.8  898  51.0 
  Stages I-III   36   40.0  1,051  48.0  54  60.0   1,139  52.0 
WV = West Virginia population, US = United States population represented by the Surveillance, Epidemiology and End Results 
(SEER) population.  
~  Minimally appropriate care determined using American College of Chest Physicians (ACCP) evidence-based guidelines for 
diagnosis and management of lung cancer published in January, 2003. 
#  Proportions reported are row percentages of beneficiaries receiving minimally appropriate care, or inappropriate care, within WV 
or the US population.   
*  Stages based on American Joint Committee on Cancer (AJCC), Tumor Node Metastasis (TNM) staging system.   
Source: West Virginia Cancer Registry - Medicare linked data files, 2002-2007, Surveillance, Epidemiology and End Results - 
Medicare linked data files, 2002-2007. 
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Table 2.5. Factors associated with receipt of minimally appropriate clinical guideline 
based lung cancer care among continuously enrolled Medicare Fee-for-service 
beneficiaries with incident diagnosis of lung cancer (Stages I-III) in West Virginia and in 
the United States, July 2003 through December 2006. 
      Odds Ratio (95% Confidence Interval) 
     Model 1: WV  Model 2: US  Model 3: WV + US 
        
Intercept (p-value) 0.09  0.15  0.11 
        
Population       
 WV  NA  NA  0.94 (0.78 to 1.13) 
 US  NA  NA  1 (Ref) 
        
Age (years)       
 66-69  2.50*** (1.65 to 3.79)  2.66*** (2.44 to 2.89)  2.65*** (2.44 to 2.87) 
 70-74  2.68*** (1.81 to 3.98)  2.13*** (1.97 to 2.31)  2.16*** (2.00 to 2.33) 
 75-79  1.84** (1.22 to 2.77)  1.79*** (1.66 to 1.93)  1.79*** (1.66 to 1.93) 
 80 or more  1 (Ref)  1 (Ref)  1 (Ref) 
        
Gender       
 Male  0.73* (0.56 to 0.95)  0.97 (0.92 to 1.03)  0.96 (0.91 to 1.01) 
 Female  1 (Ref)  1 (Ref)  1 (Ref) 
        
Race       
 Other  0.77 (0.25 to 2.34)  0.79*** (0.72 to 0.86)  0.79*** (0.72 to 0.86) 
 White  1 (Ref)  1 (Ref)  1 (Ref) 
        
Urban-rural 
residence 
      
 Metro  1.50 (0.82 to 2.77)  1.11 (0.90 to 1.38)  1.15 (0.94 to 1.40) 
 Urban  1.44 (0.78 to 2.66)  0.99 (0.79 to 1.22)  1.03 (0.84 to 1.26) 
 Rural  1 (Ref)  1 (Ref)  1 (Ref) 
        
Comorbidity, 
Charlson 
score       
 0  0.95 (0.68 to 1.32)  1.14*** (1.06 to 1.21)  1.13*** (1.06 to 1.20) 
 1  1.14 (0.83 to 1.55)  1.27*** (1.18 to 1.35)  1.26*** (1.18 to 1.34) 
 2 or more  1 (Ref)  1 (Ref)  1 (Ref) 
        
Percentage 
with some 
college 
education (%) ^       
 0.0-0.10  0.34 (0.09 to 1.31)  1.00 (0.02 to 45.32)  0.52 (0.01 to 0.60) 
 0.11-0.20  1.20 (0.90 to 1.59)  1.09 (0.05 to 8.79)  1.25 (0.22 to 7.16) 
 
0.21 or 
more  1 (Ref)  1 (Ref)  1 (Ref) 
        
 63
 64
Median 
household 
income ($) ^
      
 0-25,000  1.53 (0.64 to 3.66)  0.75*** (0.67 to 0.84)  0.76*** (0.68 to 0.85) 
 25,001-50,000 1.58 (0.70 to 3.59)  0.85** (0.77 to 0.94)  0.86** (0.78 to 0.95) 
  
50,001 or 
more 1 (Ref)  1 (Ref)  1 (Ref) 
WV = West Virginia population, US = United States population represented by the Surveillance, Epidemiology and End Results 
(SEER) population, Ref = reference category, NA = Not Applicable. 
*  Estimates are statistically significant (p ≤ 0.05). 
**  Estimates are statistically significant (p ≤ 0.01). 
***  Estimates are statistically significant (p ≤ 0.001). 
^  Census tract level measures of beneficiaries socioeconomic status. 
Minimally appropriate care determined using American College of Chest Physicians (ACCP) evidence-based guidelines for 
diagnosis and management of lung cancer published in January, 2003.  
Model 1: WV population (N = 956), Fit Statistics: -2 restricted log pseudo-likelihood = 4110.26, Covariance parameter estimates: 
Intercept = county, estimate = 0.33, standard error = 0.001. 
Model 2: US population (N = 21,784), Fit Statistics: -2 restricted log pseudo-likelihood = 93427.13, Covariance parameter estimates: 
Intercept = county, estimate = 0.56, standard error = 0.011. 
Model 3: Combined WV + US population (N = 22,740), Fit Statistics: -2 restricted log pseudo-likelihood = 97505.27, Covariance 
parameter estimates: Intercept = county, estimate = 0.05, standard error = 0.011. 
Source: West Virginia Cancer Registry - Medicare linked data files, 2002-2007, Surveillance, Epidemiology and End Results - 
Medicare linked data files, 2002-2007. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.6. Three-year median survival time and survival rate by cancer type and stage, and by receipt of minimally 
appropriate clinical guideline based lung cancer care, among continuously enrolled Medicare Fee-for-service beneficiaries 
with incident diagnosis of lung cancer (Stages I-III) in West Virginia and in the United States, July 2003 through December 
2004. 
  Minimally Appropriate Care ~   Inappropriate Care 
 
Median survival time, days       
(95% CI) *  
3-year survival rate              
(95% CI) *  
Median survival time, days     
(95% CI) *  
3-year survival rate              
(95% CI) * 
  
 WV  US  WV  US  WV  US  WV  US 
                  
NSCLC                 
 I  #  
983            
(797 to NA^)  -  
0.46          
(0.34 to 0.57)  
0.62           
(0.60 to 0.65)  -  -  
0.60           
(0.49 to 0.70)  
0.55           
(0.53 to 0.58) 
 II  #  -  -  
0.51           
(0.30 to 0.68)  
0.54           
(0.48 to 0.59)  
493          
(299 to 643)  
384          
(328 to 459)  
0.17           
(0.05 to 0.34)  
0.20           
(0.16 to 0.25) 
 
III @ 
#  
493            
(293 to 705)  
439          
(412 to 475)  
0.28           
(0.16 to 0.41)  
0.25           
(0.23 to 0.27)  
188          
(119 to 256)  
146          
(135 to 164)  
0.12           
(0.05 to 0.21)  
0.09           
(0.08 to 0.11) 
 I-III $ @ #
851            
(677 to 992)  
835          
(781 to 912)  
0.41           
(0.33 to 0.48)  
0.44           
(0.43 to 0.46)  
493          
(341 to 643)  
283          
(265 to 301)  
0.35           
(0.28 to 0.42)  
0.25           
(0.24 to 0.26) 
                  
SCLC                 
 I  
449            
(300 to NA^)   
585          
(464 to 701)  0  
0.28           
(0.18 to 0.39)  
211          
(71 to 366)  
324          
(204 to 474)  0  
0.16           
(0.09 to 0.26) 
 II  
490            
(21 to 958)  
423          
(276 to 618)  0  
0.14           
(0.04 to 0.31)  
150          
(3 to 552)  
276          
(99 to 498)  0  
0.06          
(0.00 to 0.25) 
 
III @ 
#  
281            
(171 to NA^)  
448          
(405 to 491)  
0.32           
(0.09 to 0.59)  
0.18           
(0.14 to 0.22)  
85           
(6 to 219)  
109          
(92 to 133)  0  
0.02           
(0.01 to 0.05) 
  
I-III @ # 
+
345            
(263 to NA^)   
457          
(428 to 509)   
0.27           
(0.07 to 0.51)   
0.19           
(0.16 to 0.23)   
150          
(16 to 219)   
135          
(109 to 160)   0   
0.05           
(0.03 to 0.07) 
WV = West Virginia population, US = United States population represented by the Surveillance, Epidemiology and End Results (SEER) population, NSCLC = Non-small cell lung cancer, SCLC = Small cell lung 
cancer, CI = confidence interval, - = median survival time not yet reached.    
*  Survival times and rates were obtained from Kaplan-Meier survival estimates. 
^  Upper limit of confidence interval is not available because of censoring.  
~  Minimally appropriate care determined using American College of Chest Physicians (ACCP) evidence-based guidelines for diagnosis and management of lung cancer published in January, 2003. Stages 
based on American Joint Committee on Cancer (AJCC), Tumor Node Metastasis (TNM) staging system. 
$  Log-rank test (p ≤ 0.05) comparing population differences in survival among beneficiaries receiving minimally appropriate care.  
@  Log-rank test (p ≤ 0.05) comparing population differences in survival among beneficiaries receiving inappropriate care. 
#  Log-rank test (p ≤ 0.05) comparing differences in survival by receipt of minimally appropriate care, among beneficiaries within US population.  
+  Log-rank test (p ≤ 0.05) comparing differences in survival by receipt of minimally appropriate care, among beneficiaries within WV population. NSCLC, Minimally appropriate care: Stage I (WV: N = 84,  
Censored = 51.2%; US: N = 1,759, Censored = 65.2%), Stage II (WV: N = 25, Censored = 52.0%; US: N = 338, Censored = 56.5%), Stage III (WV: N = 51, Censored = 29.4%; US: N = 1,765, Censored = 
29.8%), Stages I-III (WV: N = 160, Censored = 44.4%; US: N = 3,862, Censored = 48.3%).  NSCLC, Inappropriate care: Stage I (WV: N = 84, Censored = 61.9%; US: N = 1,464, Censored = 59.8%), Stage II 
(WV: N = 31, Censored = 25.8%; US: N = 343, Censored = 25.7%), Stage III (WV: N = 77, Censored = 20.8%; US: N = 2,921, Censored = 19.2%), Stages I-III (WV: N = 192, Censored = 39.6%; US: N = 
4,728, Censored = 32.3%). SCLC, Minimally appropriate care: Stage I (WV: N = 3, Censored = 66.7%; US: N = 74, Censored = 32.4%), Stage II (WV: N = 2, Censored = 0%; US: N = 26, Censored = 23.1%), 
Stage III (WV: N = 13, Censored = 38.5%; US: N = 395, Censored = 22.8%), Stages I-III (WV: N = 18, Censored = 38.9%; US: N = 495, Censored = 24.2%). SCLC, Inappropriate care: Stage I (WV: N = 5, 
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Censored = 0%; US: N = 80, Censored = 25.0%), Stage II (WV: N = 4, Censored = 25.0%; US: N = 26, Censored = 23.1%), Stage III (WV: N = 14, Censored = 0%; US: N = 409, Censored = 12.0%), Stages 
I-III (WV: N = 23, Censored = 4.3%; US: N = 515, % censored = 14.6%).  
Source: West Virginia Cancer Registry - Medicare linked data files, 2002-2007, Surveillance, Epidemiology and End Results - Medicare linked data files, 2002-2007. 
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Table 2.7. Lung cancer mortality risk associated with non-receipt of minimally 
appropriate clinical guideline based lung cancer care, among continuously enrolled 
Medicare Fee-for-service beneficiaries with incident diagnosis of lung cancer (Stages I-
III) in West Virginia and in the United States, July 2003 through December 2004. 
      Hazard Ratio (95% Confidence Interval) 
   Model 1: WV  Model 2: US  Model 3: WV + US 
        
Population       
 WV  NA  NA  0.99 (0.82 to 1.20) 
 US  NA  NA  1 (Ref) 
        
Appropriateness of care ~       
 Inappropriate care  1.60*** (1.23 to 2.10)  1.91*** (1.82 to 2.00)  1.90*** (1.81 to 1.99) 
 
Minimally appropriate 
care  1 (Ref)  1 (Ref)  1 (Ref) 
        
Lung cancer type       
 NSCLC  0.46*** (0.30 to 0.71)  0.72*** (0.66 to 0.77)  0.70*** (0.65 to 0.76) 
 SCLC  1 (Ref)  1 (Ref)  1 (Ref) 
        
AJCC TNM stage       
 I  0.38*** (0.27 to 0.53)  0.29*** (0.27 to 0.31)  0.29*** (0.27 to 0.31) 
 II  0.65* (0.46 to 0.91)  0.55*** (0.50 to 0.60)  0.55*** (0.50 to 0.60) 
 III  1 (Ref)  1 (Ref)  1 (Ref) 
        
Age (years)       
 66-69  0.70 (0.46 to 1.08)  0.62*** (0.57 to 0.67)  0.62*** (0.58 to 0.67) 
 70-74  0.69 (0.46 to 1.05)  0.71*** (0.65 to 0.77)  0.71*** (0.66 to 0.77) 
 75-79  0.76 (0.51 to 1.14)  0.78*** (0.72 to 0.84)  0.78*** (0.72 to 0.84) 
 80 or more  1 (Ref)  1 (Ref)  1 (Ref) 
        
Gender       
 Male  1.20 (0.91 to 1.58)  1.19*** (1.13 to 1.26)  1.19*** (1.13 to 1.25) 
 Female  1 (Ref)  1 (Ref)  1 (Ref) 
        
Race       
 Other  1.23 (0.50 to 2.98)  0.93* (0.86 to 0.99)  0.93* (0.86 to 0.99) 
 White  1 (Ref)  1 (Ref)  1 (Ref) 
        
Urban-rural residence       
 Metro  0.93 (0.52 to 1.66)  1.08 (0.92 to 1.27)  1.06 (0.91 to 1.24) 
 Urban  0.81 (0.44 to 1.50)  1.18 (0.99 to 1.40)  1.14 (0.96 to 1.34) 
 Rural  1 (Ref)  1 (Ref)  1 (Ref) 
        
Comorbidity, Charlson 
score       
 0  0.74 (0.54 to 1.03)  0.83*** (0.78 to 0.90)  0.83*** (0.78 to 0.89) 
 1  1.09 (0.81 to 1.46)  0.88*** (0.82 to 0.94)  0.89*** (0.83 to 0.95) 
 2 or more  1 (Ref)  1 (Ref)  1 (Ref) 
        
Percentage with some 
college education (%) ^       
 0.0-0.10  2.77*** (1.72 to 4.45)  1.49 (0.56 to 3.98)  2.09 (0.91 to 4.77) 
 0.11-0.20  0.99 (0.73 to 1.34)  1.30 (0.66 to 3.78)  1.13 (0.86 to 1.49) 
 0.21 or more  1 (Ref)  1 (Ref)  1 (Ref) 
        
Median household income 
($) ^       
 0-25,000  2.50 (0.98 to 6.38)  1.28*** (1.16 to 1.42)  1.29*** (1.17 to 1.43) 
 25,001-50,000  1.76 (0.72 to 4.30)  1.10 (0.99 to 1.22)  1.11 (1.00 to 1.22) 
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  50,001 or more   1 (Ref)   1 (Ref)   1 (Ref) 
WV = West Virginia population, US = United States population represented by the Surveillance, Epidemiology and End Results 
(SEER) population, NSCLC = Non-Small Cell Lung Cancer, SCLC = Small Cell Lung Cancer, AJCC = American Joint Committee 
on Cancer, TNM = Tumor Node Metastasis, Ref = reference category, NA = Not Applicable. 
^  Census tract level measures of beneficiaries socioeconomic status. 
*  Estimates are statistically significant (p ≤ 0.05). 
**  Estimates are statistically significant (p ≤ 0.01).   
***  Estimates are statistically significant (p ≤ 0.001).   
~  Minimally appropriate care determined using American College of Chest Physicians (ACCP) evidence-based guidelines for 
diagnosis and management of lung cancer published in January, 2003. 
Model 1: WV population (N = 393), Fit Statistics: -2 log likelihood = 2613.12 (without covariates) and 2521.42 (with covariates), 
Global null hypothesis: Likelihood ratio chi-square test = 91.70 (p ≤ 0.05). 
Model 2: US population (N = 9,677), Fit Statistics: -2 log likelihood = 103906.66 (without covariates) and 100941.84 (with 
covariates), Global null hypothesis: Likelihood ratio chi-square test = 2964.82 (p ≤ 0.05). 
Model 3: Combined WV + US population (N = 10,070), Fit Statistics: -2 log likelihood = 108543.65 (without covariates) and 
105501.06 (with covariates), Global null hypothesis: Likelihood ratio chi-square test = 3042.59 (p ≤ 0.05). 
Source: West Virginia Cancer Registry - Medicare linked data files, 2002-2007, Surveillance, Epidemiology and End Results - 
Medicare linked data files, 2002-2007. 
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CHAPTER 3: 
TIMELINESS OF LUNG CANCER CARE AND ASSOCIATED HEALTH OUTCOMES 
AMONG ELDERLY MEDICARE FEE-FOR-SERVICE BENEFICIARIES IN WEST 
VIRGINIA AND IN THE UNITED STATES 
 
Introduction 
Lung cancer is the most common cause of cancer death among elderly in the United 
States (US).1  Despite significant advances in treatment options, prognosis associated 
with lung cancer diagnosis remains poor, with five year survival of approximately 10%.  
Cancer stage at diagnosis is the most important factor for survival among patients with 
lung cancer.  If diagnosed at an early stage, standard surgical resection can result in 
five year survival rates of approximately 40% among patients with non-small cell lung 
cancer (NSCLC).2  Among patients diagnosed with early stage small cell lung cancer 
(SCLC), five-year survival rates of approximately 14% can be achieved with 
chemotherapy and radiation therapy.3  Unfortunately, most lung cancers are found too 
late to cure, and the median survival times among those patients is typically 6 to 12 
months.2;3   
Delays in lung cancer diagnosis can be attributed to patient’s delay in seeking 
medical services, and/or physician delay in diagnosis.  These delays may primarily 
result from lack of routine lung cancer screening tests for the general public.  
Furthermore, delayed diagnosis may also occur as lung cancer patients present with 
symptoms such as cough and dyspnoea, which are very common in general practice.  
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Reducing diagnostic delays may increase the proportion of early stage cancers, and 
improve survival.  
Elderly carry a disproportionate burden of lung cancer, since approximately 81% 
of those living with lung cancer are 60 years of age or older.1  Therefore, significant 
reduction in lung cancer mortality can also be achieved if the elderly receive timely and 
medically effective therapies following diagnosis.  As lung cancer care requires complex 
coordination of services by a medical or surgical specialist, the traditional approach of 
referring patients for consultation with multiple specialists in a sequential fashion often 
results in care that is perceived slow.  To establish standards for timely lung cancer 
care, clinical opinion-based guidelines have been published by the British Thoracic 
Society (BTS), the RAND Corporation, and by the American College of Chest 
Physicians (ACCP).4-6  However, extensive studies in European Union member 
countries have found delays in time to diagnosis and treatment of lung cancer than 
recommended in clinical opinion-based guidelines.7-21  A few studies performed in the 
US have shown mixed results.22-28  Dransfield and colleagues (2006) found median time 
to resection among NSCLC patients (104 days) exceed the 56-day maximum 
recommended by BTS.23  Similarly, Gould and colleagues (2008) found time to 
treatment among NSCLC patients often longer than recommended.28  On the contrary, 
Riedel and colleagues (2006)  found less than expected median time to treatment 
initiation (22 days), while evaluating the benefits of multidisciplinary thoracic oncology 
clinics in a Veterans Affairs setting.22  In another study from Massachusetts, no 
differences in time to treatment were observed between Asian immigrants compared to 
non-Asians.26  While multidisciplinary clinics have been recommended in the literature 
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to improve timeliness of care, patient care coordination through a dedicated lung mass 
clinic or a multidisciplinary clinic have not shown any reduction in delays in the US.4;22;23   
Various factors have been associated with less timely care, and they include 
atypical symptoms, comorbid conditions, teaching hospital setting, receipt of curative 
(versus palliative) radiotherapy, initial referral to a non-respiratory physician, 
requirement for multiple diagnostic tests, and care received at more than one health 
care facility.11;14;29-32  However, gender,30 household income,14;30 hospital volume,30 rural 
residence,30 and distance travelled to obtain care14 have not been associated with 
timeliness of lung cancer care.  Mixed results were observed in studies that examined 
effect of age on timeliness of lung cancer care.11;29-31
While timely lung cancer care is important, its impact on health outcomes 
remains unclear.  Three studies from non-US countries reported poorer survival among 
patients with delayed diagnosis and treatment.33-35  However, four other studies from 
non-US countries found better median survival among patients that received less timely 
care.8;10;36;37  Similarly in the US, while two studies found no benefits in survival 
following timely care, only one study found survival benefits among patients with a 
solitary pulmonary nodule, making it unclear whether or not more timely care improves 
health outcomes.25;27;28  Delay in treatment also failed to explain the observed higher 
mortality risk from NSCLC in the only large population based study from Hawaii.24
Improving timeliness of lung cancer care is important regardless of its effect on 
health outcomes.  It is particularly important for patients residing in rural areas of the 
US.  Many rural areas of the US are economically underdeveloped and medically 
underserved,38;39 and the elderly in these regions carry a higher burden of lung cancer 
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compared to their urban counterparts.40  These rural areas are also known to report a 
higher prevalence of lung cancer and a higher crude all-cause mortality rate among the 
elderly.41;42  One such area is the Appalachian region, a population representing 8.1% 
of the total US population.42  West Virginia (WV) is the only state situated entirely within 
the Appalachian region and is the third most rural state in the nation.42  Fifty of the 55 
counties in the state are designated as medically underserved areas, and all or part of 
40 counties in the state are classified as health professional shortage areas.43  During 
2002-2006, the age-adjusted lung cancer incidence rate (WV: 481.5 per 100,000, US: 
378.5 per 100,000), and mortality rate (WV: 390.6 per 100,000, US: 310.8 per 100,000) 
among the elderly were higher in the state in comparison to rest of the country.44;45  
Interestingly, the proportional difference in age-adjusted lung cancer mortality rates 
among the elderly from WV and the US was lower than the difference in age-adjusted 
lung cancer incidence rates.  This might suggest better survival outcomes among 
elderly lung cancer patients in WV as compared to the US; however, such a hypothesis 
remains unexplored.  The observed lung cancer disparities in the rural population can 
be attributed to limited access to quality medical care facilities, less access to or 
utilization of early cancer detection programs, increased prevalence of behavioral risk 
factors like tobacco use and sedentary life style, and socioeconomic factors, such as 
low income and education.46-52  In addition to being medically underserved, the rural 
population may also experiences variations in the quality, availability, and accessibility 
of services when compared to their urban counterparts.53   
While numerous studies have examined timeliness of lung cancer care, a 
majority of them have been conduced in European Union healthcare settings.7-21  Few 
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studies performed in the US were either limited to small sample sizes, restricted to 
NSCLC patients, included both elderly and non-elderly patients, focused on specific 
demographic subgroups, performed within specific health care settings, or failed to 
examine health outcomes associated with timely care.22-28;54  As elderly carry a 
disproportionate burden of lung cancer in the US, studies that examine timeliness of 
lung cancer care, based on clinical opinion-based guidelines, and the associated health 
outcomes in the elderly are much needed.1  Furthermore, comparison of variations in 
timeliness of lung cancer care based on clinical opinion-based guidelines, and the 
associated health outcomes among the elderly from a diverse region like WV with those 
in the US may help to explain the observed geographical disparities in lung cancer 
mortality.  To this end, the main focus of this study is to investigate and compare the 
timeliness of lung cancer care based on clinical opinion-based guidelines, among the 
elderly in WV, and in a representative US population.  Specifically the objectives of this 
study include: (1) to compare delays in diagnosis and treatment among elderly with lung 
cancer in the WV-US populations; (2) to compare the proportion of elderly receiving 
timely lung cancer care based on clinical opinion-based guidelines in the WV-US 
populations; (3) to compare the factors associated with receipt of timely lung cancer 
care based on clinical opinion-based guidelines in the WV-US elderly populations; (4) to 
compare survival outcomes by receipt of timely lung cancer care based on clinical 
opinion-based guidelines in the WV-US elderly populations; and (5) to compare lung 
cancer mortality risk associated with non-receipt of timely lung cancer care based on 
clinical opinion-based guidelines in the WV-US elderly populations. 
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Methods 
 
Data sources 
This retrospective study was conducted using cancer registry linked Medicare data files 
for the years 2002 through 2007.  While the cancer registry data files provide clinical, 
demographic, cause of death, and initial treatment information for elderly individuals 
with lung cancer in selected geographic regions, the Medicare administrative data files 
provided the health service claims information for care provided by physicians, inpatient 
hospital stays, hospital outpatient clinics, home health care agencies, skilled nursing 
facilities, and hospice programs.   
Specifically, the Surveillance, Epidemiology, and End Results (SEER) - Medicare 
linked data files were purchased from the National Cancer Institute, and were used to 
estimate the timeliness of lung cancer care based on clinical opinion-based guidelines 
in the elderly US population.  The data from SEER program are representative of the 
US cancer incidence and mortality as they contain information from 20 population-
based cancer registries covering approximately 28 percent of the US population.55
To estimate the timeliness of lung cancer care based on clinical opinion-based 
guidelines in the elderly WV population, we used West Virginia Cancer Registry 
(WVCR) - Medicare linked data files.  The WVCR-Medicare linked data files are similar 
in structure to the SEER-Medicare linked data files and represent data from the West 
Virginia Cancer Registry, which does not participate in the SEER program.  Details on 
the creation of WVCR-Medicare linked data files can be found elsewhere.56
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Study populations 
We initially identified all Medicare Fee-for-service (FFS) beneficiaries, aged 66 years 
and older with incident lung cancer (Stages I-IV) diagnosis during the years 2003 
through 2006 from the SEER-Medicare linked data files (hereafter referred to as ‘US 
population’) and the WVCR-Medicare linked data files (hereafter referred to as ‘WV 
population’), separately.  Lung cancer diagnosis was identified among individuals in the 
cancer registry files using International Classification of Diseases for Oncology (ICD-O) 
codes (C34.0, C34.1, C34.2, C34.3, C34.8, C34.9, and C33.9).  Lung cancer stage was 
identified using American Joint Committee on Cancer (AJCC), Tumor Node Metastasis 
(TNM), 3rd edition stage (for 2003 diagnosis) and 6th edition stage (for 2004-2006 
diagnosis).57;58  While Medicare eligibility starts at age 65, we only included 
beneficiaries aged 66 years and older at the time of diagnosis so that we would have a 
full year of Medicare claims before lung cancer diagnosis for assessing comorbidity.  
We then excluded individuals with multiple primary cancer diagnosis or whose diagnosis 
was made only at the time of death (death certificate review/autopsy diagnosis).  We 
also excluded beneficiaries who were enrolled in Medicare managed care plan or who 
had non-continuous Medicare Part A and Part B enrollment in the year prior to 
diagnosis and during the year following diagnosis.  This is because their Medicare files 
would not have complete treatment information.  The remaining cohorts of continuously 
enrolled elderly Medicare FFS beneficiaries in the WV and US populations (study 
cohorts) were then used to compare delays in diagnosis and treatment.  To compare 
the proportion of beneficiaries receiving timely lung cancer care, based on clinical 
opinion-based guidelines, and to compare the factors associated with receipt of timely 
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lung cancer care, we subset the study cohorts to include only those beneficiaries that 
received any treatment during the year following diagnosis. 
Given the limited years of data available for follow-up in our data sources, we 
further subset the above study cohorts for survival analysis.  Specifically, we selected 
beneficiaries with lung cancer diagnosis during the years 2003 and 2004 in the study 
cohorts, and who received any treatment during the year following the diagnosis.  We 
then followed these beneficiaries for three years after the incident lung cancer diagnosis 
to determine lung cancer specific mortality.  These subsets of study cohorts were then 
used to compare survival outcomes by receipt of timely lung cancer care and to 
compare lung cancer mortality risk associated with non-receipt of timely lung cancer 
care. 
 
Assessing delays in diagnosis and treatment 
Continuously enrolled elderly Medicare FFS beneficiaries in the WV and US populations 
were followed during the year prior to the incident lung cancer diagnosis to determine 
delays in diagnosis.  The delays in diagnosis were categorized as ’symptom to chest x-
ray’ delay, ‘chest x-ray to specialist visit’ delay, specialist delay, and referral delay.  
Given the retrospective nature of our data sources, we estimated the occurrence of 
earliest lung cancer symptoms by identifying the date of the earliest Medicare claim, 
which had an International Classification of Diseases (ICD-9) code associated with 
symptoms of primary tumor (cough, weight loss, dyspnea, chest pain, hemoptysis, bone 
pain, clubbing, fever, weakness, superior vena cava obstruction, dysphagia, wheezing 
and stridor), symptoms of intrathoracic spread (recurrent laryngeal nerve palsy, pancost 
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tumor/superior sulcus tumor, horner syndrome), symptoms of extrathoracic metastases 
(headache, nausea\vomiting, seizures, confusion, personality change, musculoskeletal 
pain, syncope, lympadenopathy\enlargement of lymph nodes, hoarseness, 
hepatomegaly, papilledema), or paraneoplastic syndromes (Appendix 3.1).  The 
‘symptom to chest x-ray’ delay was then defined as the time from the earliest Medicare 
claim date, which had an ICD-9 code associated with lung cancer symptom, until the 
date of first Medicare claim for a chest x-ray.  The ‘chest x-ray to specialist visit’ delay 
was defined as the time from the first Medicare claim for a chest x-ray until the date of 
first Medicare claim on which the service provider was a specialist, such as 
respiratory/chest physician, pulmonologist, oncologist, cardiologist, or 
thoracic/cardiac/regular surgeon.  The specialist delay was defined as the time from the 
Medicare claim for the first specialist appointment until the date of cancer diagnosis.  
Among beneficiaries that were referred to the specialist, referral delay was defined as 
the time from the last Medicare claim associated with services provided by the referring 
physician, until the date of first Medicare claim on which the service provider was the 
referred specialist.  The overall delay in diagnosis was defined as the time from the 
earliest Medicare claim date, which had an ICD-9 code associated with lung cancer 
symptom, until the date of cancer diagnosis.  Delays in diagnosis were identified only 
among those beneficiaries who had Medicare claims associated with events of interest 
necessary to calculate the type of delay. 
Continuously enrolled elderly Medicare FFS beneficiaries in the WV and US 
populations were followed for one year following incident lung cancer diagnosis to 
determine delays in treatment.  Specifically, treatment delay was defined as the time 
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from cancer diagnosis until the date of first Medicare claim for surgery, radiation, or 
chemotherapy.  Lung cancer specific treatments and procedures were identified from 
the Medicare claim data files using appropriate ICD-9 diagnosis and procedure codes, 
Healthcare Common Procedure Coding System (HCPCS) codes, Current Procedural 
Terminology (CPT) codes and revenue center codes (Appendix 3.1).   
 
Assessing receipt of timely lung cancer care based on clinical opinion-based guidelines 
Timeliness of lung cancer care based on clinical opinion-based guidelines (hereafter 
referred to as ‘timely care’) was determined among continuously enrolled elderly 
Medicare FFS beneficiaries who received treatment during the year following an 
incident lung cancer diagnosis in the WV and US populations.  Timely care was defined 
using clinical opinion-based guidelines published by the BTS, and the RAND 
Corporation.4;5  The British Thoracic Society recommends duration between first 
consultation with respiratory physician and surgery to be no more than eight weeks, 
between physician referral to see a clinical oncologist and start of radiotherapy to be no 
more than seven weeks, and between physician referral to see an oncologist and start 
of chemotherapy to be no more than four weeks, approximately.4  On the other hand, 
the RAND Corporation recommends that any planned treatment should be offered 
within six weeks of the diagnosis date.5  To incorporate recommendations from both 
guidelines, we defined timely care by selecting the maximum duration allowed under 
either guideline for a given type of treatment.  Specifically, initial treatment was 
considered timely if the duration between diagnosis date and treatment date was no 
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more than eight weeks for surgery, seven weeks for radiotherapy, and six weeks for 
chemotherapy. 
 
Dependent variables 
The primary outcome of interest was receipt of timely lung cancer care based on clinical 
opinion-based guidelines, which was categorized as (a) timely care, or (b) non-timely 
care.  Survival time in days was calculated for each beneficiary from the time of incident 
lung cancer diagnosis to date of death or the three year follow-up cutoff date, which 
ever came first.  To estimate lung cancer specific survival, beneficiaries who were not 
found to be deceased by the cutoff date, or who died due to causes other than lung 
cancer were censored at that time and considered to be alive.  We measured lung 
cancer specific survival, instead of overall survival, as we wanted to determine the 
association between receipt of timely lung cancer care based on clinical opinion-based 
guidelines and survival. 
While exact date of lung cancer diagnosis was available in the WVCR-Medicare 
linked data files to calculate survival time, the SEER-Medicare linked data files only 
contained the month and year of diagnosis.  Hence, to approximate the date of lung 
cancer diagnosis in the US population, we used the earliest Medicare claim date, which 
had a lung cancer diagnosis code, and which was in the month of lung cancer 
diagnosis.  This approximation is appropriate given the high level of agreement (nearly 
90%) within one month of diagnosis between the SEER diagnosis date and the first 
Medicare claim date with a cancer diagnosis.59  In cases were beneficiaries had no 
Medicare claims with a lung cancer diagnosis code, earliest date from any claim in the 
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month of cancer diagnosis was used as the date of diagnosis.  Finally, in beneficiaries 
with no Medicare claim in the month of diagnosis, the date of diagnosis was 
approximated as the 15th day of the diagnosis month.  Date of death was identified from 
Medicare enrollment records. 
 
Independent variables 
The main independent variables were lung cancer type and stage, age at diagnosis, 
gender, race, urban-rural residence, Charlson comorbidity index score, and census tract 
level measures of education and income.  These variables were considered in our 
analysis because of their prognostic significance.  Lung cancer type was categorized 
based on cell histology.  Beneficiaries with ICD-O histology codes 8000-8040 or 8046-
9989 were categorized as NSCLC, and those with codes 8041-8045 were categorized 
as SCLC.  Lung cancer stage was categorized based on AJCC TNM staging 
system.57;58  Age at diagnosis was categorized as 66-69 years, 70-74 years, 75-79 
years, and 80 years and older.  Given that WV population is predominantly White, race 
was classified as White and others.  Based on Rural-Urban Continuum codes 
developed by the US Department of Agriculture (USDA), urban-rural residence was 
categorized as Metro, Urban, and Rural.  Charlson comorbidity index score was 
calculated using diagnosis and procedure codes reported in Medicare inpatient claims 
from the year prior to incident lung cancer diagnosis.60-62  Comorbidities related to 
cancer were excluded from the index score.  The Charlson comorbidity index score was 
used to categorize comorbidity into three groups: 0, 1 and 2 or more, with a higher 
score indicating a greater burden of comorbid illness.   
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Given the lack of individual socioeconomic status measures in our data sources, 
we used as proxy the year 2000 US Census tract level measures of college education 
and income.63  Specifically, we used the percentage of individuals in the census tract 
with some college education as a proxy measure for education, and categorized it 
based on tertile distribution (using WV population) as 0%-0.10%, 0.11%-0.20%, and 
0.21% or greater.  Similarly, we used median household income at the census tract 
level as a proxy measure of income and categorized it based on tertile distribution 
(using the WV population) as $0-25,000, $25,000-50,000, and $50,001 or more.   
 
Data Analysis 
The Pearson chi-square test was used to determine unadjusted associations between 
categorical variables of interest.  Median delays (with 25% and 75% interquartiles) in 
diagnosis and treatment were calculated for each population.  Non-parametric tests 
were used to compare delays, as the distribution was not normal.  The Mann-Whitney 
test was used for pair wise comparison of delays, and the Kruskal-Wallis test was used 
for analyses involving multiple groups. 
Three hierarchical generalized logistic models were constructed with PROC 
GLIMMIX procedure in SAS 9.2 64 to assess the association between independent 
variables and the receipt of timely care.  In each model, the estimated probability of a 
beneficiary receiving timely care conditioned on a set of predictor variables was 
modeled.  First and second model included beneficiaries from the WV and US 
populations, respectively.  The third model was constructed to determine population 
variation in likelihood of beneficiaries receiving timely care, and therefore included 
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beneficiaries from both populations combined.  The hierarchical model was chosen as 
individual measures of socioeconomic status were not available in our data sources, 
and since we relied on census tract level measures of education and income.  This was 
done by treating census tract as a random effect to account for potential correlation 
among beneficiaries within the same county.  Odds ratios, 95% confidence intervals, 
and two-sided p-values were calculated for each predictor. 
Non-parametric estimates of the survivor function by receipt of timely care were 
calculated for each population using the Kaplan-Meier method.  The log-rank test was 
used to assess the statistical significance of the differences in survival outcomes.  
Three-year survival estimates were also computed by receipt of timely care within each 
population.  Stratified analysis was performed by lung cancer type and stage within 
each population. 
Three multivariate Cox proportional hazards models were constructed to 
estimate lung cancer mortality risk associated with non-receipt of timely care.  First and 
second model included beneficiaries from the WV and US populations, respectively.  
The third model was constructed to determine population variation in lung cancer 
mortality risk, and therefore included beneficiaries from both populations combined.  To 
evaluate the proportional hazards assumption, we plotted smoothed Schoenfeld 
residuals against time and found no evidence of a systematic deviation from 
proportional hazards in any model.  Variance in all Cox models were adjusted to 
account for patient clustering at the census tract level by use of the robust inference of 
Lin and Wei.65  Stratified analysis was performed by lung cancer type and stage within 
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each population.  Adjusted hazard ratios, 95% confidence intervals, and their two-sided 
p-values were calculated for each predictor. 
All data were analyzed using the SAS Version 9.2 (SAS Institute, Cary, NC) 
statistical software package.64  Results were considered to be statistically significant 
when p ≤ 0.05.  This study was approved by the West Virginia Institutional Review 
Board, and is in full compliance with federal, state, and institutional regulations and 
guidelines. 
 
 
Results 
 
Study population characteristics 
Based on study inclusion and exclusion criteria, we identified 1,924 beneficiaries in WV 
population, and 48,850 beneficiaries in the US population.  Table 3.1 shows the 
distribution of clinical and sociodemographic characteristics of these beneficiaries by 
type of lung cancer.  Compared to beneficiaries with NSCLC in the US population, 
beneficiaries with NSCLC in WV population were younger, male, white, resided in non-
metro areas, had higher comorbidity score, and were diagnosed at earlier stages (p ≤ 
0.05).  Similarly, compared to beneficiaries with SCLC in the US population, 
beneficiaries with SCLC in WV population were of white race, resided in non-metro 
areas, and were diagnosed at earlier stages (p ≤ 0.05).  In both populations, 
beneficiaries with SCLC were diagnosed at late stages, compared to beneficiaries with 
NSCLC (p ≤ 0.05).  In the US population, compared to beneficiaries with SCLC, 
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beneficiaries with NSCLC were older, male, of non-white race, resided in metro areas, 
and had lower comorbidity scores (p ≤ 0.05). 
 
Delays in diagnosis and treatment 
Table 3.2 shows the earliest lung cancer symptoms reported among beneficiaries in the 
WV and US populations.  In both population, common symptoms of primary tumor 
included chest pain, cough, weakness, and dyspnea.  Table 3.3 shows the delays in 
diagnosis and treatment among beneficiaries in the WV and US populations.  Median 
delay from symptom to diagnosis was approximately six months in each population.  
Diagnosis to treatment interval was less than a month on average, and was shorter 
among beneficiaries in the WV population as compared to the US population (p ≤ 0.05).  
Compared to beneficiaries in the US population, beneficiaries in the WV population had 
shorter referral delay, specialist delay, ‘diagnosis to surgery’ delay, and ‘diagnosis to 
chemotherapy’ delay (p ≤ 0.05).  However, ‘chest x-ray to specialist visit’ delay was 
longer among beneficiaries in WV population as compared to the US population (p ≤ 
0.05).   
Table 3.4 shows the delays in diagnosis and treatment in relation to clinical 
characteristics among beneficiaries in the WV and US populations.  Longer delay in 
symptom to diagnosis was observed among female beneficiaries and among 
beneficiaries residing in urban areas in the WV population as compared to the US 
population (p ≤ 0.05).  However, beneficiaries with no comorbid illness had shorter 
‘symptom to diagnosis’ delay in the WV population, as compared to the US population 
(p ≤ 0.05).  Significant population variation in diagnosis to treatment interval was 
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observed by lung cancer type, stage, age, gender, race, urban-rural residence, and by 
comorbidity score.  In all comparisons, the diagnosis to treatment interval was shorter 
among beneficiaries in WV population than in the US population (p ≤ 0.05).  Within the 
two populations, beneficiaries with longer symptom to diagnosis delay were old aged, 
male sex, had higher comorbidity score, and were diagnosed at early stages (p ≤ 0.05).  
Significant variation in symptom to diagnosis delay by lung cancer type, race and urban-
rural residence were only observed among beneficiaries in the US population (p ≤ 0.05).  
Longer diagnosis to treatment interval was observed among beneficiaries with NSCLC, 
and who were diagnosed at earlier stages, in both populations (p ≤ 0.05).  Significant 
variation in diagnosis to treatment interval by age, race and comorbidity score were only 
observed among beneficiaries in the US population (p ≤ 0.05).   
 
Receipt of timely care 
In both populations, the proportion of beneficiaries receiving timely care was highest 
among those receiving radiation as initial therapy (WV: 80.1%; US: 80.3%).  Among 
beneficiaries receiving chemotherapy as initial treatment, the proportion was higher in 
the WV population than in the US population (79.6% vs. 74.6%).  However, the 
proportion was lower among beneficiaries receiving surgery as initial treatment in WV 
population than in the US population (75.9% vs. 76.8%). 
Table 3.5 shows the descriptive characteristics of beneficiaries by receipt of 
timely care in the WV and US populations.  Overall, the proportion of beneficiaries 
receiving timely care was 78.7% in the WV population and 77.5% in the US population.  
However, this population variation in overall receipt of timely care was not significant.  
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Significant population variation in receipt of timely care was observed only among 
beneficiaries diagnosed in the year 2004.  Specifically, the proportion of beneficiaries 
diagnosed in the year 2004 receiving timely care was higher in the WV population as 
compared to the US population (83.2% vs. 78.7%) (p ≤ 0.05).  In both populations, 
compared to beneficiaries receiving non-timely care, beneficiaries receiving timely care 
had SCLC and were diagnosed at late stage (p ≤ 0.05).  Variations in receipt of timely 
care by age, race, urban-rural residence, comorbidity score, and year of diagnosis were 
only observed among beneficiaries in the US population (p ≤ 0.05).  
   
Factors associated with receipt of timely care 
Controlling for all sociodemographic variables, lung cancer type and stage remained 
strong predictors of receipt of timely care in all three models (Table 3.6).  Specifically, 
compared to beneficiaries with late stage diagnosis, beneficiaries diagnosed at early 
stage were less likely to receive timely care and these odds gradually increased with 
increase in stage at diagnosis (p ≤ 0.05).  Beneficiaries with NSCLC were also less 
likely to receive timely care as compared to beneficiaries with SCLC (p ≤ 0.05).  While 
no other factor significantly predicted receipt of timely care in model 1 (WV population), 
age, race, comorbidity score, and census tract level measure of income significantly 
predicted receipt of timely care in model 2 (US population) and model 3 (Combined 
population).  Compared to beneficiaries aged 80 years and older, beneficiaries aged 66 
to 69 years were 10% more likely to receive timely care (p ≤ 0.05).  Beneficiaries of non-
white race were 21% less likely to receive timely care as compared to whites (p ≤ 0.05).  
The likelihood of receipt of timely care was also higher among beneficiaries with low 
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comorbidity score compared to those with high comorbidity score (p ≤ 0.05).  Finally, the 
likelihood of receipt of timely care decreased with decrease in median household 
income (p ≤ 0.05).  Gender, urban-rural residence, and census tract level measure of 
education were not statistically significant in any model.  After controlling for all 
sociodemographic variables, population variation in likelihood of beneficiaries receiving 
timely care was not significant. 
 
Survival outcomes by receipt of timely care 
Table 3.7 shows the three year survival rates and median survival times by receipt of 
timely care and by lung cancer type, among beneficiaries in the WV and US 
populations.  Overall, timely care was associated with poorer survival outcomes only 
among beneficiaries in the US population (p ≤ 0.05).  In stratified analysis by lung 
cancer type, similar results were observed among beneficiaries in the US population (p 
≤ 0.05).  However, in the WV population timely care was associated with poorer survival 
outcomes only among beneficiaries with SCLC (p ≤ 0.05).  Among those beneficiaries 
receiving non-timely care, survival outcomes were also poorer in the WV population as 
compared to the US population (p ≤ 0.05).  Among beneficiaries receiving timely care, 
survival outcomes were better in the WV population as compared to the US population 
(p ≤ 0.05).  Significant population variations in survival by receipt of timely care were 
also observed among beneficiaries in the stratified analysis by cancer type.  
Figure 3.1 compares the three year Kaplan-Meier survival curves by cancer 
stage and by receipt of timely care in the WV and US populations.  In both populations, 
among beneficiaries with early stage disease (stage I or stage II) better survival 
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outcomes with receipt of timely care were observed, but were not significant.  However, 
timely care was associated with significantly poorer survival outcomes among 
beneficiaries with stage IV disease in the WV population, and among those with stage 
III/IV disease in the US population.  Significant population variation in survival outcomes 
by receipt of timely care were also observed among beneficiaries with late stage 
disease (stage III or stage IV), and were generally poorer in the WV population as 
compared to the US population. 
 
Lung cancer mortality risk associated with non-receipt of timely care  
In all Cox proportional hazards models, the adjusted lung cancer mortality risk was 
significantly lower among beneficiaries not receiving timely care, relative to those who 
did receive timely care (Table 3.8).  Specifically, lung cancer mortality risk among 
beneficiaries not receiving timely care decreased by 25% in the WV population, by 32% 
in the US population, and by 31% in the combined population (p ≤ 0.05).  In all models, 
NSCLC diagnosis, early stage disease, and young age were the only other factors 
independently associated with lower lung cancer specific mortality (p ≤ 0.05).  While no 
other factor was independently associated with lung cancer specific mortality in model 1 
(WV population), male sex, higher comorbidity score, less education and low income, 
were significantly associated with higher lung cancer specific mortality in model 2 (US 
population) and model 3 (Combined population).  After controlling for all clinical and 
sociodemographic variables, and for timeliness of care, population variation in lung 
cancer mortality risk was significantly higher among beneficiaries in the WV population 
as compared to the US population. 
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 In stratified analysis by lung cancer type, receipt of non-timely care was 
associated with lower lung cancer specific mortality within each population (p ≤ 0.05) 
(Table 3.9).  However, in stratified analysis by cancer stage, similar results were 
observed only among beneficiaries with stage IV disease in the WV population and 
among those with stage III/IV disease in the US population (p ≤ 0.05). 
 
Discussion 
Compared to other types of cancer, lung cancer diagnosis in the elderly is usually 
associated with poor prognosis.  This burden is especially higher among elderly residing 
in rural and medically underserved regions of the US.38-40  Reducing delays in diagnosis 
and treatment of lung cancer have the potential to prolong survival in this population.  In 
this study, using cancer registry-linked Medicare administrative data files, we compared 
geographic variations in timeliness of lung cancer care and associated health outcomes 
among elderly in a representative rural and medically underserved state population, and 
in a representative US population. 
Overall, delays in diagnosis and treatment ranged widely and also varied 
significantly among beneficiaries with lung cancer in the WV and US populations.  The 
median delay from symptom to diagnosis was more than six months in either 
population.  Such delays may occur, as several invasive procedures may be needed to 
establish the diagnosis.  These delays could be minimized if all investigations are 
planned during the initial visit to a physician.  Compared to the US population, ‘chest x-
ray to specialist visit’ delay was longer among beneficiaries in the WV population.  This 
may have resulted from shortage of qualified health professionals in the medically 
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underserved state.  Longer ‘symptom to diagnosis’ delay was also observed among 
female beneficiaries and among beneficiaries residing in urban areas in the WV 
population, as compared to the US population.  Diagnosis to treatment intervals were 
similar to that reported in a prior study by Riedel and colleagues, and were shorter 
among beneficiaries in the WV population as compared to the US population.22  In 
either population, surgically treated patients had longer delays than those treated non-
surgically, a difference that is likely to reflect the extra time needed to refer patents to 
thoracic surgeon for additional treatment consideration.  A multidisciplinary team 
approach involving both surgeons and oncologist in the care process, may help to 
minimize such delay.6  Population variations in diagnosis and treatment delay were also 
observed by clinical characteristics, and may be related to differences in disease 
severity, comorbid illness burden, physician and/or individual treatment preferences.   
Timely care was received by most beneficiaries in each population and was 
highest among those receiving radiotherapy.  Contrary to what we expected, the 
proportion of beneficiaries receiving timely care did not vary between the two 
populations.  Controlling for other factors, beneficiaries with NSCLC disease, as 
compared to SCLC disease, and those with early stage diagnosis as compared to late 
stage diagnosis, were less likely to receive timely care in both populations.  This finding 
is likely as patients with limited disease may have to wait significantly longer for 
treatment than those with advanced disease.6  The finding also indicates that severity of 
disease at presentation may influence the speed of the medical decision-making 
process.  Differences in receipt of timely care by age, race, comorbidity, and census 
tract level measure of income were only observed in the US population.  Contrary to 
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results from a prior study, increasing age was inversely associated with receipt of timely 
care in the US population.29  This may occur as compared to younger individuals some 
physicians may be conservative in their choice of aggressive treatment for the elderly, 
given its impact on patient morbidity and quality of life.  Similar to results found in prior 
studies, comorbidity was inversely associated with receipt of timely care in the US 
population.30;36  This may be due to less aggressive treatment approach by physicians 
in elderly with higher comorbidities, or due to individual preference to avoid aggressive 
treatments in favor of better quality of life.  Increasing poverty was associated with a 
decrease in likelihood of receipt of timely care in the US population.  Compared to the 
US population, the WV population is poorer and that may explain the non-significance of 
income on receipt of timely care among beneficiaries in the WV population.  Similar to 
results found in a prior study, gender, urban-rural residence, and education were not 
associated with receipt of timely care in either population.30  After controlling for all 
sociodemographic variables, likelihood of receipt of timely care among beneficiaries in 
the WV and US populations were not significantly different. 
This study is one of the few that have assessed the influence of timely lung 
cancer care on survival outcomes.  Contrary to what would be expected, the results of 
this study indicate that non-timely care is not associated with poorer prognosis in lung 
cancer.  This results corroborate findings from earlier studies.8;10;24;36;37  Survival 
outcomes associated with receipt of timely care varied by lung cancer type and stage 
among beneficiaries in both the populations.  Similar to findings from prior studies, the 
association between shorter delay and poorer outcomes was most pronounced in 
patients with advanced stage disease in both populations.37  Compared to the US 
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population, survival outcomes were poorer among beneficiaries receiving non-timely 
care and among those with late stage disease in the WV population.  In both 
populations, we found the adjusted lung cancer mortality risk significantly lower among 
beneficiaries not receiving timely care than those who did receive such care.  However, 
the magnitude of risk associated with non-receipt of timely care was higher in the WV 
population than in the US population.  Young age, early stage disease, and NSCLC 
diagnosis were the only other factors independently associated with lower lung cancer 
mortality risk in both populations.  This is true given that the treatment management for 
beneficiaries is easier among those with early stage disease compared to late stage 
disease, and is also easier also among those with NSCLC diagnosis compared to SCLC 
diagnoses.  Variations in lung cancer mortality risk by sex, comorbidity score, education 
and income were only observed in the US population.  In stratified analysis, by cancer 
type and stage, we again found the adjusted lung cancer mortality risk significantly 
lower among beneficiaries not receiving timely care than those who did receive such 
care, and the results were most pronounced in patients with advanced stage disease.  
After controlling for the variability associated with receipt of timely care and all 
sociodemographic variables, lung cancer mortality risk was significantly higher among 
beneficiaries in WV population as compared to the US population.  This finding 
highlights the need to address underlying geographic disparities in lung cancer risk. 
Based on mathematical models of lung cancer growth, it takes 10-15 years from 
appearance of the first cancer cell to the possibility of detecting lung cancer by 
conventional chest x-ray.66  Given this slow growth, it seems unlikely that the prognosis 
is changed by delay in diagnosis or treatment, and the results from this study agree to 
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that theory.  However, the tumor volume expands exponentially, and it can turn from 
being potentially curable to incurable over a period of 1 month.67  Timely care may 
therefore be beneficial in patients with tumors with aggressive phenotypes.  
Nonetheless, delays in diagnosis and treatment should be avoided, as it may increase 
psychological stress in patients.68     
Although delays in diagnosis and treatment varied between the two populations, 
significant population variation in receipt of timely care was not observed in this study.  
These findings are contrary to what would be expected given that the WV population is 
more rural and medically underserved, and has a higher lung cancer mortality rate, as 
compared to the US population.  The finding suggests that observed geographic 
differences in lung cancer mortality may not be associated with variation in receipt of 
timely care among elderly beneficiaries with an incident diagnosis of lung cancer.  
However, population variation in lung cancer mortality risk was observed in this study.  
This may have resulted from higher lung cancer incidence in WV population, as 
compared to the US population.  Higher incidence may also partly explain the disparities 
seen in lung cancer mortality among these populations.  Future cancer prevention 
efforts directed towards promoting smoking cessation are much needed in rural WV 
population, where the smoking prevalence rates are the highest in the nation.69  In the 
long run, these cancer prevention efforts can help reduce the incidence of lung cancer 
in this rural population which in turn can help reduce the geographic disparities in lung 
cancer mortality. 
The findings from this study are subject to several limitations.  Although we used 
cancer registry linked claims data, an inherent limitation of using administrative claims 
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data for epidemiologic studies is the possibility of misclassification as a result of coding 
errors.70;71  However, claims data have been evaluated for their utility as a source of 
epidemiologic or health services information in cancer patients.70-74  Increasing the use 
of these types of data to assess the quality of cancer care has also been identified as a 
priority by the Institute of Medicine.75  Studies using claims data are usually population 
based and have the potential to address a number of priority questions regarding the 
quality of cancer care and health care disparities.  These population-based studies 
provide valuable information for future planning and prioritization of health programs 
that improve cancer outcomes.  Therefore, there is an increasing interest in analyzing 
large health claims databases to assess treatment and outcomes for cancer.70;71;75
The results of this study are generalizable only to the elderly Medicare FFS 
population aged 66 years and older, as encounter data for Medicare recipients enrolled 
in the managed care plan were not available for this study.  There was a small increase 
in the percentage of Medicare recipients enrolled in managed care during the study 
years in both populations; in 2007 it was ~16% in WV population and ~19% in the US 
population.76  Information on care received by the Medicare recipients outside of the 
Medicare system or through non-Medicare providers was also not available in the 
claims data for our study.  However, Medicare is the largest and most comprehensive 
insurance provider to the elderly in the US.  Racial disparities in cancer outcomes could 
not be ascertained in this study as the populations were predominantly White. 
One of the inclusion criteria for cohort selection in this study was continuous 
enrollment in Medicare Part A and B during the study period.  This resulted in the non-
inclusion of individuals with non-continuous enrollment and the loss of individuals who 
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were enrolled intermittently.  Given the limitations in our data sources, the delays in 
diagnosis and treatment were defined appropriately using claim dates, and may not be 
exact.  Retrospective review of health services usage to estimate date of earliest lung 
cancer symptoms was limited to the year prior to diagnosis since findings from prior 
research have shown delays in symptom to diagnosis to be less than a year.77  Our 
estimates of ‘symptom to diagnosis’ delay may be biased, as beneficiaries in whom 
earliest symptom date could not be identified were excluded from our analysis.  These 
beneficiaries may have either had no health services usage or may have had no 
Medicare claim with an ICD-9 code associated with lung cancer symptom in the year 
prior to diagnosis.  It is less likely that we missed any reported lung cancer symptom as 
the list of symptoms searched for in this study was comprehensive, and was derived 
from ACCP guidelines for management and treatment of lung cancer (Appendix 3.1).78  
Overall, date of earliest lung cancer symptom was identified in 88% of beneficiaries in 
WV population, and in 90% of beneficiaries in the US population.  Our estimates of 
‘symptom to diagnosis’ delay may also be biased, as the earliest symptom identified 
may have been unrelated to lung cancer.  We acknowledge that our definition of timely 
care may be too narrow, and that given the heterogeneity of patients seen by 
physicians, receipt of non-timely care or no care may still be considered appropriate.  
Furthermore, given the limitations in our data sources we could not determine whether 
delays in lung cancer diagnosis and treatment were attributable to patient’s delay in 
seeking medical services.  None the less, our definition of timely care provides a 
conceptual framework to assess and compare patterns of care that were prevalent 
during the years 2002 through 2007.  Because of limited data availability at the time of 
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study, we were unable to conduct a long-term (5-10 years) follow-up to assess the 
health outcomes associated with receipt of timely care.  Individual level socioeconomic 
measures of educational attainment, marital status, and family income were also 
unavailable for this study.  However aggregate measures of socioeconomic status at the 
census tract level from 2000 decennial census data were used as a proxy.  Finally, our 
definition of timely versus non-timely care is limited to the data recorded in the claims 
such as the presence or absence of ICD-9 diagnosis and procedure codes, HCPCS 
procedure codes, CPT procedure codes and revenue center codes.  Future studies can 
overcome the barriers seen in this study by collecting data on physician behaviors and 
patient preferences on treatment choices. 
This study is the first of its kind to compare geographic variations in timely lung 
cancer care based on clinical opinion-based guidelines and associated health outcomes 
among elderly Medicare FFS beneficiaries.  Although lung cancer diagnostic and 
management services are covered under Medicare program, delays in diagnosis and 
treatment among recipients in the Medicare FFS population are a concern.  Increasing 
patient awareness of lung cancer symptoms and better coordination of care among 
providers may help to reduce the delays in diagnosis and treatment.  Results of this 
study also emphasize the need to address disparities in receipt of timely care among 
recipients in the Medicare FFS population.  Although longer delay in treatment is not 
associated with poorer prognosis, delayed care may increase the risk of disease 
progression and psychological stress in patients.  Finally, increased lung cancer risk 
and incidence among the elderly from economically underdeveloped and medically 
underserved regions, such as WV, may be the reason behind observed geographical 
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disparities in lung cancer mortality.  Promoting smoking cessation among individuals 
residing in such rural areas has the potential to reduce observed geographic disparities 
in lung cancer mortality. 
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Figure 3.1. Kaplan-Meier survival curves by cancer stage, and by receipt of timely lung 
cancer care, based on clinical opinion-based guidelines, among continuously enrolled 
Medicare Fee-for-service beneficiaries with incident diagnosis of lung cancer in West 
Virginia and in the United States from 2003 through 2004.  Curves (unadjusted) show 
cause-specific mortality. 
 
WV = West Virginia population, US = United States population represented by the Surveillance, Epidemiology and End Results 
(SEER) population, CI = confidence interval, - = median survival time not yet reached.   
Stage based on American Joint Committee on Cancer (AJCC), Tumor Node Metastasis (TNM) system.   
*  Survival times and rates were obtained from Kaplan-Meier survival estimates.   
^  Upper limit of confidence interval is not available because of censoring. 
Timeliness of lung cancer care determined using British Thoracic Society and RAND Corporation clinical opinion-based guidelines 
for diagnosis and management of lung cancer. 
#  Log-rank test (p ≤ 0.05) comparing differences in survival by receipt of timely care, among beneficiaries within US population.  
+  Log-rank test (p ≤ 0.05) comparing differences in survival by receipt of timely care, among beneficiaries within WV population.  
$  Log-rank test (p ≤ 0.05) comparing population differences in survival among beneficiaries receiving timely care.  
@  Log-rank test (p ≤ 0.05) comparing population differences in survival among beneficiaries receiving non-timely care. 
Source: West Virginia Cancer Registry - Medicare linked data files, 2002-2007, Surveillance, Epidemiology and End Results - 
Medicare linked data files, 2002-2007. 
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Table 3.1. Descriptive characteristics of continuously enrolled Medicare Fee-for-service 
beneficiaries with incident diagnosis of lung cancer in West Virginia and in the United 
States from 2003 through 2006. 
 Proportion (%) 
 NSCLC  SCLC Characteristics 
 WV  US  WV   US 
          
Overall, n (%) 
 
1,641    
(85.3)  
42,089  
(86.2)  
283       
(14.7)  
6,761     
(13.8) 
          
AJCC TNM stage * # + ^         
 I  27.1  20.8  7.1  5.5 
 II  9.4  4.5  4.6  2.1 
 III  23.6  29.3  25.8  30.3 
 IV  39.9  45.5  62.5  62.1 
          
Age (years) * ^         
 66-69  22.6  19.1  25.8  23.8 
 70-74  29.9  25.9  30.0  28.9 
 75-79  26.3  26.0  23.7  26.1 
 80 or more  21.2  28.9  20.5  21.1 
          
Gender * ^         
 Male  58.0  52.1  53.0  47.4 
 Female  42.0  47.9  47.0  52.6 
          
Race * # ^         
 Other  2.1  13.3  0.7  9.4 
 White  97.9  86.7  99.3  90.6 
          
Urban-rural residence * # + ^         
 Metro  54.2  83.1  60.4  80.1 
 Urban  40.1  14.9  32.5  17.3 
 Rural  5.7  2.0  7.1  2.6 
          
Comorbidity, Charlson score * ^         
 0  26.9  31.9  30.0  29.7 
 1  30.0  28.6  30.0  28.5 
 2 or more  43.1  39.5  39.9  41.8 
          
Year of diagnosis * ^         
 2003  22.1  26.7  25.1  26.0 
 2004  25.5  24.5  25.4  26.2 
 2005  25.9  24.6  25.4  24.5 
  2006   26.6  24.2  24.0   23.3 
WV = West Virginia population, US = United States population represented by the Surveillance, Epidemiology and End Results 
(SEER) population, NSCLC = Non-Small Cell Lung Cancer, SCLC = Small Cell Lung Cancer, AJCC = American Joint Committee 
on Cancer, TNM = Tumor Node Metastasis. 
*  Chi-square test (p ≤ 0.05) measuring association between beneficiary characteristics and population type, among beneficiaries 
with non-small cell lung cancer.  
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#  Chi-square test (p ≤ 0.05) measuring association between beneficiary characteristics and population type, among beneficiaries 
with small cell lung cancer.   
+  Chi-square test (p ≤ 0.05) measuring association between beneficiary characteristics and cancer type, among beneficiaries in 
West Virginia population. 
^  Chi-square test (p ≤ 0.05) measuring association between beneficiary characteristics and cancer type, among beneficiaries in 
United States population.   
Source: West Virginia Cancer Registry - Medicare linked data files, 2002-2007, Surveillance, Epidemiology and End Results - 
Medicare linked data files, 2002-2007.
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Table 3.2. Earliest symptoms reported among continuously enrolled Medicare Fee-for-
service beneficiaries with incident diagnosis of lung cancer in West Virginia and in the 
United States from 2003 through 2006.    
 West Virginia       (N = 1,702)  
United States ~      
(N = 43,833) Symptom  ^
 No.  %  No.  % 
          
Symptom of primary tumor         
 Cough  262  15.4  6,143  14.0 
 Weight loss  88  5.2  2,087  4.8 
 Dyspnea  252  14.8  6,820  15.6 
 Chest pain  372  21.9  8,947  20.4 
 Hemoptysis  0  0.0  0  0.0 
 Bone pain  44  2.6  1,107  2.5 
 Clubbing  0  0.0  3  0.0 
 Fever  35  2.1  925  2.1 
 Weakness  254  14.9  6,519  14.9 
 Superior vena cava obstruction  1  0.1  71  0.2 
 Dysphagia  30  1.8  680  1.6 
 Wheezing and stridor  31  1.8  462  1.1 
          
Symptoms of intrathoracic spread  37  2.2  1,228  2.8 
Symptoms of extrathoracic 
metastases  240  14.1  6,501  14.8 
Paraneoplastic syndromes  337  19.8  9,553  21.8 
~  United States population represented by the Surveillance, Epidemiology and End Results (SEER) population. 
^  Earliest symptoms reported among beneficiaries were identified from the earliest Medicare claim in the year prior to cancer 
diagnosis, which had an International Classification of Disease (ICD-9) code associated with lung cancer symptom.   
Source: West Virginia Cancer Registry - Medicare linked data files, 2002-2007, Surveillance, Epidemiology and End Results - 
Medicare linked data files, 2002-2007.
Table 3.3. Delays in diagnosis and treatment among continuously enrolled Medicare Fee-for-service beneficiaries with 
incident diagnosis of lung cancer in West Virginia and in the United States from 2003 through 2006.     
  West Virginia   United States ~
Type of delay ^
 N  
Median 
(days)  25-75% IQR (days)  N  
Median 
(days)  
25-75% IQR 
(days) 
              
Symptom to diagnosis +  1,702  189  39 to 313  43,833  187  36 to 308 
 Symptom to chest x-ray  1,591  9  0 to 136  37,302  15  0 to 154 
 
Chest x-ray to specialist visit 
* 662  21  2 to 109  19,066  14  2 to 69 
 Referral delay *  513  0  0 to 6  14,349  1  0 to 7 
 Specialist delay *  662  11  2 to 73  19,066  14  5 to 63 
              
Diagnosis to treatment *  1,420  22  7 to 44  32,441  25  12 to 45 
 Diagnosis to surgery *  407  29  0 to 56  7,073  33  13 to 55 
 Diagnosis to radiation  597  20  8 to 41  13,644  22  10 to 42 
  Diagnosis to chemotherapy * 416  21  11 to 38   11,724  25  13 to 43 
IQR = Interquartile range.   
~  United States population represented by the Surveillance, Epidemiology and End Results (SEER) population. 
*  Mann-Whitney test (p ≤ 0.05) comparing population differences in delay between beneficiaries from West Virginia population and the United States population.   
+  The number of beneficiaries included in the calculation of median delay varied by type of delay, as not all beneficiaries experienced the event of interest necessary to calculate the 
delay. 
^  'Symptom to diagnosis' delay is time from the earliest Medicare claim date, which had an International Classification of Disease (ICD-9) code associated with lung cancer symptom, 
until the date of cancer diagnosis. 'Symptom to chest x-ray' delay is the time from the earliest Medicare claim date, which had an ICD-9 code associated with lung cancer symptom, 
until the date of first Medicare claim for a chest x-ray.  'Chest x-ray to specialist' delay is the time from the first Medicare claim for chest x-ray, until the date of first Medicare claim on 
which the service provider was a specialist.  Specialist delay is the time from the Medicare claim for the first specialist appointment until the date of cancer diagnosis.  Referral delay 
is the time from the last Medicare claim associated with services provided by the referring physician, until the date of first Medicare claim on which the service provider was the 
referred specialist.  'Diagnosis to treatment' interval is the time from cancer diagnosis, until the date of first Medicare claim for surgery, radiation, or chemotherapy.   
Source: West Virginia Cancer Registry - Medicare linked data files, 2002-2007, Surveillance, Epidemiology and End Results - Medicare linked data files, 2002-2007.
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Table 3.4. Delays (in days) in diagnosis and treatment in relation to clinical characteristics among continuously enrolled 
Medicare Fee-for-service beneficiaries with incident diagnosis of lung cancer in West Virginia and in the United States 
from 2003 through 2006. 
  Symptom to diagnosis delay ^   Diagnosis to treatment interval ^
 WV  US  WV  US Characteristics 
 N  Median (IQR)  N Median (IQR)  N Median (IQR)  N  Median (IQR) 
                  
Lung cancer type ~ @ †                 
 NSCLC #  1,456  193 (43 to 311)  37,792  188 (38 to 308)  1,217  24 (8 to 48)  27,643  27 (13 to 48) 
 SCLC #  246  155 (21 to 314)  6,041  178 (27 to 306)  203  14 (7 to 28)  4,798  18 (8 to 31) 
                  
AJCC TNM stage + ~ @ †                
 I #  418  222 (66 to 319)  8,428  219 (63 to 319)  388  29 (6 to 55)  6,878  34 (15 to 58) 
 II #  154  215 (69 to 314)  1,847  188 (40 to 311)  133  29 (11 to 56)  1,682  33 (17 to 56) 
 III #  407  175 (35 to 308)  12,916  189 (37 to 307)  342  22 (8 to 41)  9,679  26 (13 to 47) 
 IV #  723  167 (28 to 307)  20,642  169 (28 to 302)  557  19 (7 to 35)  14,202  20 (9 to 37) 
                  
Age (years) + ~ †                 
 66-69  384  152 (23 to 307)  8,441  146 (24 to 293)  355  22 (8 to 45)  7,404  24 (11 to 43) 
 70-74 #  509  187 (43 to 307)  11,487  174 (31 to 304)  454  22 (7 to 42)  9,483  25 (12 to 46) 
 75-79 #  442  195 (44 to 308)  11,477  197 (42 to 311)  365  22 (10 to 43)  8,559  25 (12 to 46) 
 80 or more #  367  223 (54 to 322)  12,428  213 (54 to 315)  246  20 (7 to 49)  6,995  26 (12 to 48) 
                  
Gender + ~                 
 Male #  921  151 (31 to 295)  21,904  162 (27 to 299)  783  21 (7 to 42)  16,645  25 (12 to 45) 
 Female * #  781  225 (60 to 322)  21,929  209 (49 to 315)  637  22 (8 to 48)  15,796  25 (12 to 46) 
                  
Race ~ †                 
 Other  30  221 (77 to 325)  5,500  191 (41 to 313)  21  26 (15 to 56)  3,846  27 (12 to 51) 
 White #  1,672  189 (39 to 312)  38,333  187 (36 to 307)  1,399  21 (7 to 44)  28,595  25 (12 to 45) 
                  
Urban-rural 
residence ~                 
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 Metro #  943  181 (34 to 309)  36,248  190 (38 to 308)  778  21 (7 to 48)  27,020  25 (12 to 46) 
 Urban *  656  194 (42 to 317)  6,648  167 (30 to 304)  551  22 (8 to 43)  4,759  25 (12 to 43) 
 Rural #  103  209 (78 to 298)  937  169 (27 to 299)  91  19 (7 to 41)  662  25 (12 to 44) 
                  
Comorbidity, 
Charlson score + ~ †                 
 0 *  388  29 (8 to 218)  12,127  43 (11 to 222)  368  22 (9 to 45)  10,271  24 (12 to 43) 
 1 #  518  171 (47 to 304)  12,932  171 (40 to 296)  450  21 (7 to 43)  9,832  25 (12 to 45) 
 2 or more #  796  253 (112 to 329)  18,774  259 (122 to 331)  602  22 (7 to 44)  12,338  26 (12 to 47) 
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WV = West Virginia population, US = United States population represented by the Surveillance, Epidemiology and End Results (SEER) population, NSCLC = Non-Small Cell Lung 
Cancer, SCLC = Small Cell Lung Cancer, AJCC = American Joint Committee on Cancer, TNM = Tumor Node Metastasis, IQR = 25-75% Interquartile range. 
*  Mann-Whitney test (p ≤ 0.05) comparing population differences in 'symptom to diagnosis' delay between beneficiaries from West Virginia population and the United States 
population.   
#  Mann-Whitney test (p ≤ 0.05) comparing population differences in ‘diagnosis to treatment’ interval between beneficiaries from West Virginia population and the United States 
population.   
+  Kruskal-Wallis/Mann-Whitney test (p ≤ 0.05) comparing differences in 'symptom to diagnosis' delay among beneficiaries within West Virginia population.   
@  Kruskal-Wallis/Mann-Whitney test (p ≤ 0.05) comparing differences in ‘diagnosis to treatment’ interval among beneficiaries within West Virginia population.   
~  Kruskal-Wallis/Mann-Whitney test (p ≤ 0.05) comparing differences in 'symptom to diagnosis' delay among beneficiaries within the United States population.   
†  Kruskal-Wallis/Mann-Whitney test (p ≤ 0.05) comparing differences in ‘diagnosis to treatment’ interval among beneficiaries within the United States population. 
^  'Symptom to diagnosis' delay is time from the earliest Medicare claim date, which had an International Classification of Disease (ICD-9) code associated with lung cancer symptom, 
until the date of cancer diagnosis.  ‘Diagnosis to treatment’ interval is the time from cancer diagnosis, until the date of first Medicare claim for surgery, radiation, or chemotherapy. 
Source: West Virginia Cancer Registry - Medicare linked data files, 2002-2007, Surveillance, Epidemiology and End Results - Medicare linked data files, 2002-2007. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.5. Descriptive characteristics by receipt of timely lung cancer care, based on 
clinical opinion-based guidelines, among continuously enrolled Medicare Fee-for-
service beneficiaries with incident diagnosis of lung cancer in West Virginia and in the 
United States from 2003 through 2006. 
  Timely Care ~  Non-timely Care 
 WV  US  WV  US Characteristics 
 No.  % #  No.  % #  No.  % #  No.  % #
                  
Overall  1,118  78.7  25,139  77.5  302  21.3  7,302  22.5 
                  
Lung cancer type + ^               
 NSCLC  935  76.8  20,960  75.8  282  23.2  6,683  24.2 
 SCLC  183  90.2  4,179  87.1  20  9.9  619  12.9 
                  
AJCC TNM stage + ^               
 I  287  74.0  4,924  71.6  101  26.0  1,954  28.4 
 II  99  74.4  1,220  72.5  34  25.6  462  27.5 
 III  271  79.2  7,315  75.6  71  20.8  2,364  24.4 
 IV  461  82.8  11,680  82.2  96  17.2  2,522  17.8 
                  
Age (years) ^                 
 66-69  279  78.6  5,857  79.1  76  21.4  1,547  20.9 
 70-74  365  80.4  7,330  77.3  89  19.6  2,153  22.7 
 75-79  284  77.8  6,642  77.6  81  22.2  1,917  22.4 
 80 or more  190  77.2  5,310  75.9  56  22.8  1,685  24.1 
                  
Gender                 
 Male  626  79.9  12,953  77.8  157  20.1  3,692  22.2 
 Female  492  77.2  12,186  77.1  145  22.8  3,610  22.9 
                  
Race ^                 
 Other  14  66.7  2,818  73.3  7  33.3  1,028  26.7 
 White  1,104  78.9  22,321  78.1  295  21.1  6,274  21.9 
                  
Urban-rural 
residence ^
                
 Metro  596  76.6  20,833  77.1  182  23.4  6,187  22.9 
 Urban  446  80.9  3,777  79.4  105  19.1  982  20.6 
 Rural  76  83.5  529  79.9  15  16.5  133  20.1 
                  
Comorbidity, 
Charlson score ^
                
 0  284  77.2  8,123  79.1  84  22.8  2,148  20.9 
 1  361  80.2  7,638  77.7  89  19.8  2,194  22.3 
 2 or more  473  78.6  9,378  76.0  129  21.4  2,960  24.0 
                  
Year of diagnosis ^               
 2003  264  79.8  6,762  79.1  67  20.2  1,786  20.9 
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 2004 *  306  83.2  6,450  78.7  62  16.8  1,749  21.3 
 2005  278  77.0  6,214  77.5  83  23.0  1,804  22.5 
  2006   270   75.0  5,713  74.4  90  25.0   1,963  25.6 
WV = West Virginia population, US = United States population represented by the Surveillance, Epidemiology and End Results 
(SEER) population, NSCLC = Non-Small Cell Lung Cancer, SCLC = Small Cell Lung Cancer, AJCC = American Joint Committee 
on Cancer, TNM = Tumor Node Metastasis.   
~  Timeliness of lung cancer care determined using British Thoracic Society and RAND Corporation clinical opinion-based guidelines 
for diagnosis and management of lung cancer. 
#  Proportions reported are row percentages of beneficiaries receiving timely care, or non-timely care, within WV or the US 
population.  
*  Chi-square test (p ≤ 0.05), measuring association between receipt of timely care and population type, among beneficiaries within 
each row category. 
+  Chi-square test (p ≤ 0.05) measuring association between beneficiary characteristics and receipt of timely care, among 
beneficiaries in West Virginia population. 
^  Chi-square test (p ≤ 0.05) measuring association between beneficiary characteristics and receipt of timely care, among 
beneficiaries in United States population.   
Source: West Virginia Cancer Registry - Medicare linked data files, 2002-2007, Surveillance, Epidemiology and End Results - 
Medicare linked data files, 2002-2007.
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Table 3.6. Factors associated with receipt of timely lung cancer care, based on clinical 
opinion-based guidelines, among continuously enrolled Medicare Fee-for-service 
beneficiaries with incident diagnosis of lung cancer in West Virginia and in the United 
States from 2003 through 2006. 
      Odds Ratio (95% Confidence Interval) 
     Model 1: WV  Model 2: US  Model 3: WV + US 
        
Intercept (p-value) 0.11  0.07  0.09 
        
Population       
 WV  NA  NA  1.03 (0.85 to 1.24) 
 US  NA  NA  1 (Ref) 
        
Lung cancer type      
 NSCLC  0.40*** (0.24 to 0.66)  0.51*** (0.47 to 0.56)  0.51*** (0.47 to 0.56) 
 SCLC  1 (Ref)  1 (Ref)  1 (Ref) 
        
AJCC TNM stage      
 I  0.67* (0.48 to 0.93)  0.59*** (0.55 to 0.64)  0.59*** (0.56 to 0.64) 
 II  0.69 (0.43 to 1.09)  0.60*** (0.53 to 0.68)  0.60*** (0.54 to 0.68) 
 III  0.83 (0.58 to 1.19)  0.68*** (0.64 to 0.73)  0.69*** (0.64 to 0.73) 
 IV  1 (Ref)  1 (Ref)  1 (Ref) 
        
Age (years)       
 66-69  1.06 (0.70 to 1.59)  1.10* (1.02 to 1.20)  1.10* (1.01 to 1.19) 
 70-74  1.24 (0.84 to 1.85)  1.02 (0.94 to 1.10)  1.02 (0.95 to 1.10) 
 75-79  1.06 (0.71 to 1.58)  1.07 (1.00 to 1.16)  1.07 (0.99 to 1.15) 
 80 or more  1 (Ref)  1 (Ref)  1 (Ref) 
        
Gender       
 Male  1.16 (0.89 to 1.52)  1.05 (0.99 to 1.10)  1.05 (1.00 to 1.11) 
 Female  1 (Ref)  1 (Ref)  1 (Ref) 
        
Race       
 Other  0.60 (0.21 to 1.69)  0.79*** (0.73 to 0.86)  0.79*** (0.73 to 0.86) 
 White  1 (Ref)  1 (Ref)  1 (Ref) 
        
Urban-rural 
residence 
      
 Metro  0.63 (0.33 to 1.19)  0.89 (0.72 to 1.11)  0.86 (0.70 to 1.06) 
 Urban  0.91 (0.48 to 1.73)  1.01 (0.80 to 1.26)  1.00 (0.80 to 1.23) 
 Rural  1 (Ref)  1 (Ref)  1 (Ref) 
        
Comorbidity, 
Charlson 
score       
 0  0.85 (0.61 to 1.17)  1.13*** (1.06 to 1.20)  1.12*** (1.05 to 1.19) 
 1  1.07 (0.78 to 1.47)  1.08* (1.01 to 1.15)  1.07* (1.01 to 1.14) 
 2 or more  1 (Ref)  1 (Ref)  1 (Ref) 
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Percentage 
with some 
college 
education ^       
 0.0-0.10  0.70 (0.24 to 2.08)  0.62 (0.01 to 0.69)  0.60 (0.51 to 0.72) 
 0.11-0.20  1.01 (0.74 to 1.37)  0.69 (0.11 to 0.75)  1.02 (1.00 to 1.90) 
 ≥ 0.21  1 (Ref)  1 (Ref)  1 (Ref) 
        
Median 
household 
income ^
      
 0-25000  0.74 (0.33 to 1.63)  0.89* (0.80 to 0.98)  0.89* (0.80 to 0.98) 
 25001-50000  1.03 (0.49 to 2.17)  0.93 (0.84 to 1.01)  0.93 (0.85 to 1.02) 
  ≥ 50001   1 (Ref)  1 (Ref)  1 (Ref) 
WV = West Virginia population, US = United States population represented by the Surveillance, Epidemiology and End Results 
(SEER) population, Ref = reference category, NA = Not Applicable, NSCLC = Non-Small Cell Lung Cancer, SCLC = Small Cell 
Lung Cancer, AJCC = American Joint Committee on Cancer, TNM = Tumor Node Metastasis. 
*  Estimates are statistically significant (p ≤ 0.05).   
**  Estimates are statistically significant (p ≤ 0.01). 
***  Estimates are statistically significant (p ≤ 0.001). 
^  Census tract level measures of beneficiaries socioeconomic status. 
Model 1: WV population (N = 1,420), Fit Statistics: -2 restricted log pseudo-likelihood = 6639.58, Covariance parameter estimates: 
Intercept = county, estimate = 0.14, standard error = 0.10. 
Model 2: US population (N = 32,441), Fit Statistics: -2 restricted log pseudo-likelihood = 150424.20, Covariance parameter 
estimates: Intercept = county, estimate = 0.09, standard error = 0.02. 
Model 3: Combined WV + US population (N = 33,861), Fit Statistics: -2 restricted log pseudo-likelihood = 157037.00, Covariance 
parameter estimates: Intercept = county, estimate = 0.09, standard error = 0.02. 
Timeliness of lung cancer care determined using British Thoracic Society and RAND Corporation clinical opinion-based guidelines 
for diagnosis and management of lung cancer. 
Source: West Virginia Cancer Registry - Medicare linked data files, 2002-2007, Surveillance, Epidemiology and End Results - 
Medicare linked data files, 2002-2007. 
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Table 3.7. Three-year median survival time and survival rate by cancer type, and by receipt of timely lung cancer care, 
based on clinical opinion-based guidelines, among continuously enrolled Medicare Fee-for-service beneficiaries with 
incident diagnosis of lung cancer in West Virginia and in the United States from 2003 through 2004. 
 Timely Care ~  Non-timely Care   
 WV  US  WV  US 
          
Overall $ @ #         
 N  570  13,212  129  3,535 
 Percent censored  30.9%  25.2%  31.8%  32.8% 
 Median survival time, days (95% CI) *  299 (262 to 364)  273 (266 to 282)  467 (344 to 692)  491 (466 to 508) 
 3-year survival rate (95% CI) *  0.26 (0.22 to 0.30)  0.21 (0.20 to 0.22)  0.27 (0.19 to 0.35)  0.28 (0.27 to 0.30) 
          
NSCLC $ @ #         
 N  473  10,949  122  3,269 
 Percent censored  34.7%  27.9%  32.8%  33.9% 
 Median survival time, days (95% CI) *  364 (276 to 460)  281 (271 to 291)  472 (344 to 705)  500 (479 to 520) 
 3-year survival rate (95% CI) *  0.30 (0.26 to 0.35)  0.24 (0.23 to 0.25)  0.28 (0.20 to 0.37)  0.29 (0.28 to 0.31) 
          
SCLC $ + #         
 N  97  2,263  7  266 
 Percent censored  12.4%  12.4%  14.3%  20.3% 
 Median survival time, days (95% CI) *  236 (164 to 270)  252 (239 to 266)  427 (113 to 958)  372 (324 to 428) 
  3-year survival rate (95% CI) *  0.06 (0.02 to 0.12)  0.07 (0.06 to 0.09)  0  0.16 (0.11 to 0.21) 
WV = West Virginia population, US = United States population represented by the Surveillance, Epidemiology and End Results (SEER) population, NSCLC = Non-small cell lung 
cancer, SCLC = Small cell lung cancer, CI = confidence interval. 
*  Survival times and rates were obtained from Kaplan-Meier survival estimates. 
~  Timeliness of lung cancer care determined using British Thoracic Society and RAND Corporation clinical opinion-based guidelines for diagnosis and management of lung cancer. 
$  Log-rank test (p ≤ 0.05) comparing population differences in survival among beneficiaries receiving timely care.  
@  Log-rank test (p ≤ 0.05) comparing population differences in survival among beneficiaries receiving non-timely care. 
#  Log-rank test (p ≤ 0.05) comparing differences in survival by receipt of timely care, among beneficiaries within US population. 
+  Log-rank test (p ≤ 0.05) comparing differences in survival by receipt of timely care, among beneficiaries within WV population.    
Source: West Virginia Cancer Registry - Medicare linked data files, 2002-2007, Surveillance, Epidemiology and End Results - Medicare linked data files, 2002-2007. 
 
 
 
Table 3.8. Lung cancer mortality risk associated with receipt of non-timely lung cancer 
care, based on clinical opinion-based guidelines, among continuously enrolled Medicare 
Fee-for-service beneficiaries with incident diagnosis of lung cancer in West Virginia and 
in the United States from 2003 through 2004. 
      Hazard Ratio (95% Confidence Interval) 
   Model 1: WV  Model 2: US  Model 3: WV + US 
        
Population       
 WV  NA  NA  1.14* (1.00 to 1.29) 
 US  NA  NA  1 (Ref) 
        
Timeliness of care ~       
 Non-timely care  0.75* (0.60 to 0.95)  0.68*** (0.66 to 0.71)  0.69*** (0.66 to 0.72) 
 Timely care  1 (Ref)  1 (Ref)  1 (Ref) 
        
Lung cancer type       
 NSCLC  0.78* (0.61 to 0.99)  0.94** (0.90 to 0.98)  0.93** (0.89 to 0.98) 
 SCLC  1 (Ref)  1 (Ref)  1 (Ref) 
        
AJCC TNM stage       
 I  0.16*** (0.12 to 0.22)  0.15*** (0.14 to 0.16)  0.15*** (0.14 to 0.16) 
 II  0.28*** (0.20 to 0.40)  0.28*** (0.25 to 0.31)  0.28*** (0.25 to 0.31) 
 III  0.49*** (0.39 to 0.62)  0.52*** (0.50 to 0.54)  0.52*** (0.50 to 0.54) 
 IV  1 (Ref)  1 (Ref)  1 (Ref) 
        
Age (years)       
 66-69  0.76* (0.57 to 1.00)  0.70*** (0.66 to 0.75)  0.71*** (0.67 to 0.75) 
 70-74  0.74* (0.56 to 0.98)  0.75*** (0.71 to 0.79)  0.75*** (0.71 to 0.79) 
 75-79  0.93 (0.70 to 1.25)  0.80*** (0.77 to 0.84)  0.81*** (0.77 to 0.85) 
 80 or more  1 (Ref)  1 (Ref)  1 (Ref) 
        
Gender       
 Male  1.10 (0.91 to 1.32)  1.24*** (1.20 to 1.28)  1.23*** (1.19 to 1.27) 
 Female  1 (Ref)  1 (Ref)  1 (Ref) 
        
Race       
 Other  1.27 (0.61 to 2.61)  0.97 (0.90 to 1.04)  0.97 (0.91 to 1.04) 
 White  1 (Ref)  1 (Ref)  1 (Ref) 
        
Urban-rural residence       
 Metro  0.99 (0.62 to 1.58)  1.00 (0.88 to 1.14)  1.01 (0.89 to 1.14) 
 Urban  1.18 (0.73 to 1.91)  0.99 (0.87 to 1.13)  1.01 (0.88 to 1.15) 
 Rural  1 (Ref)  1 (Ref)  1 (Ref) 
        
Comorbidity, Charlson 
score 
      
 0  0.92 (0.74 to 1.14)  0.87*** (0.83 to 0.91)  0.87*** (0.83 to 0.91) 
 1  0.93 (0.76 to 1.14)  0.90*** (0.86 to 0.94)  0.90*** (0.86 to 0.94) 
 2 or more  1 (Ref)  1 (Ref)  1 (Ref) 
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Percentage with some 
college education ^
      
 0.0-0.10  0.99 (0.43 to 2.29)  1.91** (1.18 to 3.11)  1.15* (0.56 to 2.36) 
 0.11-0.20  0.86 (0.69 to 1.07)  1.89** (1.15 to 3.05)  0.89 (0.72 to 1.09) 
 ≥ 0.21  1 (Ref)  1 (Ref)  1 (Ref) 
        
Median household income ^       
 0-25000  1.18 (0.66 to 2.11)  1.22*** (1.13 to 1.33)  1.22*** (1.13 to 1.33) 
 25001-50000  0.96 (0.56 to 1.63)  1.10* (1.02 to 1.19)  1.10* (1.02 to 1.18) 
  ≥ 50001   1 (Ref)  1 (Ref)   1 (Ref) 
WV = West Virginia population, US = United States population represented by the Surveillance, Epidemiology and End Results 
(SEER) population, NSCLC = Non-Small Cell Lung Cancer, SCLC = Small Cell Lung Cancer, AJCC = American Joint Committee 
on Cancer, TNM = Tumor Node Metastasis, Ref = reference category, NA = Not Applicable. 
*  Estimates are statistically significant (p ≤ 0.05). 
**  Estimates are statistically significant (p ≤ 0.01).   
***  Estimates are statistically significant (p ≤ 0.001).   
^  Census tract level measures of beneficiaries socioeconomic status. 
Model 1: WV population (N = 699), Fit Statistics: -2 log likelihood = 5767.84 (without covariates) and 5511.39 (with covariates), 
Global null hypothesis: Likelihood ratio chi-square test = 256.4 (p ≤ 0.05). 
Model 2: US population (N = 16,747), Fit Statistics: -2 log likelihood = 223470.70 (without covariates) and 217646.99 (with 
covariates), Global null hypothesis: Likelihood ratio chi-square test = 5823.7 (p ≤ 0.05). 
Model 3: Combined WV + US population (N = 17,446), Fit Statistics: -2 log likelihood = 233349.14 (without covariates) and 
227268.20 (with covariates), Global null hypothesis: Likelihood ratio chi-square test = 6075.9 (p ≤ 0.05). 
~  Timeliness of lung cancer care determined using British Thoracic Society and RAND Corporation clinical opinion-based guidelines 
for diagnosis and management of lung cancer. 
Source: West Virginia Cancer Registry - Medicare linked data files, 2002-2007, Surveillance, Epidemiology and End Results - 
Medicare linked data files, 2002-2007. 
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Table 3.9. Adjusted lung cancer mortality risk associated with receipt of non-timely lung 
cancer care, based on clinical opinion-based guidelines, by cancer type and stage, 
among continuously enrolled Medicare Fee-for-service beneficiaries with incident 
diagnosis of lung cancer in West Virginia and in the United States from 2003 through 
2004. 
  Hazard Ratio ^ (95% Confidence Interval) 
   WV  US 
      
Lung cancer type     
 NSCLC  0.77* (0.60 to 0.98)  0.68*** (0.65 to 0.71) 
 SCLC  0.33*** (0.19 to 0.57)  0.68*** (0.60 to 0.78) 
      
AJCC TNM stage     
 I  1.22 (0.73 to 2.06)  1.01 (0.90 to 1.13) 
 II  0.69 (0.30 to 1.56)  1.04 (0.82 to 1.31) 
 III  0.78 (0.49 to 1.23)  0.71*** (0.66 to 0.76) 
  IV   0.53*** (0.39 to 0.74)  0.58*** (0.55 to 0.62) 
WV = West Virginia population, US = United States population represented by the Surveillance, Epidemiology and End Results 
(SEER) population, NSCLC = Non-Small Cell Lung Cancer, SCLC = Small Cell Lung Cancer, AJCC = American Joint Committee 
on Cancer, TNM = Tumor Node Metastasis. 
*  Estimates are statistically significant (p ≤ 0.05). 
***  Estimates are statistically significant (p ≤ 0.001).   
^  Hazard ratios associated with receipt of non-timely care (Reference: Receipt of timely care), adjusted for age, gender, race, urban-
rural residence, comorbidity, and census tract level measure of education and income. 
Timeliness of lung cancer care determined using British Thoracic Society and RAND Corporation clinical opinion-based guidelines 
for diagnosis and management of lung cancer. 
Stage I: WV: N = 205, US: N = 3,478; Stage II: WV: N = 60, US: N = 766; Stage III: WV: N = 163, US: N = 5,291; Stage IV: WV: N = 
271, US: N = 7,212.  NSCLC: WV: N = 595, US: N = 14,218; SCLC: WV: N = 104, US: N = 2,529.   
Source: West Virginia Cancer Registry - Medicare linked data files, 2002-2007, Surveillance, Epidemiology and End Results - 
Medicare linked data files, 2002-2007. 
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CHAPTER 4: 
PATTERNS OF RECEIPT OF TOBACCO-USE CESSATION COUNSELING 
SERVICES AND ASSOCIATED HEALTH OUTCOMES AMONG ELDERLY MEDICARE 
FEE-FOR-SERVICE BENEFICIARIES WITH LUNG CANCER, AND WITH A HISTORY 
OF TOBACCO USE, IN WEST VIRGINIA 
 
Introduction 
Tobacco use is the leading preventable cause of lung cancer in the United States (US).  
It accounts for 90% of all lung cancer cases, and for 87% of all lung cancer deaths in 
the US.1  The causal association of tobacco use with lung cancer is one of the most 
thoroughly documented causal relationships in biomedical research.2;3  More individuals 
die of lung cancer each year than the next three most common cancers combined 
(colon, breast, and prostate), and the efforts to decrease lung cancer mortality have 
been focused on early detection and treatment of lung cancer and smoking avoidance 
and cessation.4-7        
Clinical practice guidelines for preventive care in lung cancer have been 
published by American Society of Clinical Oncology (ASCO), authors Biesalski et al, 
Cancer Guidance Group (CGG), College des Medecins du Quebec, National Cancer 
Institute (NCI), US Department of Health and Human Services (DHHS), and US 
Preventive Services Task Force.8-13  While these guidelines recommend smoking 
cessation among asymptomatic individuals, it is strongly encouraged among individuals 
diagnosed with lung cancer.  This is because, growing evidence suggests that smoking 
may compromise the effectiveness of lung cancer treatment, reduce the tolerance of 
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patients for lung cancer treatment, and increase the risk of complications.14  Specifically, 
continued smoking following lung cancer diagnosis can interfere with cancer therapies, 
such as radiation therapy and chemotherapy, increase risk of infection due to surgery 
and decrease post-operative wound healing.14
Prior research has shown smoking to be common among patients at the time of 
lung cancer diagnosis, and that patients continue to smoke following diagnosis.  In one 
study of smoking behavior among 840 adults with stage I non-small cell lung cancer 
(NSCLC), 60% of patients were smokers at the time of diagnosis, and only 40% of them 
had quit smoking after two years.15  However, almost 90% of patients had made one or 
more attempts to quit smoking, suggesting an increased motivation to quit.15  Continued 
smoking after lung cancer diagnosis was associated with lower quality of life among 
patients in one study.16  Among lung cancer patients receiving surgery, a history of 
smoking doubled the likelihood of complications in another study.17   
Continued smoking, following lung cancer diagnosis, also increases the risk of 
metachronous tumors/new primary cancer for up to 20 years after original diagnosis.14  
In two studies of survivors of small cell lung cancer (SCLC), the risk of a second cancer 
was higher among those who continued to smoke, and the risk was particularly higher 
following curative-intent therapy.18;19  However, in individuals who stopped smoking at 
the time of diagnosis, the risk was no higher than in those who had stopped smoking at 
least six months before diagnosis.   
Studies examining survival outcomes associated with continued smoking have 
reported mixed results.  In one study of patients with SCLC, continued smokers had the 
poorest survival, followed by patients who had quit at diagnosis, and then by patients 
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who had quit on average 2.5 years before diagnosis.20  However, survival curves of 
recent ex-smokers did not differ statistically from continued smokers.  In another study, 
no significant differences in prognosis in resected stage I NSCLC patients, were 
observed on the basis of smoking status.21  Regardless of its impact on survival, 
promoting smoking cessation among lung cancer patients at the time of diagnosis is 
much needed.  Time of cancer diagnosis has also been described as a teachable 
moment for intervening with smokers and providing cessation treatment.22
Given the fact that smoking is common among patients with lung cancer, 
preventive care services, such as tobacco-use cessation counseling can have a 
profound impact on health outcomes.  To that end, many insurance agencies including 
Medicare cover tobacco-use cessation counseling services.  Beginning in March 2005, 
the Centers for Medicare and Medicaid Services (CMS) began providing coverage for 
tobacco-use cessation counseling for outpatient and hospitalized beneficiaries, who 
were smokers and had a disease or adverse health effect that is tobacco related or who 
were taking a medication whose metabolism or effect is affected by tobacco use.23  
However, the use of such services and its impact on health outcomes among elderly 
lung cancer patients remains unknown.  To this end, the main focus of this study is to 
determine the patterns of receipt of tobacco-use cessation counseling services among 
elderly Medicare Fee-for-service (FFS) beneficiaries with lung cancer and with a history 
of tobacco use in a state population.  Specifically, the objectives of this study include: 
(1) to determine the proportion of elderly lung cancer patients receiving tobacco-use 
cessation counseling services; (2) to determine the factors associated with receipt of 
tobacco-use cessation counseling services among elderly lung cancer patients; (3) to 
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determine survival benefits associated with receipt of tobacco-use cessation counseling 
services among elderly lung cancer patients; and (4) to determine lung cancer mortality 
risk associated with non-receipt of tobacco-use cessation counseling services among 
elderly lung cancer patients. 
 
Methods 
 
Data sources 
This retrospective study was conducted using cancer registry linked Medicare data files 
for the years 2004 through 2007.  While cancer registry data files provide clinical, 
demographic, cause of death, initial treatment, and tobacco-use history information for 
elderly individuals with lung cancer in selected geographic regions, the Medicare 
administrative data files provided the health service claims information for care provided 
by physicians, inpatient hospital stays, hospital outpatient clinics, home health care 
agencies, skilled nursing facilities, and hospice programs.   
Specifically, the West Virginia Cancer Registry (WVCR) - Medicare linked data 
files were used to estimate the receipt to tobacco-use cessation counseling services 
and associated health outcomes among elderly lung cancer patients with a history of 
tobacco use.  The WVCR-Medicare linked data files are similar in structure to the well 
known Surveillance, Epidemiology, and End Results (SEER) - Medicare linked data 
files, and represent data from the West Virginia (WV) Cancer Registry, which does not 
participate in the SEER program.  Unlike the SEER-Medicare data files, the WVCR-
Medicare data files contain information on history of tobacco use among individuals 
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diagnosed with lung cancer, and were therefore used for this study.  Details on the 
creation of WVCR-Medicare linked data files can be found elsewhere.24  West Virginia is 
also the third most rural state in the nation, and is the only state situated entirely within 
the Appalachian region, a region well known for cancer disparities.25  The state has the 
second highest lung cancer death rate and the highest smoking prevalence rate 
(26.8%) in the nation.26  During 2002-2006, the age-adjusted lung cancer incidence rate 
(WV: 481.5 per 100,000, US: 378.5 per 100,000), and mortality rate (WV: 390.6 per 
100,000, US: 310.8 per 100,000) among the elderly were higher in the state in 
comparison to rest of the country.27;28  Fifty of the 55 counties in the state are 
designated as medically underserved areas, and all or part of 40 counties in the state 
are classified as health professional shortage areas.29  The state is similar to many 
other rural and medically underserved states, and therefore serves as an excellent 
laboratory for studying and addressing lung cancer disparities in the rural and medically 
underserved population. 
 
Study population 
We initially identified all Medicare FFS beneficiaries, aged 66 years and older with an 
incident lung cancer diagnosis between July 1, 2005 and October 31, 2007, and with a 
history of tobacco use from the WVCR-Medicare linked data files.  Lung cancer 
diagnosis was identified among individuals in the cancer registry files using International 
Classification of Diseases for Oncology (ICD-O) codes (C34.0, C34.1, C34.2, C34.3, 
C34.8, C34.9, and C33.9).  Lung cancer stage was identified using American Joint 
Committee on Cancer (AJCC), Tumor Node Metastasis (TNM), 6th edition stage.30;31  
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While Medicare eligibility starts at age 65, we only included beneficiaries aged 66 years 
and older at the time of diagnosis, so that we would have a full year of Medicare claims 
before lung cancer diagnosis for assessing comorbidity.  We then excluded individuals 
with multiple primary cancer diagnosis or whose diagnosis was made only at the time of 
death (death certificate review/autopsy diagnosis).  We also excluded beneficiaries who 
were enrolled in Medicare managed care plan or who had non-continuous Medicare 
Part A and Part B enrollment in the year prior to diagnosis, and during the two months 
following diagnosis.  This is because their Medicare files would not have complete 
health services usage information.  The remaining cohort (Cohort A) of continuously 
enrolled elderly Medicare FFS beneficiaries was then used to determine the proportion 
of beneficiaries receiving tobacco-use cessation counseling services, and to determine 
the factors associated with receipt of tobacco-use cessation counseling services. 
Given the limited years of data available for follow up in our data sources, we 
identified a separate cohort to determine association between receipt of tobacco-use 
cessation counseling services and survival outcomes.  Specifically, we selected 
beneficiaries aged 66 years and older, with an incident lung cancer diagnosis (Stages I-
IV) between July 1, 2005 and December 31, 2005, and with a history of tobacco use 
from the WVCR-Medicare linked data files.  We then excluded individuals with multiple 
primary cancer diagnosis or whose diagnosis was made only at the time of death (death 
certificate review\autopsy diagnosis).  We also excluded beneficiaries who were 
enrolled in Medicare managed care plan or who had non-continuous Medicare Part A 
and Part B enrollment, in the year prior to diagnosis and during the year following 
diagnosis.  The remaining cohort (Cohort B) was then followed for two years following 
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the incident lung cancer diagnosis to determine lung cancer specific mortality.  This 
cohort was then used to determine survival benefits associated with receipt of tobacco-
use cessation counseling services, and to determine lung cancer mortality risk 
associated with non-receipt of tobacco-use cessation counseling services. 
 
Assessing receipt of tobacco-use cessation counseling services 
In both cohort A and B, continuously enrolled elderly Medicare FFS beneficiaries were 
followed for two months following incident lung cancer diagnosis to determine receipt of 
tobacco-use cessation counseling services.  A cessation counseling session refers to 
face-to-face patient contact by the practitioner following an incident lung cancer 
diagnosis and can be minimal (3 minutes or less), intermediate (3-10 minutes), or 
intensive (greater than 10 minutes).  Tobacco-use cessation counseling services were 
identified from the Medicare claim data files using appropriate Current Procedural 
Terminology (CPT) codes (Appendix 4.1).   
 
Dependent variables 
The primary outcome of interest was receipt of tobacco-use cessation counseling 
services, which was categorized as: (a) receipt, or (b) non-receipt.  Survival time in days 
was calculated for each beneficiary from the time of incident lung cancer diagnosis to 
date of death or the two year follow-up cutoff date, which ever came first.  To estimate 
lung cancer specific survival, beneficiaries who were not found to be deceased by the 
cutoff date, or who died due to causes other than lung cancer were censored at that 
time and considered to be alive.  We measured lung cancer specific survival instead of 
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overall survival, since we wanted to determine the association between receipt of 
tobacco-use cessation counseling services and survival. 
 
Independent variables 
The main independent variables were lung cancer type and stage, age at diagnosis, 
gender, race, urban-rural residence, Charlson comorbidity index score, census tract 
level measures of education and income, and receipt of minimally appropriate clinical 
guideline based lung cancer care.  These variables were considered in our analysis 
because of their prognostic significance.  Lung cancer type was categorized based on 
cell histology.  Beneficiaries with ICD-O histology codes 8000-8040 or 8046-9989 were 
categorized as NSCLC, and those with codes 8041-8045 were categorized as SCLC.  
Lung cancer stage was categorized based on AJCC TNM staging system.30;31  Age at 
diagnosis was categorized as 66-69 years, 70-74 years, 75-79 years, and 80 years and 
older.  Given that the WV population is predominantly White, race was classified as 
White and others.  Based on Rural-Urban Continuum codes developed by the US 
Department of Agriculture (USDA), urban-rural residence was categorized as Metro, 
Urban, and Rural.  Charlson comorbidity index score was calculated using diagnosis 
and procedure codes reported in Medicare inpatient claims from the year prior to the 
incident lung cancer diagnosis.32-34  Comorbidities related to cancer were excluded from 
the index score.  The Charlson comorbidity index score was used to categorize 
comorbidity into three groups: 0, 1 and 2 or more, with a higher score indicating a 
greater burden of comorbid illness.   
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Given the lack of individual socioeconomic status measures in our data sources, 
we used as proxy, the year 2000 US Census tract level measures of college education 
and income.35  Specifically, we used the percentage of individuals in the census tract 
with some college education as a proxy measure for education, and categorized it 
based on tertile distribution as 0%-0.10%, 0.11%-0.20%, and 0.21% or greater.  
Similarly, we used median household income at the census tract level as a proxy 
measure of income, and categorized it based on tertile distribution as $0-25,000, 
$25,000-50,000, and $50,001 or more.   
To account for the variability in receipt of lung cancer treatment while estimating 
lung cancer mortality risk associated with non-receipt of tobacco-use cessation 
counseling services, we estimated the receipt of minimally appropriate clinical guideline 
based lung cancer care among beneficiaries in cohort B.  Specifically, continuously 
enrolled elderly Medicare FFS beneficiaries in cohort B were followed for one year 
following incident lung cancer diagnosis to determine receipt of minimally appropriate 
clinical guideline based lung cancer care (hereafter referred to as ‘minimally appropriate 
care’).  Minimally appropriate care was defined using the American College of Chest 
Physicians (ACCP) evidence-based guidelines for diagnosis and management of lung 
cancer, published in January, 2003.36  We choose ACCP evidence-based guidelines, as 
they are the most comprehensive of all published clinical guidelines.36-40  Figure 4.1 
shows the algorithm adapted from the ACCP guidelines, and used to determine receipt 
of minimally appropriate care.  Lung cancer specific treatments and procedures were 
identified from the Medicare claim data files using appropriate International 
Classification of Diseases (ICD-9) diagnosis and procedure codes, Healthcare Common 
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Procedure Coding System (HCPCS) codes, Current Procedural Terminology (CPT) 
codes and revenue center codes (Appendix 4.1). 
 
Data Analysis 
The Pearson chi-square test was used to determine unadjusted associations between 
categorical variables of interest.  Hierarchical generalized logistic model was 
constructed with PROC GLIMMIX procedure in SAS 9.2 41 to assess the association 
between independent variables and the receipt of tobacco-use cessation counseling 
services.  In the model, the estimated probability of a beneficiary receiving tobacco-use 
cessation counseling services conditioned on a set of predictor variables was modeled.  
The hierarchical model was chosen as individual measures of socioeconomic status 
were not available in our data sources, and that we relied on census tract level 
measures of education and income.  This was done by treating census tract as a 
random effect to account for potential correlation among beneficiaries within the same 
county.  Odds ratios, 95% confidence intervals, and two-sided p-values were calculated 
for each predictor. 
Nonparametric estimates of the survivor function by receipt of tobacco-use 
cessation counseling services were calculated using the Kaplan-Meier method.  The 
log-rank test was used to assess the statistical significance of the differences between 
the survival curves.  Two-year survival estimates were also computed by receipt of 
tobacco-use cessation counseling services. 
Two multivariate Cox proportional hazards models were constructed to estimate 
lung cancer mortality risk associated with non-receipt of tobacco-use cessation 
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counseling services.  While the first model controlled for variability in beneficiary’s 
clinical and sociodemographic characteristics, the second model additionally controlled 
for the variability in receipt of lung cancer treatment.  To evaluate the proportional 
hazards assumption, we plotted smoothed Schoenfeld residuals against time and found 
no evidence of a systematic deviation from proportional hazards in any model.  
Variance in Cox models were adjusted to account for patient clustering at the census 
tract level by use of the robust inference of Lin and Wei.42  Adjusted hazard ratios, 95% 
confidence intervals and their two-sided p-values were calculated for each predictor. 
All data were analyzed using the SAS Version 9.2 (SAS Institute, Cary, NC) 
statistical software package.41  Results were considered to be statistically significant 
when p ≤ 0.05.  This study was approved by the West Virginia Institutional Review 
Board, and is in full compliance with federal, state, and institutional regulations and 
guidelines. 
 
 
Results 
Based on study inclusion and exclusion criteria, we identified 922 continuously enrolled 
elderly Medicare FFS beneficiaries in cohort A.  Table 4.1 shows the distribution of 
clinical and sociodemographic characteristics of these beneficiaries by type of lung 
cancer.  Overall, majority of beneficiaries had late stage disease, were in the age group 
70-74 years, were of white race, resided in metro areas, and had comorbidity scores of 
two or more.  While a majority of these beneficiaries had NSCLC (82.8%), the 
distribution of beneficiary characteristics by lung cancer type did not vary significantly, 
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except by cancer stage.  Specifically, compared to beneficiaries with SCLC, 
beneficiaries with NSCLC were diagnosed at earlier stages (p ≤ 0.05). 
 
Receipt of tobacco-use cessation counseling services 
Table 4.2 shows the descriptive characteristics of beneficiaries by receipt of tobacco-
use cessation counseling services.  Overall, the proportion of beneficiaries receiving 
tobacco-use cessation counseling services was high (76.7%) in the study population.  
Receipt of tobacco-use cessation counseling services was higher among beneficiaries 
with early stage disease compared to those with late stage disease (p ≤ 0.05).  
Compared to older beneficiaries, the proportion of beneficiaries receiving tobacco-use 
cessation counseling services was also higher among younger beneficiaries, and the 
proportions significantly decreased with increase in age.  Receipt of tobacco-use 
cessation counseling services was also higher among beneficiaries residing in rural 
areas as compared to those residing in non-rural areas (p ≤ 0.05).  Variations in receipt 
of tobacco-use cessation counseling services by lung cancer type, gender, race, 
comorbidity score, and year of diagnosis were not observed among beneficiaries in the 
study population.  
 
Factors associated with receipt of tobacco-use cessation counseling services 
Controlling for all sociodemographic variables, age remained a strong predictor of 
receipt of tobacco-use cessation counseling services (Table 4.3).  Compared to 
beneficiaries aged 80 years and older, beneficiaries aged 66 to 69 years were more 
than twice likely to receive tobacco-use cessation counseling services, and these odds 
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gradually decreased with increase in age.  Other significant predictors of receipt of 
tobacco-use cessation counseling services were lung cancer stage and rural-urban 
residence.  Specifically, beneficiaries with early stage disease were 55-65% more likely 
to receive tobacco-use cessation counseling services as compared to those with late 
stage disease.  However, the likelihood of receipt of tobacco-use cessation counseling 
services was lower among beneficiaries residing in non-rural areas as compared to 
those residing in rural areas.  Lung cancer type, gender, race, comorbidity, and census 
tract level measure of education and urban-rural residence were not statistically 
significant in the model. 
 
Survival benefits associated with receipt of tobacco-use cessation counseling services 
Figure 4.2 compares the two year Kaplan-Meier survival curves by receipt of tobacco-
use cessation counseling services in cohort B.  The unadjusted two year survival rates 
and median survival times were significantly greater among beneficiaries receiving 
tobacco-use cessation counseling services as compared to those not receiving such 
services (p ≤ 0.05).  Specifically, for beneficiaries who received tobacco-use cessation 
counseling services, the two year median survival time exceeded by 159 days in the 
study population (p ≤ 0.05).   
 
Lung cancer mortality risk associated with non-receipt of tobacco-use cessation 
counseling services  
Controlling for variability in beneficiary’s clinical and sociodemographic characteristics, 
the adjusted lung cancer mortality risk among beneficiaries not receiving tobacco-use 
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cessation counseling services was higher, but not significant (Table 4.4).  The 
magnitude of this risk decreased slightly after controlling for variability in receipt of 
minimally appropriate care among beneficiaries.  Receipt of minimally appropriate care, 
early stage disease, young age, rural residence, higher comorbid illness, and higher 
education, were the only factors independently associated with lower lung cancer 
specific mortality in the study population. 
 
Discussion 
Smoking is common among patients diagnosed with lung cancer.  Promoting smoking 
cessation in these patients is important, as continued smoking has substantial adverse 
effects on treatment effectiveness, risk of second primary malignancies, and quality of 
life.  Lung cancer diagnosis can be used by healthcare providers as a teachable 
moment for smoking cessation, as a patient’s motivation and interest in smoking 
cessation may increase after such an event.  In this study, using cancer registry-linked 
Medicare administrative data files, we determined the patterns of receipt of tobacco-use 
cessation counseling services among elderly Medicare FFS beneficiaries with lung 
cancer and with a history of tobacco use. 
Tobacco-use cessation counseling services were received by more than half of 
all elderly Medicare FFS beneficiaries in the study population.  The use of these 
services was higher among younger beneficiaries, and after controlling for other factors, 
increasing age at diagnosis was associated with decline in receipt of tobacco-use 
cessation counseling services.  This finding may have resulted from variation in 
physician practice patterns, and/or individual treatment preferences.  Compared to 
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younger individuals, poor prognosis is common among older individuals, and that may 
influence physician’s decision to not provide tobacco-use cessation counseling services.  
This observed variation in receipt of tobacco-use cessation counseling services may 
also be related to differences in disease severity, and burden of comorbid illness among 
beneficiaries.  Furthermore, older individuals with poor prognosis may choose to not 
receive such services, regardless of its impact on health outcomes.  Receipt of tobacco-
use cessation counseling was also higher among elderly with early stage disease, as 
compared to those with late stage disease.  This finding is expected, as beneficiaries 
with early stage disease are good candidates for curative therapy, and are expected to 
survive longer than those with late stage disease.  Therefore, beneficiaries with early 
stage disease can expect to have substantial benefits in health outcomes following 
smoking cessation, as compared to those with late stage disease.  This finding is similar 
to that reported in one study, where patients with late stage disease were less likely to 
enroll in smoking cessation programs as compared to those with early stage disease.43  
Surprisingly, receipt of tobacco-use cessation counseling was found to be higher among 
beneficiaries residing in rural areas as compared to those residing in non-rural areas.  
This finding may have resulted from the fact that prevalence of smoking is higher 
among beneficiaries in rural areas, and that awareness of risks associated with 
continued smoking may be higher among these individuals and their providers, resulting 
in increased receipt of tobacco-use cessation counseling services.  
Prior studies of impact of smoking cessation following lung cancer diagnosis on 
survival outcomes have shown mixed results.  Although in this study we could not 
determine the success or failure of tobacco-use cessation counseling attempt, receipt of 
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such services by beneficiaries was associated with longer survival times.  However, it is 
very likely that this finding may have resulted from the increased disease severity 
among beneficiaries who did not receive tobacco-use cessation counseling services.  
When controlled for, such variability in patient clinical and sociodemographic 
characteristics, the adjusted lung cancer mortality risk was higher, but not significant, 
among beneficiaries not receiving tobacco-use cessation counseling services.  Even 
after controlling for the variability in lung cancer care received among beneficiaries, the 
adjusted lung cancer mortality risk remained unchanged.  Receipt of minimally 
appropriate care, early stage disease, young age, rural residence, higher comorbid 
illness, and higher education, were the only factors independently associated with lower 
lung cancer mortality risk.  This finding is expected, as prognosis is better among 
beneficiaries receiving minimally appropriate care and among those with early stage 
disease.  Although findings from this study show no increase in adjusted lung cancer 
mortality risk among beneficiaries not receiving tobacco-use cessation counseling 
services, promoting smoking cessation at any stage of the disease is important.   
The findings from this study are subject to several limitations.  A major limitation 
of this study is the lack of information on success or failure of tobacco-use cessation 
counseling attempts among beneficiaries receiving such services.  Specifically, the data 
sources used for this study do not capture information on whether or not a beneficiary 
quit smoking following the receipt of tobacco-use cessation counseling services.  Such 
information is necessary to accurately quantify the health benefits associated with 
receipt of tobacco-use cessation counseling services.  Given the limited years of follow-
up data, the frequency and intensity of tobacco-use cessation counseling attempts 
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among beneficiaries was also not examined in this study.  Also, any variation in type of 
counseling services offered by different providers was not captured in our data sources, 
and was not controlled for in our analysis.  Although we used cancer registry-linked 
claims data, an inherent limitation of using administrative claims data for epidemiologic 
studies is the possibility of misclassification as a result of coding errors.44;45  However, 
claims data have been evaluated for their utility as a source of epidemiologic or health 
services information in cancer patients.44-48  Increasing the use of these types of data to 
assess the quality of cancer care also has been identified as a priority by the Institute of 
Medicine.49  Studies using claims data are typically population-based and have the 
potential to address a number of priority questions regarding the quality of cancer care 
and health care disparities.  These population-based studies provide valuable 
information for future planning and prioritization of health programs that improve cancer 
outcomes.  Therefore, there is an increasing interest in analyzing large health claims 
databases to assess treatment and outcomes for cancer.44;45;49
The results of this study are generalizable only to the elderly Medicare FFS 
population, aged 66 years and older, as encounter data for Medicare recipients enrolled 
in the managed care plan were not available for this study.  There was a small increase 
in the percentage of Medicare recipients enrolled in managed care during the study 
years; in 2007 it was ~16% in WV population.50  Information on care received by the 
Medicare recipients outside of the Medicare system or through non-Medicare providers 
was also not available in the claims data for our study.  However, Medicare is the 
largest and the most comprehensive insurance provider to the elderly in the US.  Racial 
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disparities in cancer outcomes could not be ascertained in this study, as the population 
was predominantly White. 
One of the inclusion criteria for cohort selection in this study was continuous 
enrollment in Medicare Part A and B during the study period.  This resulted in the non-
inclusion of individuals with non-continuous enrollment and the loss of individuals who 
were enrolled intermittently.  Although the WV legislative rule requires cancer reporting 
sources to provide patient’s tobacco-use history to the WVCR, few records with missing 
information on patient’s tobacco-use history were identified and therefore excluded from 
these study.  It is very likely that these individuals may have been diagnosed at the time 
of death (death certificate review/autopsy diagnosis) or the cancer reporting source may 
have failed to collect information on their tobacco-use history.  We acknowledge that our 
definition of receipt of minimally appropriate care may be too narrow, and that given the 
heterogeneity of patients seen by physicians, receipt of no therapy may still be 
considered as appropriate care.  None the less, our definition of receipt of minimally 
appropriate care provides a conceptual framework to assess and control for treatment 
variability among beneficiaries.  Because of limited data availability at the time of study, 
we were unable to conduct a long-term (5-10 year) follow-up to assess the health 
outcomes associated with receipt of tobacco-use cessation counseling services.  
Individual-level socioeconomic measures of educational attainment, marital status, and 
family income were also unavailable for this study.  However, aggregate measures of 
socioeconomic status at the census tract level from 2000 decennial census data were 
used as a proxy.  Finally our assessment of tobacco-use cessation counseling services 
is limited to the data recorded in the claims.  Future studies can overcome the barriers 
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seen in this study by collecting data on success/failure of counseling attempts, and 
physician behaviors/patient preferences in using tobacco-use cessation counseling 
services. 
Significant reduction in lung cancer mortality can be achieved if elderly receive 
timely and medically effective treatments.  Promoting smoking cessation through 
tobacco-use cessation counseling services is of vital importance to ensure success of 
such treatments.  The diagnosis of lung cancer can be used as a teachable moment for 
smoking cessation.  Although smoking cessation is beneficial, barriers to successful 
smoking cessation attempt include patient’s unwillingness to quit, comorbid conditions, 
or lack of access to care.43  Given that motivation to quit smoking may vary among 
smokers, physicians may benefit by understanding the underlying motivational issues 
through application of theories of behavior change.  Specifically, the Stages of Change 
Model suggests that most individuals attempting to quit smoking may go through 
several predictable stages, from pre-contemplation to contemplation to preparation and, 
finally, to action.  Successful counseling would help to move patients along these 
stages, until they are more motivated to quit. 
This study is the first of its kind to determine the patterns of receipt of tobacco-
use cessation counseling services among elderly Medicare FFS beneficiaries with lung 
cancer, and with a history of tobacco use.  Although preventive care services, such as 
tobacco-use cessation counseling services are covered under Medicare program, 
underutilization of these services among elderly lung cancer patients with a history of 
tobacco use, is a concern.  Most patients with smoking-related cancer would be 
motivated to quit smoking at the time of diagnosis, and promoting smoking cessation in 
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these individuals may improve health outcomes.  Although some encouraging results 
have been demonstrated with use of tobacco-use cessation counseling services in this 
study, more empirical studies of such interventions are needed.  Also, future cancer 
prevention efforts should be directed towards promoting smoking cessation in rural 
populations, such as West Virginia, where the smoking prevalence rates are the highest 
in the nation.  In the long run, these cancer prevention efforts can help reduce the 
incidence of lung cancer, which in turn can help reduce the burden of lung cancer 
mortality.   
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Figure 4.1. Algorithm adapted from American College of Chest Physicians (ACCP) 
evidence-based guidelines for diagnosis and management of lung cancer published in 
January, 2003, and used to determine receipt of minimally appropriate clinical guideline 
based lung cancer care. 
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Figure 4.2. Kaplan-Meier survival curves (with 95% confidence limits) by receipt of 
tobacco-use cessation counseling services among continuously enrolled Medicare Fee-
for-service beneficiaries with an incident diagnosis of lung cancer (Stages I-IV) and with 
a history of tobacco use in West Virginia, July 2005 through December 2005.  Curves 
(unadjusted) show cause-specific mortality.  
 
CI = confidence interval. 
*  Survival times and rates were obtained from Kaplan-Meier survival estimates. 
~  Receipt of tobacco-use cessation counseling services. 
Log-rank test (p ≤ 0.05) comparing differences in survival by receipt of tobacco-use cessation counseling services. 
Source: West Virginia Cancer Registry - Medicare linked data files, 2004-2007. 
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Table 4.1. Descriptive characteristics of continuously enrolled Medicare Fee-for-service 
beneficiaries with an incident diagnosis of lung cancer and with a history of tobacco use 
in West Virginia, July 2005 through October 2007. 
 Proportion (%) Characteristics 
 NSCLC  SCLC 
      
Overall, n (%) 
 
764              
(82.8)  
158             
(17.1) 
      
AJCC TNM stage *     
 I  17.9  4.4 
 II  8.5  1.3 
 III  22.0  21.5 
 IV  27.6  38.0 
 Unstaged  24.0  34.8 
      
Age (years)     
 66-69  23.4  28.5 
 70-74  29.8  27.2 
 75-79  24.9  25.3 
 80 or more  21.9  19.0 
      
Gender     
 Male  57.3  50.0 
 Female  42.7  50.0 
      
Race     
 Other  2.2  0.0 
 White  97.8  100.0 
      
Urban-rural residence     
 Metro  55.8  58.2 
 Urban  38.9  34.8 
 Rural  5.4  7.0 
      
Comorbidity, Charlson score     
 0  20.7  24.7 
 1  30.1  26.6 
 2 or more  49.2  48.7 
      
Year of diagnosis     
 2005 (July-Dec)  21.1  19.6 
 2006  47.0  47.5 
  2005 (Jan-Oct)   31.9  32.9 
NSCLC = Non-Small Cell Lung Cancer, SCLC = Small Cell Lung Cancer, AJCC = American Joint Committee on Cancer, TNM = 
Tumor Node Metastasis. 
*  Chi-square test (p ≤ 0.05) measuring association between beneficiary characteristics and cancer type, among beneficiaires in 
West Virginia. 
Source: West Virginia Cancer Registry - Medicare linked data files, 2004-2007. 
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Table 4.2. Descriptive characteristics by receipt of tobacco-use cessation counseling 
services, among continuously enrolled Medicare Fee-for-service beneficiaries with an 
incident diagnosis of lung cancer and with a history of tobacco use in West Virginia, July 
2005 through October 2007.    
  Receipt ~  Non-receipt Characteristics 
 No.  %  No.  % 
          
Overall  707  76.7  215  23.3 
          
Lung cancer type         
 NSCLC  595  77.9  169  22.1 
 SCLC  112  70.9  46  29.1 
          
AJCC TNM stage *         
 I  126  87.5  18  12.5 
 II  58  86.6  9  13.4 
 III  156  77.2  46  22.8 
 IV  196  72.3  75  27.7 
 Unstaged  171  71.8  67  28.2 
          
Age (years) *         
 66-69  182  81.3  42  18.8 
 70-74  224  82.7  47  17.3 
 75-79  172  74.8  58  25.2 
 80 or more  129  65.5  68  34.5 
          
Gender         
 Male  388  75.0  129  25.0 
 Female  319  78.8  86  21.2 
          
Race         
 Other  12  70.6  5  29.4 
 White  695  76.8  210  23.2 
          
Urban-rural 
residence *
        
 Metro  387  74.7  131  25.3 
 Urban  271  77.0  81  23.0 
 Rural  49  94.2  3  5.8 
          
Comorbidity, 
Charlson score 
        
 0  147  74.6  50  25.4 
 1  216  79.4  56  20.6 
 2 or more  344  75.9  109  24.1 
          
Year of diagnosis         
 2005 (July-Dec)  146  76.0  46  24.0 
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 2006  331  76.3  103  23.7 
 2007 (Jan-Oct)  230  77.7  66  22.3 
NSCLC = Non-Small Cell Lung Cancer, SCLC = Small Cell Lung Cancer, AJCC = American Joint Committee on Cancer, TNM = 
Tumor Node Metastasis.  
~  Receipt of tobacco-use cessation counseling services. 
*  Chi-square test (p ≤ 0.05) measuring association between beneficiary characteristics and receipt of tobacco-use cessation 
counseling services, among beneficiaries in West Virginia. 
Source: West Virginia Cancer Registry - Medicare linked data files, 2004-2007.     
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Table 4.3. Factors associated with receipt of tobacco-use cessation counseling services 
among continuously enrolled Medicare Fee-for-service beneficiaries with an incident 
diagnosis of lung cancer and with a history of tobacco use in West Virginia, July 2005 
through October 2007.     
      
Odds Ratio   95% Confidence Interval   p-value 
        
Intercept (p-value)  NA  NA  0.24 
        
Lung cancer type       
 NSCLC  1.31  0.86 to 1.99  0.20 
 SCLC  1 (Ref) 
        
AJCC TNM stage       
 Unstaged  1.05  0.70 to 1.59  0.81 
 I  2.65**  1.47 to 4.80  < 0.01 
 II  2.55*  1.16 to 5.59  0.02 
 III  1.16  0.74 to 1.81  0.52 
 IV  1 (Ref) 
        
Age (years)       
 66-69  2.58***  1.60 to 4.15  < 0.001 
 70-74  2.69***  1.71 to 4.25  < 0.001 
 75-79  1.68*  1.08 to 2.61  0.02 
 80 or more  1 (Ref) 
        
Gender       
 Male  0.83  0.59 to 1.16  0.27 
 Female  1 (Ref) 
        
Race       
 Other  0.68  0.20 to 2.34  0.52 
 White  1 (Ref) 
        
Urban-rural 
residence       
 Metro  0.16**  0.04 to 0.55  < 0.01 
 Urban  0.19**  0.05 to 0.67  < 0.01 
 Rural  1 (Ref) 
        
Comorbidity, 
Charlson score       
 0  0.93  0.61 to 1.41  0.74 
 1  1.27  0.86 to 1.88  0.23 
 2 or more  1 (Ref) 
        
Percentage with 
some college 
education ^       
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 0.0-0.10  0.34  0.10 to 1.20  0.09 
 0.11-0.20  1.00  0.68 to 1.46  0.99 
 ≥ 0.21  1 (Ref) 
        
Median household 
income ^
      
 0-25000  0.79  0.27 to 2.35  0.67 
 25001-50000  0.89  0.32 to 2.51  0.83 
  ≥ 50001   1 (Ref) 
NSCLC = Non-Small Cell Lung Cancer, SCLC = Small Cell Lung Cancer, AJCC = American Joint Committee on Cancer, TNM = 
Tumor Node Metastasis, Ref = reference category, NA = Not Applicable. 
*  Estimates are statistically significant (p ≤ 0.05). 
**  Estimates are statistically significant (p ≤ 0.01). 
***  Estimates are statistically significant (p ≤ 0.001). 
^  Census tract level measures of beneficiaries socioeconomic status. 
WV population (N = 956), Fit Statistics: -2 restricted log pseudo-likelihood = 4308.15, Covariance parameter estimates: Intercept = 
county, estimate = 0.17, standard error = 0.16. 
Source: West Virginia Cancer Registry - Medicare linked data files, 2004-2007. 
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Table 4.4. Lung cancer mortality risk associated with non-receipt of tobacco cessation 
counseling services among continuously enrolled Medicare Fee-for-service 
beneficiaries with an incident diagnosis of lung cancer (Stages I-IV) and with a history of 
tobacco use in West Virginia, July 2005 through December 2005. 
      Hazard Ratio (95% Confidence Interval) 
     Model 1  Model 2 
      
Tobacco-use cessation 
counseling services     
 Non-receipt  1.78 (0.87 to 3.64)  1.22 (0.59 to 2.51) 
 Receipt  1 (Ref)  1 (Ref) 
      
Appropriateness of care ~     
 In-appropriate care  NA  2.34** (1.38 to 3.95) 
 Minimally appropriate care  NA  1 (Ref) 
      
Lung cancer type     
 NSCLC  1.04 (0.64 to 0.1.71)  0.68 (0.39 to 1.17) 
 SCLC  1 (Ref)  1 (Ref) 
      
AJCC TNM stage     
 I  0.06*** (0.02 to 0.18)  0.08*** (0.03 to 0.23) 
 II  0.30** (0.12 to 0.74)  0.33* (0.14 to 0.82) 
 III  0.51** (0.31 to 0.82)  0.67 (0.42 to 1.06) 
 IV  1 (Ref)  1 (Ref) 
      
Age (years)     
 66-69  0.46* (0.22 to 0.94)  0.48* (0.24 to 0.96) 
 70-74  0.69 (0.31 to 1.55)  0.78 (0.36 to 1.68) 
 75-79  0.48* (0.24 to 0.96)  0.45* (0.22 to 0.91) 
 80 or more  1 (Ref)  1 (Ref) 
      
Gender     
 Male  0.62 (0.37 to 1.03)  0.70 (0.43 to 1.13) 
 Female  1 (Ref)  1 (Ref) 
      
Race     
 Other  0.70 (0.11 to 4.28)  0.85 (0.16 to 4.42) 
 White  1 (Ref)  1 (Ref) 
      
Urban-rural residence     
 Metro  3.12* (1.22 to 7.96)  3.06* (1.11 to 8.46) 
 Urban  2.63 (0.96 to 7.21)  2.45 (0.86 to 6.97) 
 Rural  1 (Ref)  1 (Ref) 
      
Comorbidity, Charlson 
score 
    
 0  2.44*** (1.46 to 4.08)  2.66*** (1.56 to 4.55) 
 1  0.77 (0.43 to 1.39)  0.79 (0.44 to 1.43) 
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 2 or more  1 (Ref)  1 (Ref) 
      
Percentage with some 
college education ^
    
 0.0-0.10  7.77*** (2.50 to 9.08)  7.24*** (2.23 to 9.98) 
 0.11-0.20  0.67 (0.45 to 1.01)  0.79 (0.51 to 1.25) 
 ≥ 0.21  1 (Ref)  1 (Ref) 
      
Median household income ^     
 0-25000  0.76 (0.26 to 2.19)  0.69 (0.26 to 1.83) 
 25001-50000  1.27 (0.57 to 2.80)  1.18 (0.61 to 2.28) 
  ≥ 50001   1 (Ref)  1 (Ref) 
NSCLC = Non-Small Cell Lung Cancer, SCLC = Small Cell Lung Cancer, AJCC = American Joint Committee on Cancer, TNM = 
Tumor Node Metastasis, Ref = reference category, NA = Not Applicable. 
*  Estimates are statistically significant (p ≤ 0.05). 
**  Estimates are statistically significant (p ≤ 0.01).   
***  Estimates are statistically significant (p ≤ 0.001).   
^  Census tract level measures of beneficiaries socioeconomic status. 
~  Minimally appropriate care determined using American College of Chest Physicians (ACCP) evidence-based guidelines for 
diagnosis and management of lung cancer published in January, 2003. 
Model 1: N = 140, Fit Statistics: -2 log likelihood = 835.92 (without covariates) and 758.44 (with covariates), Global null hypothesis: 
Likelihood ratio chi-square test = 77.48 (p ≤ 0.05). 
Model 2: N = 140, Fit Statistics: -2 log likelihood = 835.92 (without covariates) and 750.10 (with covariates), Global null hypothesis: 
Likelihood ratio chi-square test = 85.82 (p ≤ 0.05). 
Source: West Virginia Cancer Registry - Medicare linked data files, 2004-2007. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 154
Bibliography 
 
 (1)  Peto R, Lopez AD, Boreham J, et al. Mortality from smoking in developed 
countries 1950-2000: indrect estimates from national vital statistics. Oxford, UK: 
Oxford University Press, 1994. 
 (2)  US Department of Health, and Human Services (US-DHHS). Reducing the health 
consequences of smoking: 25 years of progress; a report of the Surgeon 
General. Washington, DC: US Goverment Printing Office, 1989. 
 (3)  Zaridze D,.Peto R Tobacco: a major international health hazard. Lyon, France: 
International Agency for Research on Cancer, 1986. 
 (4)  Kelley MJ, McCrory DC. Prevention of lung cancer: summary of published 
evidence. Chest 2003; 123(1 Suppl):50S-59S. 
 (5)  Greenlee RT, Hill-Harmon MB, Murray T et al. Cancer statistics, 2001. CA 
Cancer J Clin 2001; 51(1):15-36. 
 (6)  American Cancer Society. Cancer Facts and Figures, 2012. Available 
at:http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/docume
nts/document/acspc-031941.pdf. Accessed on: January 15, 2013. 
 (7)  U.S. National Institutes of Health. National Cancer Institute: SEER Cancer 
Statistics Review, 1973-2008. Available at: 
http://seer.cancer.gov/csr/1975_2009_pops09/index.html. Accessed on: January 
15, 2013. 
 (8)  Cancer Guidence Group. Guidance on commissioning ancer services; improving 
outcomes in lung cancer: the manual. London, JK: National Health Service 
Executive, 1998. 
 (9)  Colllege des medecins du Quebec. Clinical practice guidelines: smoking 
prevention and cessation; May 1999. Available at: 
http://www.cmq.org/tabacang.pdf. Accessed on: August 16, 2012. 
 (10)  National Cancer Institute. Lung cancer (PDQ): prevention; March 2001. Available 
at: http://www.cancer.gov/cancer_information/pdq. Accessed on: December 
16,2012. 
 (11)  Fiore MC, Bailey WC, Cohen SJ, et al. Treating tobacco use and dependence: 
clinical practice guideline. Rockville, MD: US Department of Health and Human 
Services, Public Health Service, 2000. 
 (12)  US Preventive Services Task Force. Screening for lung cancer. In: Guide to 
clinical preventive services. 2nd ed. Baltimore, MD: Williams & Wilkins, 1996; 
135-139. 
 155
 (13)  Biesalski HK, Bueno de MB, Chesson A et al. Consensus statement on lung 
cancer. Lung Cancer Panel. Eur J Cancer Prev 1997; 6(4):316-322. 
 (14)  National Cancer Institute: PDQ® Smoking in cancer care. Bethesda, MD: 
National Cancer Institute. Date last modified 10/23/2012. Available at: 
http://www.cancer.gov/cancertopics/pdq/supportivecare/smokingcessation/Health
Professional. Accessed on January 19, 2013. 
 (15)  Gritz ER, Nisenbaum R, Elashoff RE et al. Smoking behavior following diagnosis 
in patients with stage I non-small cell lung cancer. Cancer Causes Control 1991; 
2(2):105-112. 
 (16)  Garces YI, Yang P, Parkinson J et al. The relationship between cigarette 
smoking and quality of life after lung cancer diagnosis. Chest 2004; 126(6):1733-
1741. 
 (17)  Kearney DJ, Lee TH, Reilly JJ et al. Assessment of operative risk in patients 
undergoing lung resection. Importance of predicted pulmonary function. Chest 
1994; 105(3):753-759. 
 (18)  Richardson GE, Tucker MA, Venzon DJ et al. Smoking cessation after successful 
treatment of small-cell lung cancer is associated with fewer smoking-related 
second primary cancers. Ann Intern Med 1993; 119(5):383-390. 
 (19)  Tucker MA, Murray N, Shaw EG et al. Second primary cancers related to 
smoking and treatment of small-cell lung cancer. Lung Cancer Working Cadre. J 
Natl Cancer Inst 1997; 89(23):1782-1788. 
 (20)  Johnston-Early A, Cohen MH, Minna JD et al. Smoking abstinence and small cell 
lung cancer survival. An association. JAMA 1980; 244(19):2175-2179. 
 (21)  Gail MH, Eagan RT, Feld R et al. Prognostic factors in patients with resected 
stage I non-small cell lung cancer. A report from the Lung Cancer Study Group. 
Cancer 1984; 54(9):1802-1813. 
 (22)  Gritz ER, Fingeret MC, Vidrine DJ et al. Successes and failures of the teachable 
moment: smoking cessation in cancer patients. Cancer 2006; 106(1):17-27. 
 (23)  Centers for Medicare and Medicaid Services: National Coverage Determination 
for Smoking and Tobacco-Use Cessation Counseling (210.4). Available at: 
http://www.cms.hhs.gov/mcd. Accessed on January 19, 2013. 
 (24)  Nadpara PA, Madhavan SS. Linking Medicare, Medicaid, and Cancer Registry 
data to study the burden of cancers in West Virginia. Medicare Medicaid Res Rev 
2012; 2(4):E1-E25. 
 (25)  Cancer death rates--Appalachia, 1994-1998. MMWR Morb Mortal Wkly Rep 
2002; 51(24):527-529. 
 156
 (26)  Vital signs: current cigarette smoking among adults aged >/=18 years--United 
States, 2005-2010. MMWR Morb Mortal Wkly Rep 2011; 60(35):1207-1212. 
 (27)  United States Cancer Statistics: 1999-2006 Incidence, WONDER On-line 
Database. United States Department of Health and Human Services, Centers for 
Disease Control and Prevention and National Cancer Institute; 2010. Available at 
http://wonder.cdc.gov/cancer-v2006.html. Accessed on: January 15, 2013. 
 (28)  United States Cancer Statistics: 1999-2006 Mortality, WONDER On-line 
Database. United States Department of Health and Human Services, Centers for 
Disease Control and Prevention; 2010. Available at: 
http://wonder.cdc.gov/CancerMort-v2006.html. Accessed on: January 15, 2013. 
 (29)  West Virginia Health Care Authority (WVHCA) West Virginia State Health Plan. 
2010. Available at: http://www.hcawv.org/PolicyPlan/shpBmat/shpProPiper.pdf. 
Accessed on: September 17, 2011. 
 (30)  Mountain CF. A new international staging system for lung cancer. Chest 1986; 
89(4 Suppl):225S-233S. 
 (31)  Mountain CF. Revisions in the International System for Staging Lung Cancer. 
Chest 1997; 111(6):1710-1717. 
 (32)  Charlson ME, Pompei P, Ales KL et al. A new method of classifying prognostic 
comorbidity in longitudinal studies: development and validation. J Chronic Dis 
1987; 40(5):373-383. 
 (33)  Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with 
ICD-9-CM administrative databases. J Clin Epidemiol 1992; 45(6):613-619. 
 (34)  Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use 
with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol 1993; 
46(10):1075-1079. 
 (35)  US Census Bureau. 2000 Census of Population and Housing, Summary File 3: 
Washington, DC: US Census Bureau; 2002. Available at: 
http://www.census.gov/census2000/sumfile3.html. Accessed on : October 15, 
2011. 
 (36)  Diagnosis and management of lung cancer: ACCP evidence-based guidelines. 
American College of Chest Physicians. Chest 2003; 123(1 Suppl):D-337S. 
 (37)  Pfister DG, Johnson DH, Azzoli CG et al. American Society of Clinical Oncology 
treatment of unresectable non-small-cell lung cancer guideline: update 2003. J 
Clin Oncol 2004; 22(2):330-353. 
 157
 (38)  Clinical practice guidelines for the treatment of unresectable non-small-cell lung 
cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology. 
J Clin Oncol 1997; 15(8):2996-3018. 
 (39)  National Comprehensive Cancer Network and American Cancer Society: Lung 
Cancer: Treatment Guidelines for Patients. Version 1, December 2001. Available 
at: http://www.nccn.org. Accessed on: January 15, 2013. 
 (40)  National Cancer Institute: Physician Data Query Cancer Information Summaries. 
Available at: http://www.nci.nih.gov/cancerinfo/pdf/treatment/non-small-cell-
lung/healthprofessional/. Accessed on: January 15, 2013. 
 (41)  SAS Institute Inc. SAS 9.1.3 Help and Documentation. SAS Institute Inc., Cary, 
NC; 2000-2004. 
 (42)  Lin DY, Wei LJ. The robust inference for the Cox Proportional Hazards Model. J 
Am Stat Assoc 1989; 84(408):1074-1078. 
 (43)  Martinez E, Tatum KL, Weber DM et al. Issues related to implementing a 
smoking cessation clinical trial for cancer patients. Cancer Causes Control 2009; 
20(1):97-104. 
 (44)  Potosky AL, Riley GF, Lubitz JD et al. Potential for cancer related health services 
research using a linked Medicare-tumor registry database. Med Care 1993; 
31(8):732-748. 
 (45)  Doebbeling BN, Wyant DK, McCoy KD et al. Linked insurance-tumor registry 
database for health services research. Med Care 1999; 37(11):1105-1115. 
 (46)  Cooper GS, Yuan Z, Stange KC et al. The sensitivity of Medicare claims data for 
case ascertainment of six common cancers. Med Care 1999; 37(5):436-444. 
 (47)  Du X, Freeman JL, Warren JL et al. Accuracy and completeness of Medicare 
claims data for surgical treatment of breast cancer. Med Care 2000; 38(7):719-
727. 
 (48)  Brooks JM, Chrischilles E, Scott S et al. Information gained from linking SEER 
Cancer Registry Data to state-level hospital discharge abstracts. Surveillance, 
Epidemiology, and End Results. Med Care 2000; 38(11):1131-1140. 
 (49)  Hewitt M, Simone JV. Enhancing Data Systems to Improve the Quality of Cancer 
Care. Washington, DC: National Academies Press; 2000. 
 (50)  The Kaiser Family Foundation. Medicare and Medicare Advantage enrollment. 
Available at: 
http://www.statehealthfacts.org/comparecat.jsp?cat=6&rgn=6&rgn=1. Accessed 
on : January 15, 2013.
 158
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 5 
 
 159
CHAPTER 5: 
SUMMARY AND CONCLUSIONS 
 
Study Summary 
In the United States (US), lung cancer is the second most diagnosed cancer and the 
leading cause of cancer deaths in both men and women.1;2  It causes more deaths than 
the next three most common cancers combined (colon, breast, and prostate).1-3  The 
number of deaths due to lung cancer has increased approximately 4.3% between 1999 
and 2008 from 152,156 to 158,656.4  The elderly carry a disproportionate burden of lung 
cancer and this pattern is expected to persist as the estimated number of elderly in the 
US doubles to nearly 70 million by 2030.   
Significant improvements have been made during the past decade in treatment 
and survival after the diagnosis of cancer.5  Still, substantial disparities exist in both 
cancer outcomes and the receipt of guideline-based cancer-related health care.6  Lack 
of timely and high quality cancer care is still a concern and it might be attributable to 
variations in the use of appropriate standards of care and the resulting treatment 
variations.7;8
 A significant reduction in lung cancer mortality can be achieved if elderly patients 
receive timely and medically effective therapies.  Unfortunately, many rural areas of the 
US are economically underdeveloped and medically underserved.9;10  The elderly in 
these regions carry a higher burden of lung cancer compared to their urban 
counterparts.11  These rural areas are also known to report a higher prevalence of lung 
cancer and a higher crude all-cause mortality rates among elderly.12  One such area is 
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the Appalachian region, a population representing 8.1% of the total US population.13  
West Virginia (WV) is the only state situated entirely within the Appalachian region and 
is the third most rural state in the nation.13  Fifty of the 55 counties in the state are 
designated as medically underserved areas, and all or part of 40 counties in the state 
are classified as health professional shortage areas.14  During 2002-2006, the age-
adjusted lung cancer incidence rate (WV: 481.5 per 100,000, US: 378.5 per 100,000), 
and mortality rate (WV: 390.6 per 100,000, US: 310.8 per 100,000) among the elderly 
was higher in the state in comparison to rest of the country.15;16  Interestingly, the 
proportional difference in age-adjusted lung cancer mortality rates, among the elderly 
from WV and the US, was lower than the difference in age-adjusted lung cancer 
incidence rates.  This might suggest better survival outcomes among elderly lung 
cancer patients in WV as compared to the US; however, such a hypothesis remains 
unexplored.  The observed lung cancer disparities in rural populations can be attributed 
to limited access to quality medical care facilities; less access to or utilization of early 
cancer detection programs; increased prevalence of behavioral risk factors, such as 
tobacco use and sedentary life style, and socioeconomic factors, such as low income 
and education.17-23  In addition to being medically underserved, the rural population may 
also experience variations in the quality, availability, and accessibility of services when 
compared to their urban counterparts.24   
Using cancer registry linked Medicare data files, this study compared the 
appropriateness and timeliness of lung cancer care among elderly, in a representative 
rural and medically underserved WV state population, with a representative US 
population.  The study also determines the patterns of receipt of tobacco-use cessation 
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counseling services among elderly lung cancer patients with a history of tobacco use.  
The purpose of this study was to fill critical gaps in clinical guideline based lung cancer 
care and outcomes literature.  First, the study examined the appropriateness of lung 
cancer care and associated health outcomes among WV-US elderly populations.  While 
numerous studies have examined lung cancer treatment variations in the US, 
comprehensive evaluation of variations in clinical guideline based lung cancer care and 
its impact on health outcomes in the elderly remains unexplored.  Furthermore, no 
information is currently available about geographic variations in clinical guideline based 
lung cancer care and associated health outcomes among WV-US elderly populations.  
Therefore, we investigate and compare the appropriateness of lung cancer care based 
on clinical guidelines and associated health outcomes among elderly Medicare fee-for-
service (FFS) beneficiaries in a representative rural and medically underserved WV 
state population, and in a representative US population. 
The second study examined the timeliness of lung cancer care among the 
elderly.  Timeliness of care is important dimension of cancer care quality.  While 
numerous studies have examined timeliness of lung cancer care, a majority of them 
have been conduced in European Union healthcare settings.25-39  Few studies 
performed in the US were either limited to small sample sizes, restricted to non-small 
cell lung cancer (NSCLC) patients, included both elderly and non-elderly patients, 
focused on specific demographic subgroups, performed within specific health care 
settings, or failed to examine health outcomes associated with timely care.40-47  As the 
elderly carry a disproportionate burden of lung cancer in the US, studies that examine 
timeliness of lung cancer care based on clinical opinion-based guidelines, and the 
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associated health outcomes in the elderly are much needed.2  Furthermore, there is no 
study that compares geographic variations in timeliness of lung cancer care based on 
clinical opinion-based guidelines, and the associated health outcomes among WV-US 
elderly populations.  Therefore, in the second study we investigate and compare the 
timeliness of lung cancer care based on clinical opinion-based guidelines among elderly 
Medicare FFS beneficiaries in a representative rural and medically underserved WV 
state population and in a representative US population. 
The third study in this project was conducted with the purpose of determining the 
receipt of tobacco-use cessation counseling services among elderly lung cancer 
patients with a history of tobacco use.  Smoking is common among patients diagnosed 
with lung cancer and promoting smoking cessation in these patients is important, as 
continued smoking has substantial adverse effects on treatment effectiveness, risk of 
second primary malignancies, and quality of life.  In the third study, we examined the 
patterns of receipt of tobacco-use cessation counseling services among elderly 
Medicare FFS beneficiaries, with lung cancer and with a history of tobacco use, in a 
state (West Virginia) population.  Together, the three studies provide an in-depth view of 
patterns of lung cancer care in the WV and US elderly populations, and contribute 
uniquely to the clinical guideline based lung cancer care and outcomes literature.  The 
results from each of the three studies have been discussed in detail in the previous 
chapters.  Key results from each of the three studies and their implications on lung 
cancer care are discussed below. 
 In the first study, treatment patterns varied significantly among beneficiaries with 
lung cancer in the WV and US populations.  Despite availability of various treatment 
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options to treat the disease, many beneficiaries did not receive any treatment in either 
population.  Minimally appropriate clinical guideline based lung cancer care (hereafter 
referred to as ‘minimally appropriate care’) was only received by less than half of all 
beneficiaries in each population.  However, the likelihood of receipt of minimally 
appropriate care among beneficiaries in the WV and US populations was not 
significantly different. 
Receipt of minimally appropriate care by beneficiaries was associated with longer 
survival times in both populations.  Although beneficiaries receiving minimally 
appropriate care in the WV population had greater median survival times, compared to 
the US population, their three year survival rates were significantly lower.  In both 
populations, we found the adjusted lung cancer mortality risk significantly higher among 
beneficiaries not receiving minimally appropriate care than those who did receive such 
care.  However, the magnitude of risk associated with non-receipt of minimally 
appropriate care was lower in WV population than in the US population.  When 
controlled for the variability associated with receipt of minimally appropriate care and all 
sociodemographic variables, lung cancer mortality risk was no different among 
beneficiaries in the WV and US populations. 
The second study assessed the timeliness of lung cancer care among elderly in 
WV-US populations.  The study revealed that delays in diagnosis and treatment ranged 
widely, and also varied significantly among beneficiaries with lung cancer in the WV and 
US populations.  Timely lung cancer care based on clinical opinion-based guidelines 
(hereafter referred to as ‘timely care’) was received by most beneficiaries in each 
population and was highest among those receiving radiotherapy.  Contrary to what is 
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expected, the proportion of beneficiaries receiving timely care did not vary between the 
two populations.  This study is one of the few that have assessed the influence of timely 
lung cancer care on survival outcomes.  Contrary to what would be expected, the 
results of this study indicate that non-timely care is not associated with poorer prognosis 
in lung cancer.  This results corroborate finding from earlier studies.26;28;42;48;49  As 
reported in other studies, the association between shorter delay and poorer outcomes 
was most pronounced in patients with advanced stage disease in both populations.49  
Compared to the US population, survival outcomes were poorer among beneficiaries 
receiving non-timely care and among those with late stage disease in the WV 
population.  In both populations, we found the adjusted lung cancer mortality risk 
significantly lower among beneficiaries not receiving timely care than those who did 
receive such care.  However, the magnitude of risk associated with non-receipt of timely 
care was higher in the WV population than in the US population.  In stratified analysis 
by cancer type and stage, we again found the adjusted lung cancer mortality risk 
significantly lower among beneficiaries not receiving timely care than those who did 
receive such care, and the results were most pronounced in patients with advanced 
stage disease.  After controlling for the variability associated with receipt of timely care 
and all sociodemographic variables, lung cancer mortality risk was significantly higher 
among beneficiaries in WV population as compared to the US population.  Regardless 
of its impact on health outcomes, delays in diagnosis and treatment should be avoided, 
as it may increase psychological stress in patients.50     
The third study revealed that tobacco-use cessation counseling services were 
received by more than half of all elderly Medicare FFS beneficiaries in the WV 
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population.  The use of these services was higher among younger beneficiaries, and 
after controlling for other factors, increasing age at diagnosis was associated with 
decline in receipt of tobacco-use cessation counseling services.  This finding may have 
resulted from variation in physician practice patterns, and/or individual treatment 
preferences.  Receipt of tobacco-use cessation counseling was also higher among the 
elderly with early stage disease as compared to those with late stage disease.  This 
finding is expected, and is similar to that reported in one study, where patients with late 
stage disease were less likely to enroll in smoking cessation programs, as compared to 
those with early stage disease.51  Surprisingly, receipt of tobacco-use cessation 
counseling was found to be higher among beneficiaries residing in rural areas, as 
compared to those residing in non-rural areas.  This finding may have resulted from the 
fact that prevalence of smoking is higher among beneficiaries in rural areas, and that 
awareness of risks associated with continued smoking may be higher among these 
individuals and their providers, resulting in increased receipt of tobacco-use cessation 
counseling services. 
Although in this study, we could not determine the success or failure of tobacco-
use cessation counseling attempts, receipt of such services by beneficiaries was 
associated with longer survival times.  However, it is very likely that this finding may 
have resulted from the increased disease severity among beneficiaries who did not 
receive tobacco-use cessation counseling services.  When controlled for such variability 
in patient clinical and sociodemographic characteristic, the adjusted lung cancer 
mortality risk was higher, but not significant, among beneficiaries not receiving tobacco-
use cessation counseling services.  Even after controlling for the variability in lung 
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cancer care received among beneficiaries, the adjusted lung cancer mortality risk 
remained unchanged.  Although findings from this study show no increase in adjusted 
lung cancer mortality risk among beneficiaries not receiving tobacco-use cessation 
counseling services, promoting smoking cessation at any stage of the disease is 
important.   
 To summarize, this project provides an in-depth view of patterns of lung cancer 
care and outcomes among elderly lung cancer patients from the WV and US 
populations.  Furthermore, the results from this project help to explain the observed 
geographic disparities in lung cancer mortality among the elderly. 
 
Significance of the study 
Significance of study I:  Appropriateness of lung cancer care and associated health 
outcomes among elderly Medicare FFS beneficiaries in West Virginia and in the United 
States 
The study reveals that although lung cancer diagnostic and management services are 
covered under Medicare program, underutilization of these services among recipients in 
the Medicare FFS population is a concern.  These results highlight the critical need to 
address disparities in receipt of minimally appropriate care among recipients in the 
Medicare FFS population.  Reducing observed treatment variations according to 
individual characteristics can help to improve the use of clinical guideline-based 
treatments in the elderly, and that in turn would improve health outcomes.  The findings 
from this study can aid policy makers and health care providers to reduce treatment 
variations in the future.  The study also reveals that although lung cancer treatment 
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patterns vary between WV-US elderly populations, significant population variation in 
receipt of minimally appropriate care, and associated lung cancer mortality risk, does 
not exist.  These findings are contrary to what would be expected, given that the WV 
population is more rural and medically underserved and has higher lung cancer 
mortality rates, compared to the US population.  The finding suggests that observed 
geographic differences in lung cancer mortality may not be associated with variation in 
receipt of minimally appropriate care among elderly beneficiaries with an incident 
diagnosis of lung cancer.  Furthermore, higher lung cancer incidence in the WV 
population, as compared to the US population, may partly explain the disparities seen in 
lung cancer mortality among these populations.  Therefore, this study reveals the urgent 
need for future cancer prevention efforts directed towards promoting smoking cessation 
in a rural WV population where the smoking prevalence rates are the highest in the 
nation.  In the long run, these cancer prevention efforts can help to reduce the incidence 
of lung cancer in this rural population which in turn can help to reduce the geographic 
disparities in lung cancer mortality. 
 
Significance of study II:  Timeliness of lung cancer care and associated health 
outcomes among elderly Medicare FFS beneficiaries in West Virginia and in the United 
States 
Lung cancer care may require complex coordination of services by medical and surgical 
specialists, and the traditional approach of referring patients for consultation with 
multiple specialists in a sequential fashion often results in care that is perceived as 
slow.  Timely lung cancer care based on clinical opinion-based guidelines is important 
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to reduce the burden of lung cancer among elderly.  The results from this study reveal 
that although lung cancer diagnostic and management services are covered under the 
Medicare program, delays in diagnosis and treatment among recipients in the Medicare 
FFS population exists, and are a concern.  Increasing patient awareness of lung cancer 
symptoms, and better coordination of care among providers, may help to reduce the 
delays in diagnosis and treatment.  Results of this study also emphasize the need to 
address disparities in receipt of timely care among recipients in the Medicare FFS 
population.  The study also revealed that longer delays in treatment are not associated 
with poorer prognosis.  Nonetheless, delayed care should be avoided as it may increase 
the risk of disease progression and psychological stress in patients.   
Finally, this study reveals that although delays in diagnosis and treatment varied 
between the WV-US populations, significant population variation in receipt of timely care 
does not exist.  These findings are similar to that observed in the first study and are 
contrary to what would be expected given that WV population is more rural and 
medically underserved, and has higher lung cancer mortality rates as compared to the 
US population.  This finding suggests that observed geographic differences in lung 
cancer mortality may not be associated with variation in receipt of timely care, and may 
have resulted from differences in lung cancer incidence.  Future cancer prevention 
efforts directed towards promoting smoking cessation can help to reduce the incidence 
of lung cancer in the rural WV population, which in turn can help reduce the geographic 
disparities in lung cancer mortality. 
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Significance of study III:  Patterns of receipt of tobacco-use cessation counseling 
services usage and associated health outcomes among elderly Medicare FFS 
beneficiaries with lung cancer and a history of tobacco use in West Virginia   
Smoking is common among patients diagnosed with lung cancer and promoting 
smoking cessation among these individuals through tobacco-use cessation counseling 
services is of vital importance to ensure treatment success.  The diagnosis of lung 
cancer can be used as a teachable moment for smoking cessation.  However, the 
results from this study show that although preventive care services, such as tobacco-
use cessation counseling services, are covered under the Medicare program, 
underutilization of these services among elderly lung cancer patients with a history of 
tobacco use exists and is a concern.  The study also reveals that there are survival 
benefits associated with receipt of tobacco-use cessation counseling services.  
However, more empirical studies of such interventions are needed to accurately 
quantify the benefits of such services.  The results suggests that promoting smoking 
cessation among lung cancer patients in rural populations, such as West Virginia where 
the smoking prevalence rates are the highest in the nation, is much needed. 
 
 
 
Study Limitations 
For each of the three studies, their limitations have been discussed in detail previously.  
However, a general summary of the overall study limitations has been provided in this 
section.  Although we used cancer registry-linked claims data, an inherent limitation of 
using administrative claims data for epidemiologic studies is the possibility of 
misclassification as a result of coding errors.52;53  However, claims data have been 
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evaluated for their utility as a source of epidemiologic or health services information in 
cancer patients.52-56  Increasing the use of these types of data to assess the quality of 
cancer care also has also been identified as a priority by the Institute of Medicine.57  
Studies using claims data are usually population-based and have the potential to 
address a number of priority questions regarding the quality of cancer care and health 
care disparities.  These population-based studies provide valuable information for future 
planning and prioritization of health programs that improve cancer outcomes.  
Therefore, there is increasing interest in analyzing large health claims databases to 
assess treatment and outcomes for cancer.52;53;57
The results of this study are generalizable only to the elderly Medicare FFS 
population, aged 66 years and older, as encounter data for Medicare recipients enrolled 
in the managed care plan were not available for this study.  There was a small increase 
in the percentage of Medicare recipients enrolled in managed care during the study 
years in both populations; in 2007 it was ~16% in WV population and ~19% in the US 
population.58  Information on care received by the Medicare recipients outside of the 
Medicare system, or through non-Medicare providers, was also not available in the 
claims data for our study.  However, Medicare is the largest and most comprehensive 
insurance provider for the elderly in the US.  Racial disparities in cancer outcomes could 
not be ascertained in this study as the populations were predominantly White. 
One of the inclusion criteria for cohort selection in this study was continuous 
enrollment in Medicare Part A and B during the study period.  This resulted in the non-
inclusion of individuals with non-continuous enrollment and the loss of individuals who 
were enrolled intermittently.  Because of limited data availability at the time of study, we 
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were unable to conduct a long-term (5-10 year) follow-up to assess the health outcomes 
associated with receipt of minimally appropriate care.  Individual-level socioeconomic 
measures of educational attainment, marital status, and family income were also 
unavailable for this study.  However, aggregate measures of socioeconomic status at 
the census tract level from 2000 decennial census data were used as a proxy.   
In the first study, we acknowledge that various clinical guidelines have been 
published for lung cancer diagnosis and management, each with recommendations that 
are more or less are the same.59-63  For the purpose of that study, we choose ACCP 
guidelines for lung cancer management and outcomes, as it is the most comprehensive 
of all available guidelines.60  The algorithm we adapted from these guidelines to identify 
minimally appropriate care takes into account the limitations in our data sources.  
Specifically, information on various lung function test results and lung performance 
scores were not available in our data source, and were not considered in our analysis.  
However, these indicators of lung performance are most crucial only in planning for 
chemotherapy in NSCLC stage IV individuals who we excluded from our analysis.  Our 
estimates of proportion of beneficiaries receiving minimally appropriate care may be 
biased slightly upward, as we included patients who received minimally appropriate 
care, followed by additional unproven therapies.  We also acknowledge that our 
definition of receipt of minimally appropriate care may be too narrow and that given the 
heterogeneity of patients seen by physicians, receipt of no therapy may still be 
considered as appropriate care.  None the less, our definition of receipt of minimally 
appropriate care provides a conceptual framework to assess and compare patterns of 
care that were prevalent during the years 2002 through 2007.   
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In the second study, given the limitations in our data sources, the delays in 
diagnosis and treatment were defined appropriately, and may not be accurate.  
Retrospective review of health services usage to estimate date of earliest lung cancer 
symptoms was limited to the year prior to diagnosis since findings from prior research 
have shown delays in symptom to diagnosis to be less than a year.64  Our estimates of 
‘symptom to diagnosis’ delay may be biased, as beneficiaries in whom earliest symptom 
date could not be identified were excluded from our analysis.  These beneficiaries may 
either had no health services usage or may had no Medicare claim with an ICD-9 code 
associated with lung cancer symptom in the year prior to diagnosis.  It is less likely that 
we missed any reported lung cancer symptom as the list of symptoms searched for in 
this study was comprehensive, and was derived from ACCP guidelines for management 
and treatment of lung cancer (Appendix 3.1).65  Overall, date of earliest lung cancer 
symptom was identified in 88% of beneficiaries in WV population, and in 90% of 
beneficiaries in the US population.  Our estimates of ‘symptom to diagnosis’ delay may 
also be biased, as the earliest symptom identified may have been unrelated to lung 
cancer.  We acknowledge that our definition of timely care may be too narrow, and that 
given the heterogeneity of patients seen by physicians, receipt of non-timely care or no 
care may still be considered appropriate.  None the less, our definition of timely care 
provides a conceptual framework to assess and compare patterns of care that were 
prevalent during the years 2002 through 2007.   
A major limitation of third study was the lack of information on success or failure 
of tobacco-use cessation counseling attempts in beneficiaries receiving such services.  
Specifically, the data sources used for the third study do not capture information on 
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whether or not a beneficiary quit smoking following the receipt of tobacco-use cessation 
counseling services.  Such information is necessary to accurately quantify the health 
benefits associated with receipt of tobacco-use cessation counseling services.  Also, 
any variation in type of counseling services offered by different providers was not 
captured in our data sources, and was not controlled for in our analysis.   
Finally our definition of minimally appropriate versus inappropriate care, timely 
versus non-timely care, and receipt of tobacco-use cessation counseling service is 
limited to the data recorded in the claims such as the presence or absence of ICD-9 
diagnosis and procedure codes, HCPCS procedure codes, CPT procedure codes and 
revenue center codes.  Future studies can overcome the barriers seen in this study by 
collecting data on physician behaviors, patient preferences on treatment choices, and 
success/failure of counseling attempts. 
 
Directions for Future Research 
This study revealed that geographic disparities in lung cancer mortality among elderly 
from the WV and US populations do not result from variations in appropriateness or 
timeliness of lung cancer care.  Future studies can use both qualitative and quantitative 
tools to determine if increased lung cancer risk, fragmented health care services 
structure, and poor accessibility to services help to explain the observed geographic 
disparities in lung cancer mortality.  
Given that the study population in this project was predominately White, racial 
disparities in lung cancer care and outcomes were not observed.  Racial disparities in 
lung cancer mortality exist as the mortality rates are higher for Blacks (53.4 per 
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100,000) as compared to Whites (50.2 per 100,000).  While Black men have a far 
higher age-adjusted lung cancer death rate that White men, and Black and White 
women have similar rates.1;2  Future studies can explore the role of treatment variation 
in observed lung cancer mortality differences by race.  While the number of lung cancer 
deaths among men has reached a plateau, the number is still rising among women.4  
However, the age-adjusted death rate for lung cancer is higher for men (63.6 per 
100,000) than for women (39.0 per 100,000).  Given the fact that women were relatively 
late adopters of cigarette smoking, future studies can be carried out to determine other 
factors associated with observed gender disparities.   
Given that we could not capture the success or failure of tobacco-use cessation 
counseling attempts among beneficiaries receiving such services, future studies can be 
carried out by collecting data on success/failure of counseling attempts and physician 
behaviors/patient preferences in using tobacco-use cessation counseling services.  
Such studies can provide the evidence needed to promote tobacco-use cessation 
counseling services among lung cancer patients with a history of tobacco use. 
Finally, our study was limited to retrospective data sources.  Future studies can 
overcome the barriers seen in this project by prospectively collecting data on 
provider/patient treatment preferences.  Prospective data on elderly lung cancer patient 
experiences, needs, and concerns, as they receive care should be collected in future 
studies.  Future studies could also validate the results seen in our study among younger 
individuals.  While in this project follow up was limited to few years, future studies could 
be carried out to assess the long-term impact of treatment variation on lung cancer 
outcomes.
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Appendix 2.1. List of International Classification of Diseases (ICD-9) diagnosis and 
procedure codes, Healthcare Common Procedure Coding System (HCPCS) codes, 
Current Procedural Terminology (CPT) codes and revenue center codes, used to 
identify lung cancer specific treatments and procedures in Medicare claim data files 
 
Surgery: 
 
ICD-9: 324,3240,3249,3241,325,3250,3259,3250,323,3230,3239,3230,3229, 
3220,329,3290,3399,344,3440,3409,3228,4029,326,3260,3401,344,3440 
 
CPT: 32480,32482,32486,32663,32440,32442,32445,32488,32484,32663, 
32500,32657,38746,32520,32522,32525,32310,32320,32656 
 
Chemotherapy:  
 
ICD-9: V5811,V581,V662,V672,9925,9928,0015,3492 
 
CPT: 96400,96405,96406,96408,96410,96412,96414,96420,96422,96423, 
96425,96440,96445,96450,96520,96530,96542,96545,96549 
 
HCPCS:Q0083,Q0084,Q0085,G0355,G0356,G0357,G0358,G0359,G0360,G036
1,G0362,G0363, G9021-G9032,J9060,J9062,J9265,J9390,J9201,J9170,J9045 
 
Radiation:  
  
ICD-9: V580,V661,V671,9229,9221,9222,9223,9224,9225,9226,9227,9228 
 
CPT: 77401,77402,77403,77404,77406,77407,77408,77409,77411,77412, 
77413,77414,77416,77417,77418,77427,77431,77432,77470,77499,77520, 
77523,77750-77799 
 
HCPCS: G0256,G0261 
 
Revenue center: 0330,0333 
 
Mediastinal lymph node evaluation:  
 
ICD-9: 3425,3422,3426,325,3250  
 
CPT: 39400,32405,39000,39010,39200,39220,32662,38746 
 
Mediastinoscopy:   
 
ICD-9: 3422  
 
CPT: 39000,39010,39400 
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Appendix 3.1. List of International Classification of Diseases (ICD-9) diagnosis and 
procedure codes, Healthcare Common Procedure Coding System (HCPCS) codes, 
Current Procedural Terminology (CPT) codes, and revenue center codes used to 
identify symptoms associated with lung cancer, and lung cancer specific treatments and 
procedures in Medicare claim data files. 
 
Symptoms associated with lung cancer (ICD-9): 
 
Symptoms of primary tumor: 
      
  Cough     7862,4910  
  Weight loss     78321  
  Dyspnea     7860,7861,7862,7863, 
7864,7865,7866,7867, 
7869  
  Chest pain\Pleuritic pain   78650,78651,78652,78659 
  Hemoptysis     7863  
  Bone pain     73390  
  Clubbing     7815  
  Fever      7806,78060  
  Weakness     78079  
  Superior vena cava obstruction  4592  
  Dysphagia     7872  
  Wheezing and Stridor   78607,7861  
       
Symptoms of intrathoracic spread :     
 
  Recurrent laryngeal nerve palsy  47830,47831,47832,47833, 
47834  
  Pancost tumor/superior sulcus tumor 1623  
  Horner syndrome    3379  
       
Symptoms of extrathoracic metastases:      
 
  Headache     7840  
  Nausea\vomiting    78701,78702,78703  
  Seizures     78039  
  Confusion     2930,2931  
  Personality change    3101  
  Musculoskeletal pain   7291  
  Syncope     7802  
  Lympadenopathy\enlargement of  
lymph nodes     7856  
  Hoarseness     78449,78442  
  Hepatomegaly    7891  
  Papilledema     37700,37701,37702,37703, 
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37704  
       
Paraneoplastic syndromes:      
 
  Endrocrine     
   Nonmetastatic hypercalcaemia 27542  
   Cushing syndrome   2550  
   Gynecomastia   6111  
   Hypoglycaemia   2512  
   Hyperthyroidsm   24290,24291  
   Carcinoid syndrome   2592  
       
  Skeletal     
       
   Hypertrophic osteoarthropathy 7312  
       
  Neurologic     
       
   Mononeuritis multiplex  3545  
   Intestinal pseudo obstruction 5609  
   Lambert Eaton syndrome  1991,3581  
   Encephalomyetitis   3239  
   Neurotising myelopathy  3369  
   Cancer associated retinopathy 36210  
       
  Collagen\Vascular     
       
   Dermatomyositis   7103  
   Polymyositis    7104  
   Vasculitis    4476  
   Systemic lupus erythematosus 7100  
       
  Renal     
       
   Glomerulonephritis   5839  
   Nephrotic syndrome  5819  
       
  Metabolic     
       
   Lactic acidosis   2762  
   Hypouricemia   7906  
       
  Systemic     
       
   Anorexia    7830  
   Cachexia    7994  
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  Cutaneous     
       
   Acquires hypertrichosis languinosa 7041  
   Erythema gyratum repens  6951  
   Erythema multiforme  6951  
   Tylossi    700  
   Erythrodermia   6959  
   Exfoliative dermatitis  69589  
   Acanthosis nigricans  7012  
   Pruritus    6989  
   Urticaria    7089  
       
  Hematologic     
       
   Anemia    2859  
   Leukemoid reactions  2888  
   Thrombocytosis   2899  
   Thrombocytopenic purpura 2873  
       
  Coagulopathies     
       
   Thrombophlebitis   4519  
   Disseminated intravasular  
coagulation    2866  
 
Chest x-ray: 
 
 ICD-9 (V725,8744,8739,8749) 
CPT (71010,71015,71020,71021,71022,71023,71030,71034,71035) 
 
Surgery: 
 
ICD-9: 
324,3240,3249,3241,329,3290,3399,344,3440,3409,3228,325,3250,3259,3250  
323,3230,3239,3230,3229,3220,3220,326,3260,344,3440,3401 
 
CPT 
32480,32482,32486,32663,32440,32442,32445,32488,32484,32663,32500, 
32657,32310,32320,32656,32520,32522,32525 
 
 
Chemotherapy:  
 
ICD-9: V5811,V581,V662,V672,9925,9928,0015,3492 
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CPT:  
96400,96405,96406,96408,96410,96412,96414,96420,96422,96423,96425, 
96440,96445,96450,96520,96530,96542,96545,96549 
 
HCPCS: Q0083,Q0084,Q0085,G0355,G0356,G0357,G0358,G0359, 
G0360,G0361,G0362,G0363, G9021-G9032,J9060,J9062,J9265,J9390, 
J9201,J9170,J9045 
 
Radiation:  
  
ICD-9 
V580,V661,V671,9229,9221,9222,9223,9224,9225,9226,9227,9228 
 
CPT  
77401,77402,77403,77404,77406,77407,77408,77409,77411, 
77412,77413,77414,77416,77417,77418,77427,77431,77432,77470, 
77499,77520,77523,77750-77799 
 
HCPCS: G0256,G0261 
 
Revenue center: 0330,0333 
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Appendix 4.1. List of International Classification of Diseases (ICD-9) diagnosis and 
procedure codes, Healthcare Common Procedure Coding System (HCPCS) codes, 
Current Procedural Terminology (CPT) codes and revenue center codes, used to 
identify lung cancer specific treatments, procedures, and other health care services in 
Medicare claim data files. 
 
Surgery: 
 
ICD-9: 324,3240,3249,3241,325,3250,3259,3250,323,3230,3239,3230,3229, 
3220,329,3290,3399,344,3440,3409,3228,4029,326,3260,3401,344,3440 
 
CPT: 32480,32482,32486,32663,32440,32442,32445,32488,32484,32663, 
32500,32657,38746,32520,32522,32525,32310,32320,32656 
 
Chemotherapy:  
 
ICD-9: V5811,V581,V662,V672,9925,9928,0015,3492 
 
CPT: 96400,96405,96406,96408,96410,96412,96414,96420,96422,96423, 
96425,96440,96445,96450,96520,96530,96542,96545,96549 
 
HCPCS:Q0083,Q0084,Q0085,G0355,G0356,G0357,G0358,G0359,G0360,G036
1,G0362,G0363, G9021-G9032,J9060,J9062,J9265,J9390,J9201,J9170,J9045 
 
Radiation:  
  
ICD-9: V580,V661,V671,9229,9221,9222,9223,9224,9225,9226,9227,9228 
 
CPT: 77401,77402,77403,77404,77406,77407,77408,77409,77411,77412, 
77413,77414,77416,77417,77418,77427,77431,77432,77470,77499,77520, 
77523,77750-77799 
 
HCPCS: G0256,G0261 
Revenue center: 0330,0333 
 
Mediastinal lymph node evaluation:  
 
ICD-9: 3425,3422,3426,325,3250  
CPT: 39400,32405,39000,39010,39200,39220,32662,38746 
 
Mediastinoscopy:   
 
ICD-9: 3422  
  CPT: 39000,39010,39400 
 
Tobacco-use cessation  CPT (99201,99202,99203,99204,99205,99211,99212, 
counseling services:  99213,99214,99215,99406,99407,G0375,G0376) 
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